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Abstract
The first part of this thesis describes a "Stage 1" study involving systematic 
investigation of relationships between structure, conformation and activity of the 
Melanin Concentrating Hormone (MCH). The parent peptide and a series of 
sub-structural fragments have been prepared by solid phase synthesis and their 
biological potencies compared. It is proposed that the exocyclic sequences of MCH 
may assist positioning/binding of the molecule to achieve maximal receptor site 
interaction. The disulphide linkage is essential to the maintenance of activity, 
promoting the active conformation.
As the first stage in elucidating the shape and charge characteristics of MCH, 
the linear and cyclic 5-14 sub-structural units were used as models in !H n.m.r. 
conformational studies. In addition, molecular dynamics analyses were performed 
independendy on the cyclic 5-14 fragment and the parent peptide. The theoretical 
studies indicate that two major families of conformations may be accessed, 
determined by flexibility at Gly8. Conformational features predicted by molecular 
dynamics find support in the !H n.m.r. studies. A common predominant feature is a 
transannular hydrogen bond from the Tyr11 side chain, suggesting its importance in 
stabilising the biologically active conformation.
In the second part of this thesis, the important structural and conformational 
features revealed by the initial analyses were investigated further in the "Stage 2" 
study. Analogues of the cyclic 5-14 subunit were prepared comprising substitutions 
at Gly8 and Tyr11, the former resulting in a definable conformational constraint. 
Subsequent biological testing and conformational analyses confirm the importance of 
the substituted residues for activity, and indicate the possible geometry of Gly8 in the 
active conformation.
The third section of this thesis is concerned with synthetic approaches towards 
a suitable disulphide mimic, based on the allenyl bis-amino acids. Such a surrogate is 
required to allow further investigation of the role of cystine in promoting the 
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Abbreviations used for amino acids and the designation of 
peptides follow the rules of the IUPAC - IUB Commission on Biochemical 
Nomenclature.1 For clarity, structures are numbered sequentially, from Chapter 1 
onwards, in brackets and emphasised type. References are shown in superscripted, 
emphasised type.
*
The symbol , is given at the beginning and the end of sections 
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involved in controlling body colour in lower vertebrates.2 In teleost fish, it serves to 
concentrate melanin within the pigment cells of the skin, causing lightening. 
However, MCH is also known to induce melanosome dispersion within tetrapod 
melanophores.3 In addition, it acts as a potent pituitary regulating hormone, 
inhibiting the release of adrenocorticotropin (ACTH) in fish and mammals,4 and 
stimulating the release of growth hormone in rats.5
MCH has been isolated from several sources,6,7a,s and its primary structure 
elucidated7 as a cyclic heptadecapeptide, with a disulphide-bridged ring sequence and 
N- and C- terminal exocyclic residues. Syntheses of MCH,9'11 and various 
analogues,8,12"14 have been carried out by different groups. Determination of their 
biological activities has shown that the cyclic ring is essential.8’12
It is evident that conflicting data have also been published and that the 
topological and charge distribution properties of the cyclic system have not been 
considered until very recently.15 Knowledge of structural and conformational 
characteristics is essential to the understanding of determinants for binding and 
activity. The object of this research programme was to investigate these features and 
our findings are described.
Since the majority of the project work was concerned with solid phase peptide 
synthesis of MCH analogues required for our study, it is pertinent to review the 
salient features of this methodology. Consideration is also given to techniques which 
may be applied in the determination of relationships between peptide structure, 
conformation and activity. In addition, the biological properties of MCH as a potent
pituitary regulating hormone are examined.
1.1. SOLID PHASE PEPTIDE SYNTHESIS
Peptides16 and proteins exhibit some of the largest structural and 
functional variation of all classes of biologically active molecules. They 
are constructed from the twenty genetically coded L-amino acids, and other 
moieties, and sequences may be linear, cyclic, or branched.
It has been recognised that peptides comprising 5-50 amino acids are 
involved in many physiological processes. They may be released from the 
endocrine glands into the blood which carries them to the site of action, or 
be specialised neurotransmitters.
Synthesis can not only confirm the structures of naturally occurring 
peptides but also provide large quantities for further investigation. Thus, a 
rapid, efficient and reliable methodology is required for such purposes.
The "classical" solution phase approach to peptide synthesis has yielded 
impressive successes in the preparation of biologically active peptides.17 
Chain elongation may proceed via incremental or segment condensation 
processes. However, these procedures are not ideally suited to the 
preparation of long chain peptides. In recognition of problems inherent in 
the solution phase method, the search for a more efficient procedure 
resulted in the development of the solid phase approach.18
Solid phase peptide synthesis, first described by Merrifield,19 has 
proved to be an extremely efficient procedure for the chemical synthesis of 
peptides. The attachment of a growing peptide chain to a solid support has 
provided an element of speed and efficiency, lacking in the "classical" 
approach. The feasibility of this procedure for both manual and automated 
preparation has also been demonstrated. Indeed, the method has been 
successfully applied to the syntheses of other oligomeric structures, in 
particular DNA.20
1.1.1. The Solid Phase Principle
The essential elements of a solid phase synthesis, typical of the 
standard Merrifield approach, are outlined in Scheme 1.
Attachment of the first amino acid is effected by a covalent bond to the
ACTIVATION AND ESTERIFICATION ^  (i)
Boc.NHCHRto.OCH2----^  ^
DEPROTECTION ^  (ii)
‘ Cl H3_NCHR1CO.OCH2 --- ^  ^
CYCLE -------- NEUTRALISATION ^ (iii)
H2NCHRICO.OCH2----  ^ ^ — ( j » )
COUPLING ^  (iv)
Boc JWCHRto-NHCHR1CO.OCH2   ^ ^ ------- ( T )
CLEAVAGE ^  (v)
h3+ nc h r2c o -n h c h r 1co2'
(i) Boc-amino acid, EtOH, 80°C (ii) HCl-AcOH or TFA-DCM 
(iii) TEA-DCM (iv) Boc-amino acid, DCC, DCM (v) HBr -TFA or HF
Scheme 1
solid polymeric support It is necessary to block temporarily the amine 
function of the incoming amino acid, otherwise, once activated a 
self-condensation reaction would occur. Side chains of certain amino acid 
functionalities may also need protection that is maintained throughout the 
synthesis. Once esterification of the first amino acid is complete, the 
temporary Na -protecting group is removed. When acid is used for this 
deprotection, a neutralisation step is required to release the free amine. The 
synthesis then continues with repetitive cycles of acylation and 
deprotection, adding the succeeding amino acids one at a time in a stepwise 
manner until the desired sequence has been assembled. Reactions are
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required to proceed in extremely high yields since there is no purification 
of intermediates. Excess soluble reagent can be employed to drive 
reactions to completion and may be readily removed by simple filtration 
and washing.
Once the synthesis is complete, the peptide is released from the support 
using conditions that are least destructive toward sensitive residues.
Finally, scrupulous purification and characterisation is required so as to 
ensure the absolute integrity of the product.
Many improvements and variations of the general procedure outlined 
in Scheme 1 have developed in recent years, leading to increasingly 
sophisticated methodologies, adapted to suit the objectives of the synthetic 
endeavour.
1.1.2. Sequence Assembly Methods
Most commonly, stepwise condensation is employed where chain 
growth proceeds from the C- to N-terminal direction. The reverse is less 
favourable due to the concomitant racemisation. Convergent solid phase 
synthesis, involving coupling of protected peptide segments on the solid 
support, has also been successfully applied. This induces an overall 
simplication of the synthesis and is particularly appropriate for the 
preparation of longer sequences. However, difficulties may arise through 
low solubility of intermediates, rearrangements and racemisation. 
Anchoring may also be carried out via an amino acid side chain, or both 
components to be coupled can be anchored on separate supports, enabling 
amino and carboxyl components to be removed in separate steps.
1.1.3. Solid Supports and Reaction Media
Commonly, cross-linked polystyrene or polyamide polymers are used 
forming microporous gels, where sites are uniformly distributed throughout 
the polymeric matrix. The solvents of choice are generally DCM and 
DMF, in which the dry beads swell, forming a well solvated gel where the 
peptide chains are mobile and reagent-accessible, enabling adequate 
reaction rates to be attained. A new mixed solvent, 
N-methylpyrrolidone-dimethylsulphoxide has shown improved resin 
solvation properties and reduction of peptide chain aggregations.21
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Other non-swellable supports include a range of carbohydrates, 
macroporous polystyrenes and polyethylenes, and "controlled-pore" silica 
glass. Recent innovations have been the introduction of polypropylene 
membranes22 and cellulose disc supports.23
In continuous-flow processes,24 where reagents and solvents are 
pumped through column-packed resins, the simple gel media may be 
unsatisfactory, lacking the necessary rigidity and strength. Suitable 
supports are obtained by enclosing the gel in a rigid macroporous 
framework, such as kieselguhr.
1.1.4. Functionalisation and First Residue Attachment
The polymeric support must contain the appropriate functional groups 
onto which the first residue is anchored. The choice of functional group is 
determined by the nature of the peptide product required and compatibility 
with the overall protection strategy adopted. The linkage must remain 
stable under conditions required to effect cleavage of the temporary 
Na -protecting group.
A multitude of functionalisation methods have been described.18 The 
first Na -protected amino acid can be linked directly to a suitably 
functionalised resin. More recently, however, the quantitative introduction 
of the preformed handle derivative has proved to be particularly valuable. 
In general, a handle is defined as a bifunctional spacer that incorporates the 
features of the desired C-terminal group and serves to link the initial 
synthetic unit of the peptide chain to a previously functionalised solid 
support in two discrete steps. The most versatile strategy, illustrated in 
Scheme 2, for the phenylacetamidomethyl (PAM) handle, involves 
formation of the bond to the synthetic unit first. This allows purification 
and characterisation, before quantitative attachment to the support via an 
amide linkage. Therefore, this allows complete control over the final 
loading of the initial amino acid, and circumvents potential problems 
associated with extraneous functional groups on the resin.
A range of "safety-catch" or "multi-detachable"25 anchors may also be 
employed which are respectively cleaved in more than one step, or at more 
than one site, thus allowing formation of protected peptide segments or
Boc.NHCHRCC>2 Cs+ + BrCH2 ~ ^  ^ —  CH2CO.OCH2CO ^  ^
BocJ^HCHRCO o c h 2 —^  CH2CO.OCK2CO — ^  ^
(i)
Boc.NHCHRCO.OCH2 — N\ — c h 2c o 2h  + h 2n c h 2 —r  ^ ---- ( P
(ii)
Boc.NHCHRCO.OCH' c h2c o n h c h2— — 0
Pam System
(i) Zn, AcOH (ii) DCC, DCM , 15 h
Scheme 2
cyclic peptides.
Selected examples of various anchoring linkages and handles are given 
in Figures 1 and 2, showing compatible Na -protecting groups and 
cleavage conditions. It is therefore evident, that on cleavage, the choice of 
anchoring linkage can determine both the extent of side-chain protection 
maintained and the nature of the C-terminal functionality.
There are various methods available for acylation of the first amino 
acid to the functionalised polymer. A common methodology, when using 
chloromethyl-resins, involves reaction with the Na -protected C-terminal 
amino acid as its triethylammonium or caesium salt. For benzyl 
alcohol-resins, the Na -protected C-terminal amino acid may be coupled by
LINKAGE Compatible N** - Cleavage
Protection (product)










the use of A^A^-dicyclohexylcarbodiimide (DCC) in the presence of 
4-A^N-dimethylaminopyridine (DMAP) as a catalyst26 Conditions have 
been established for minimising DMAP promoted racemisation in this 
step.27 Cleavage of Na -Fmoc by DMAP during the esterification reaction 
was considered a potential hazard but does not appear to be significant. 
Alternative methods are available, avoiding the use of DMAP, including 
esterification of Fmoc-amino acids to benzyl alcohol-resins by using
2,6-dichlorobenzoyl chloride.28
For coupling reactions of peptide segments on the solid support, 
protected peptide fragments may be esterified through the C-terminus, or a 
free side-chain carboxyl group, onto a suitably functionalised resin.
HANDLE Compatible Na- Cleavage
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1.1.5. General Protection Schemes
The choice and optimisation of the general protection scheme is crucial 
to the success of any peptide synthesis. The temporary Na -protecting 
groups must survive during each coupling step, yet removal must be rapid, 
quantitative and free from any side reactions.
Protecting groups must also be employed for the side chains of certain 
amino acids to prevent branching or other undesired reactions. It is critical 
that they are stable to the repeated cleavage of the Na -protecting group, yet 
be readily removed when desired, with minimum side reactions.
There are two principal methods of solid phase synthesis in popular use 
today, based on different general protection schemes. These are the 
standard Boc-polystyrene and the recently developed Fmoc-polyamide29 
methodologies (nomenclature derived from the Na -protecting group and 
the nature of the solid support). The Boc-polystyrene procedure is more 
akin to the original Merrifield methodology,19 as outlined in Scheme 1, yet 
the basis of each is founded on the same principles with differing specific 
chemistries.
1.1.5.1. Boc-Polvstvrene Procedure
Commonly, the resin used is a polystyrene suspension polymer 
cross-linked with 1% of m-divinyl benzene. Reactions are usually 
performed in DCM, though favourable results have been obtained with a 
polystyrene-DMF combination.30 Differential cleavage is achieved by use 
of protecting groups with graduated acid lability. Temporary 
Na -protection is effected by employing f-butyloxycarbonyl (Boc) 
derivatives, typically cleaved by trifluoroacetic acid (TFA). The 
adamantyloxycarbonyl (Adoc) group has also found application. Although 
offering no intrinsic advantage over the Boc group, this derivative may be 
preferred in certain circumstances because of its superior solubility 
characteristics. Various benzyl ethers, esters and urethane derivatives with 
electron withdrawing substitutents, for greater acid stability, are generally 
employed for protection of hydroxyl and carboxyl based amino acid side 
chains. Alternatively, ether and ester derivatives based on cyclopentyl and 
cyclohexyl alcohols have also been used in attempts to negate certain side 
reactions associated with the benzyl substitutents, such as C-alkylation and
-10-
a  -  p rearrangements. The side-chain protecting groups require more 
vigorous conditions for removal, and anhydrous liquid hydrogen fluoride 
(HF) is often the reagent of choice.








A c h 2 a
NH-CH-C0-NH-CH-C0-NH-CH-C0-0;-CH2 
c h 3 :




This method was developed particularly as a consequence of concern 
arising from published accounts of many side reactions resulting from 
repetitive strong acid treatment used in the Boc-polystyrene procedure.31
In the Fmoc-polyamide method, the base labile 
9-fluorenylmethyloxycarbonyl (Fmoc)32 group is used for temporary 
a-amino protection. It is cleaved within seconds, via p-elimination, by 
secondary amines such as piperidine, which simultaneously scavenge the 
dibenzofulvene intermediate. The use of Fmoc enables the adoption of 
r-butyl based side-chain protection, cleaved under relatively moderate 
conditions by TFA, as opposed to more acid-stable benzyl based 
derivatives used in the Boc-polystyrene procedure. This permits the solid 
phase synthesis to be carried out under considerably milder conditions.
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Beaded polar polydimethylacrylamide is used as the solid support. It is 
freely solvated by a wide range of solvents but particularly by dipolar 
aprotic media such as DMF. This leads to an apparent reduction of peptide 
aggregation which can occur within the resin matrix and provides a 
particularly favourable reaction medium for both acylation and 
deprotection reactions.
A general protection scheme for the Fmoc-polyamide methodology is 








Other mild protection schemes may employ dithiasuccinoyl (Dts), 
2-(p-biphenylyl)propyl(2)oxycarbonyl (Bpoc) or o-nitrophenylsulphenyl 
(Nps) as alternative Na -protecting groups, cleaved by reduction, very mild 
acidolysis and nucleophilic attack respectively. Indeed the Dts group has 
been applied in a three dimensional orthogonal protection scheme.33 Since 
its cleavage may be effected by treatment with thiols, the use of t-Bu based 
side-chain protection was employed, while the third dimension was 
introduced by the o-nitrobenzyl (ONb) ester anchoring linkage, cleaved by 
photolysis. Any one of the cleavages could be performed without affecting 
the other classes, therefore enabling the synthesis of a range of partially 
protected or fully deblocked peptides.
Although general protection schemes have been outlined, certain 
bifunctional amino acids require more specialised protection. Some 
selected examples are given in Figures 5 and 6 which show compatibility 
with either the Boc-polystyrene or Fmoc-polyamide methodologies.
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Compatible With The Boc-Polystyrene Procedure:
Partial Structure Stability
NH















Na / liquid NH3
HBr - AcOH, 25°C; 
HF, 0°C ; cat. H2




Some protecting groups are also compatible with both procedures, and are 
removed by methods orthogonal to acidolysis. Some selected examples 
are given in Figure 7.
Both the Boc-polystyrene and Fmoc-polyamide procedures have had 
many successful applications. The associated mildness of the 
Fmoc-polyamide methodology may be advantageous in syntheses of 
sequences that are particularly sensitive to acid.
Compatible With The Fmoc-Polyamide Procedure:
Partial Structure Stability Removal




base Hg2+; Ag+ ;I2 ; 





















Various coupling techniques may be employed to effect elaboration of 
the peptide chain once the first-residue attachment is complete.
Use of in situ condensing agents is a commonly employed 
methodology for the activation of the carboxyl group in the presence of the 
free amine. The most popular reagents continue to be the carbodiimides of 
which DCC34 has been most widely applied. Occasionally, 
A^V'-diisopropylcarbodiimide (DIPCDI)35 has been used since it gives rise 
to more soluble urea by-products. Frequently, 1-hydroxybenzotriazole 
(HOBt)36 is also added in the presence of the condensing agent It has been 
found that HOBt is an extremely efficient catalyst in peptide bond forming 
reactions that also acts to suppress racemisation. Most likely, formation of 
the HOBt ester of the incoming Na-protected amino acid yields an 
extremely efficient acylating agent which reacts without racemisation.
Symmetrical amino acid anhydrides are also popular, highly reactive 
derivatives. They are usually prepared just prior to use from the
- 15-
corresponding Na -protected amino acid and DCC in DCM.
Mixed anhydrides have also been applied, but their use has been 
limited due to low regiospecificity in aminolysis of the anhydride. 
However, phosphinic carboxylic mixed anhydrides are potentially useful.37
Reliable reagents of choice continue to be active esters. The esters of 
N-hydroxysuccinimide have proved to be effective in solid phase syntheses. 
The p-nitrophenyl and trichlorophenyl derivatives have also been used but 
reaction rates are relatively slow. However, pentafluorophenyl (Pfp)38 (2) 
and 3,4-dihydro-3-hydroxy-4-oxo-l,2,3-benzotriazine (Dhbt)39 (3) esters 
have been found to be efficient acylating agents. The reactivity of the 





Other suitable coupling reagents include diphenylphosphoryl azide 
(DPPA)40a and diethyl phosphorocyanidate (DEPC).40b In addition, the 
oxidation-reduction condensation method developed by Mukaiyama41 is 
applicable to standard stepwise solid phase synthesis, where a combination 
of triphenylphosphine and 2,2'-dipyridyl disulphide is employed, as shown 
in Scheme 3.





XNH-CHR1-C02H + H2N-CHR2-C02Y + Ph3P + aN S,











A successful solid phase synthesis relies on efficient and reliable 
monitoring procedures to ensure that coupling reactions have proceeded to 
completion.
Widely adopted approaches are the highly sensitive ninhydrin43 and
2,4,6-trinitrobenzenesulphonic acid (TNBSA)44 tests which indicate the 
presence of unreacted free amine by a colouration response. A highly 
accurate variation of the ninhydrin test has also been developed 45
A system for the continuous-flow spectrophotometric monitoring of 
the Fmoc-polyamide solid phase method has been developed,46 allowing 
acylation and Fmoc deprotection reactions to be followed by observing 
absorption of the fluorenyl derivatives. In addition, by application of Dhbt 
esters, complete acylation reactions are indicated by fading of the transient 
yellow colour initially produced by reaction of the liberated hydroxy 
component with unreacted, resin bound amine.
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Applications of gel phase 13C and 19F n.m.r. have been reported. 
However, such processes are both time consuming and inherently lacking 
in sensitivity.
Another useful procedure employs the total hydrolysis of aliquots of 
peptidyl-resin removed after the synthetic steps. In this regard, the 
technique of using internal reference amino acids is often very useful for 
the accurate determination of yields and retention of chains on the support.
1.1.8. Cleava£e and Deprotection
Upon completion of the assembly, the peptide must be cleaved from 
the resin. During this step, side-chain protection may also be removed 
depending on the cleavage reagent used.
The common acidic cleavage reagents include HF, 
trifluoromethanesulphonic acid (TFMSA)-thioanisole and TFA. Cleavage 
under effectively neutral conditions may be effected by thiols or photolysis 
(350 nm), as appropriate to the linkage in question. In addition, the use of 
different nucleophiles enables a range of C-terminal functionalised peptides 
to be obtained. Thus, aqueous or alcoholic hydroxide yields the peptide 
acid; alcohols, in the presence of tertiary amines, affords the peptide ester, 
amines, the peptide amides; and hydrazine, the peptide hydrazide. It is 
also possible to use a-amino acid esters to cleave some of these linkages, 
thus adding an extra residue at the C-terminus, or to employ the Na -amino 
group from the same molecule for intra-molecular cyclisations.
Acid cleavages are always carried out in the presence of a carbonium 
ion scavenger such as anisole, to prevent alkylation side reactions. For 
more resistant anchoring bonds and protecting groups, a combined 
"low-high" HF procedure has been developed to provide better product 
purity.47 Thus, using a modified cleavage mixture of HF-dimethyl 
sulphide-p-cresol Oow HF concentration) most of the precursors of harmful 
carbonium ions are removed before the final strong acid step employing HF 
alone. Recently, trimethylsilyl trifluoromethanesulphonate 
(TMSOTQ-thioanisole48 has been found to be an extremely effective 
reagent for the cleavage of a peptidyl-resin linkage and a number of 
protecting groups.
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Side reactions in peptide synthesis often occur as a consequence of the 
cleavage (as explained in a subsequent section). Occasionally, it is 
advantageous to design the synthesis such that cleavage from the resin and 
removal of all or some of the side-chain protecting groups occurs in 
separate steps.
1.1.9. Purification and Characterisation
High performance liquid chromatography, particularly in the reverse 
phase (RPHPLC), has proved to be extremely valuable for the purification 
of peptides, enabling high resolution and effective discrimination of 
impurities. Other useful techniques include ion-exchange chromatography, 
gel permeation chromatography, affinity techniques and counter current 
distribution.
Effective determination of product purity requires elucidation of 
homogeneity in several chromatographic systems. Correct amino acid 
composition upon hydrolysis, consistent with spectroscopic properties, is 
required. Proton n.m.r. is also useful if the peptide is small enough and 
available in sufficient quantities. However, a powerful technique is fast 
atom bombardment (F.A.B.) mass spectrometry, which enables the 
visualisation of molecular ions in excess of 5000 a.m.u., and the 
determination of other sequence information.
1.1.10. Problems and Side Reactions
Problems may arise not only during the solid phase synthesis, but also 
as a consequence of the final cleavage.
At every deprotection/coupling cycle, any errors have a cumulative 
effect, thus it is imperative that each must proceed near-quantitatively. 
Impurities in any amino acid derivatives or in other reagents or solvents, 
which may react with resin bound product, must therefore be removed. It 
has been suggested that incomplete deprotection and coupling reactions 
may be due to inter- or intra-chain interactions. It has recently been found 
that inclusion in the coupling mixture or pre-treatment of the peptidyl-resin 
with solutions of salts known to disrupt peptide structure, gives major 
improvements in coupling efficiency in certain difficult sequences.49 If
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coupling reactions remain incomplete, then chain termination must be 
effected by acetylation. In the case of incomplete deprotections, chain 
growth can later resume and deletion peptides arise, lacking the intervening 
residue. Reversible reactions between the terminal free amine and 
functional groups on the resin may also be problematic. Growing chains 
may also be irreversibly blocked resulting in formation of terminated 
peptides. In addition, premature loss of chains from the resin or late 
initiation of chains onto superfluous functional sites, are further sources of 
cumulative errors.
Another potential cause for concern is racemisation. Although this 
does not appear to occur during normal stepwise synthesis, the activation of 
a Ca -carboxyl group, or esterification of an Na -urethane protected amino 
acid to benzyl alcohol handles or supports, has been reported to result in as 
much as 10% racemisation in some cases.27 The reaction conditions must 
therefore be carefully controlled.
The introduction of certain amino acids may also cause problems 
associated with irreversible modifications or rearrangements.50 For 
example, attempted incorporation of the third amino acid of a sequence 
may result in diketopiperazine formation, since the free Na -amino group of 
the anchored dipeptide can attack the C-terminal carbonyl. Certain 
residues, in particular glycine, are particularly susceptible but generally the 
problem may be controlled. During cleavage, strong acids such as HF and 
TFMS A can promote succinimide formation on removal of benzyl ester 
protecting groups of aspartic acid. Opening of the ring may occur in either 
direction, to give the desired peptide and a side product with the peptide 
chain extending from the P-carboxyl. The N -  O acyl shift at serine and 
threonine is also affected by this acidic treatment, though the process may 
be reversed by pH control. Further problems include intramolecular 
C-alkylation at tyrosine, involving migration of the phenolic protecting 
group, oxidative degradation of tryptophan and tyrosine, and oxidation and 
alkylation of methionine and cysteine.
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1.1.11. Synthetic Achievements
Since the synthesis of the first biologically active peptide, 
bradykinin,51 there has been a multitude of syntheses of naturally occurring 
peptides and their analogues. In Table 1, a few examples are given to 
illustrate the range of biological problems that can be approached by solid 
phase synthesis. Techniques are outlined which may be applied for the 
formation of disulphide bridges, other cyclic systems, and peptides 
containing unnatural residues. It is evident that forty or fewer residues, as 
well as longer sequences, can be reliably assembled. A most interesting 
and recent development is the solid phase synthesis of glycopeptide 
sequences,52 required for elucidating the functions of these biologically 
important compounds.
1.1.12. Conclusions
In summary, since Merrifield’s initial report on solid phase peptide 
synthesis, the field has developed immensely. This is reflected by new, 
milder, orthogonal protection schemes and efficient coupling methods. 
Chemical problems associated with the repetitive stepwise procedure have 
been largely solved by improvements in resins, functionalising procedures, 
anchoring linkages and reaction protocols. Development of more efficient 
cleavage reagents and peptide purification techniques have also been 
significant.
Although automated systems exist, the success of any peptide synthesis 
is governed by the validity of the underlying chemistry. Developing areas 
include use of solid supports for segment condensations, and anchoring of 
amino acids through their side chains to facilitate both mono- and 
bi-directional chain extension. In addition, the simultaneous application of 
both liquid phase and solid phase supports for dual anchoring, and the 
effects of the polymer on solid supported chemical reactions are also of 
interest.
Despite recent advances in molecular biology, solid phase synthesis is 
often the method of choice for the production of peptides. Though the 
underlying mechanisms responsible for the extraordinarily high biological 
potencies of certain peptides remains poorly understood, many attempts 
have been made to determine the essential structural and conformational
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Table 1
Some Peptide and Protein Like Molecules Synthesised by the Solid Phase Method.






side chain to side chain cyclisadon 
performed on resin-bound peptide; 










ammonolysis of standard benzyl 
ester-res in or acidolysis of MB HA 
resins; disulphide formed by oxidation 
of dilute solutions
20 membered ring; formed on resin- 
bound peptide; cleavage by ammonolysis
fully active hormone in 3% isolated 
purified yield, made via Boc-polystyrene 
methodology
made with PAM resin, 12% purified 
yield
prepared both by stepwise assembly, 
and by condensation in aqueous solution 
or protected segments made on the 
solid support
first synthesis of material with nearly 
full enzymatic activity in 3*5% 
isolated purified yield
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features that are required for receptor binding and activity.
1.2. DETERMINATION OF STRUCTURE-CONFORMATION- 
ACTIVITY RELATIONSHIPS
The interaction of a peptide hormone with specific macromolecules is 
thought to cause activation leading to a triggering of physiological activity.
It is clear that the mechanism of peptide hormone action differs from 
that of enzymes; i.e. such hormones do not generally possess an active site 
comprising a few vital amino acid residues. Instead, several discrete 
sequences of adjacent amino acids seem to be responsible for differing 
components of the total biological activity spectrum. Information for 
biological activity may also reside in separate residues of the sequence, 
which are brought into close proximity by conformational adaptation. In 
the cases of insulin and the oxytoxin-vasopressin group of hormones, the 
major function responsible for their biological specificities and potencies 
appears to be the overall conformation.
Efforts to understand the precise structural, conformational and 
dynamic properties of peptides which elicit multiple biological effects are 
at the forefront of modem approaches to develop a rational approach to 
drug design. For this purpose, various methodologies have been applied.
1.2.1. Classical Structure-Activity Studies
Relationships between peptide structure and biological activity can be 
readily determined by performing structure-activity studies, involving 
deletions and/or substitutions of amino acids comprising the primary 
sequence of the peptide. Replacements may be designed to alter particular 
functional groups and any change in potency may indicate the importance 
of the substituted amino acid for activity.
Although these are important preliminary analyses, structure-activity 
studies alone rarely provide insights into the bioactive conformation.
1.2.2. Conformational Studies of Bioactive Molecules
Primary conformational analysis of the native peptide hormone and
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closely related analogues, involves the application of various techniques. 
These have included X-ray crystal structure analyses, nuclear magnetic 
resonance, circular dichroism, infrared spectroscopy and theoretical 
calculations. Such methods have given an insight into the accessible 
conformations and permitted some elaboration of novel rationales for 
analogue design.
Efforts to relate conformation to biological activity have been difficult 
due to a number of inherent limitations. In particular, since most of the 
peptide hormones and neurotransmitters are small linear peptides, they 
have considerable conformational freedom. Cyclic peptides containing 
biologically active sequences are more suitable models where the usual 
flexibility of the peptide chains is reduced. The existence of several 
different conformations has to be taken into account. Conformational 
rigidity will be restricted to certain portions of the molecule and mobility 
inherent in other parts. The extent of conformational homogeneity must be 
established and of all the spectroscopic methods available, high resolution 
n.m.r. has emerged as a particularly powerful technique.
1.2.3. N.M.R. as a Method for Conformational Analysis of Peptides
The conformation of the peptide backbone can be expressed in terms of 
the torsion angles <|>,(p and co, while the side chain can be characterised by 
the angle % (Figure 8).
O 8
Figure 8
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For the purpose of assigning signals to amino acids, the search for 
coupling patterns has been enormously simplified by the use of modem 2-D 
n.m.r. techniques53, such as 1H-1H and 'H -^C  Correlation Spectroscopy 
(COSY). It is possible to obtain sequence information by means of Nuclear 
Overhauser Effects (NOE) through NOE-difference, 2D NOE (NOES Y) 
and Rotating-Frame NOESY (ROESY) experiments.53,54 Some of the 
available techniques for determining conformation are summarised in 
Table 2.
First indications concerning molecular structure are provided by a 
study of the NH shift as a function of solvent and temperature. The 
orientation of amide linkages is generally defined by hydrogen bonding 
(intra- or inter-molecular, or by interaction with the solvent).
Intermolecular hydrogen bonds, and those to the solvent, are readily 
cleaved with increasing temperature. The most meaningful results have 
been obtained in DMSO solution. In this solvent, temperature gradients in 
excess of 3ppb/°C are considered evidence of external NH orientation, 
whereas those under 2ppb/°C point to solvent shielding.
In using *H n.m.r. spectroscopic chemical shifts, anisotropic effects 
from neighbouring carboxyl groups or aromatic side chains may be 
identified as a source of information on molecular geometry. Thus the 
orientation of an a-proton of one amino acid residue in the plane of the 
carboxyl group of the adjacent amino acid leads to a considerable shift to 
lower field.
Homonuclear intramolecular NOEs between protons are caused by a 
dipolar relaxation mechanism, and there is a correlation between the 
enhancement observed and the distance between these protons. In one 
dimensional n.m.r., these effects manifest themselves by changes in signal 
intensity following irradiation at the resonance frequency of the interacting 
nucleus. NOEs can best be detected by application of the modem 2D 
techniques of NOESY and ROESY.
Of interest are 3J  (NH-CaH) coupling constants, which provide 
constraints on the backbone dihedral angle <J>. A 2D n.m.r. method has been 
developed for their accurate measurement.55 A recent report also relates 
the C^-proton chemical shifts to secondary structure in peptides 56
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Table 2
Possible Methods of Determining the Conformation of Peptides by 
N.M.R. Spectroscopy
Cause Observed Spectral Parameter Typical Information
interaction with 
environment
N-H shift as a function of 
solvent, temperature




scalar coupling vicinal coupling 
geminal coupling 
of glycine Ca H













orientation of the 
aromatic side chains






mobility line coalescence processes with relatively 
high barriers
chemical exchange H/D exchange rates extent of exposure 
of NH groups
Conformational Homogeneity in Solution
In general, differences in chemical shifts, coupling constants, and 
temperature dependence between different amino acids in the peptide 
sequence can be used as indications of conformational homogeneity. The 
smaller these differences, the greater the possibility that a rapidly 
established conformational equilibrium will cause an averaging of the 
parameters. The main indications for conformational homogeneity are 
summarised as follows:
strong differentiation of temperature gradients of the NH signals between 
separate amino acids units,
strong differentiation between chemical shifts of like amino acid units, 
large chemical shift differences between geminal diastereotopic glycine 
protons,
strong differentiation between vicinal coupling constants of diastereotopic 
protons,
large differences between NH-Ca H coupling constants.
Conformational information obtained may be supplemented by 
additional means, whether experimental or theoretical. In the latter case, 
molecular dynamics is a particularly useful technique.
Molecular Dynamics and Conformational Energetics
Theoretical methodology, for use in conjunction with experimental 
procedures, may be applied for elucidation of accessible conformations and 
associated flexibility, conformational transitions and dynamics. Molecular 
dynamics and energy minimisation techniques57 make possible a 
description of the conformational properties of the peptide in terms of the 
precise position of atoms, their fluctuations in time, and the inter-atomic 
forces acting on them. Possible active conformations may be identified 
which can be compared to those suggested by independent n.m.r. studies. 
Experimental distances obtained from the n.m.r. experiments may also be 
introduced as NOE constraints, to refine the accessible conformations.
The combination of n.m.r. and molecular modelling may indicate 
particular substitutions that can be performed which may result in further 
conformational restrictions.
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1.2.6. Conformational Restrictions of Biologically Active Peptides
It is necessary to decipher whether the conformations determined in 
solution have any relevance to the conformation in the biologically active 
state. Thus, it is beneficial to minimise such problems by use of 
conformationally constrained analogues.
Conformational restrictions may be introduced58 by local constraints, 
imposed by sterically constrained amino acids. For this purpose, 
a,p-dehydro-, N-methyl-, cyclopropyl-, a,a-dialkyl- and p,p-dialkyl-amino 
acids have been used with considerable success.59 In addition, bicyclic 
and ring contracted analogues may also be formed.
Constraints can also be introduced by incorporation of moieties 
designed to mimic certain conformational features. Recently, a novel 
spirocyclic unit was introduced, by solid phase methodology, as a p-tum 
constraint.60
Thus, these conformationally constrained analogues may be studied by 
a combination of bioassay, n.m.r. spectroscopy, and molecular dynamics to 
identify the important conformational features of the parent peptide.
1.2.7. Conclusion
In summary, n.m.r. spectroscopy is an excellent probe for recognising 
molecular conformations, due to its sensitivity to individual atoms in their 
specific environments. This has been aided by considerable advances in 
2D techniques.
We envisaged that some of the techniques* detailed above may be 
applied in the structure-conformation-activity study of the melanin 
concentrating hormone.
1.3. MELANIN CONCENTRATING HORMONE (MCH)
Many lower vertebrates undergo a change of body colour in response 
to background conditions through dispersion and concentration of melanin 
granules (melanosomes) within integumentary melanophores. It has been
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postulated that these colour changes are exhibited through dual hormone 
control by two mutually antagonistic pituitary melanophorotropic 
hormones.61
It is well known that pigment dispersion, giving rise to skin darkening, 
is regulated through a  and p-melanin stimulating hormone (MSH). Much 
is known about the biosynthesis, structure-activity and control of those 
melanin dispersing hormones, which are derived from the parent 
pro-opiomelanocortin (POMC) molecule, together with the opioid peptide, 
p-endorphin, and other related peptides.
The hormone antagonistic in function to MSH has proved more 
elusive. It was first substantially proven to exist in the pituitary and 
hypothalamus of teleost fish,6 though evidence for existence in amphibia 
was not originally forthcoming. Since the hormone causes a blanching of 
skin colour by effecting aggregation (concentration) of pigmentary 
organelles it was, appropriately, named the melanin concentrating hormone 
(MCH). Melanosome aggregation in response to MCH is reversed by an 
equimolar concentration of a-MSH.
Recent work has confirmed the involvement of a hormone in colour 
change in fish,2 and shown that it is a neuropeptide synthesised by neurones 
in the hypothalamus.7 In the case of fish, it passes in axons to the posterior 
pituitary, where it is released into the circulation to achieve its effect.
The peptide causes melanosome concentration only in fish. In the frog 
(Rana pipiens) and the lizard (Anolis carolinensis), MCH has the opposite 
effect and causes dispersion of melanosomes,3 an action suggested to be 
mediated through MSH receptors. Thus MCH exhibits both melanosome 
concentrating and dispersing actions, depending on the species studied.
MCH bioactivity and immunoreactivity has also been found in the 
brains of higher vertebrates, where the peptide apparently exerts 
physiological effects unrelated to colour change. Thus, it may serve as a 
regulator of pituitary function; in fish it is found to depress release of 
ACIH from the pituitary both in vivo and in vitro; and in rats, it exerts this 
effect in vitro, but only at higher concentration.4 MCH has been found to 
stimulate the release of growth hormone,5 and immunocytochemical studies 
on fish, amphibia and mammals, show that numerous axons protrude from
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the hypothalamic perikarya into other regions of the brain, where the 
hormone presumably exerts a neuromodulatory effect.
Teleost MCH (1) was characterised 7a on isolation in pure form from 
salmon pituitaries, and was effective at nanomolar concentrations in 
stimulating melanosome aggregation in teleost fish.
H-Asp1-rnir-Met-Arg-Cys-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Glu-Val17-OH
(1)
The structures of two kinds of mRNA encoding the salmon MCH have 
been elucidated.62 The MCH heptadecapeptide was present at the carboxyl 
terminus of a putative MCH precursor consisting of over one hundred 
amino acid residues.
1.3.1. Reported Syntheses of MCH
Salmon MCH has been synthesised by both conventional solution and 
solid phase methodologies.
The solution phase synthesis9 proceeded via successive condensation 
of four peptide fragments and the N-terminal amino acid. Following 
cleavage of protecting groups with TFMSA-thioanisole, disulphide bond 
formation was effected by air oxidation.
The first solid phase synthesis of MCH was performed by Wilkes and 
co-workers,10 by application of the Boc-polystyrene methodology.
Cleavage of the peptide from the resin and removal of all side-chain 
protecting groups was accomplished by treatment with HF. Treatment of 
the crude disulphydryl peptide with potassium ferricyanide63 resulted in 
cystine bond formation to yield the purified peptide in 14% overall yield.
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MCH has also been synthesised by the continuous-flow 
Fmoc-polyamide solid phase method.11 The cysteine residues at positions 
5 and 14 were protected as the acetamidomethyl (Acm) derivatives. 
Treatment of the complete peptidyl-resin with TFA furnished the 
fr/s-acetamidomethyl heptadecapeptide. Disulphide bond formation was 
elicited simultaneously with Acm cleavage by treatment with iodine.64
The synthetic products stimulated melanosome aggregation in teleost 
fish in concentrations comparable to the natural hormone.
1.3.2. Comparisons of Structure-Activity Studies
The bioactivities of various MCH fragments have been assessed using 
either synthetic sequences or products of enzymatic cleavage of the natural 
hormone. Collective results from studies by various workers are shown in 
Table 3.
Chemical and enzymatic modifications of MCH were conducted by 
Kawazoe et al8 to deduce the essential amino acid residues for bioactivity. 
When the N-terminal residues were removed by Edman degradation, the 
resulting fragment MCH(5-17) (5) was found to have full activity. 
Carboxypeptidase digestion of MCH gave MCH(1-14) (6) which also 
showed full bioactivity. Indeed, complete potency was also retained in the 
MCH(5-14) (7) fragment. Modification of Trp15 by o-nitrophenylsulphenyl 
chloride to yield [NPS-Trp15]MCH did not alter the potency. Modification 
of Tyr11 by tetranitromethane to form [N02-Tyrn ]MCH caused significant 
reduction of activity. Oxidation of the Met3,6 residues with hydrogen 
peroxide to afford [0-Met3,6]MCH caused partial loss of the activity. 
However, reduction and carboxamidomethylation to form 
[Acm-Cys5,14]MCH resulted in a complete loss of potency. The results 
suggest that the disulphide bridge is essential for activity and that Tyr11 
may be located in the active region.
In studies carried out by Baker et al,12 the derivative [0-Met3,6]MCH 
possessed virtually full bioactivity, greater than that detected by Kawazoe 
et al. The iodinated Tyr11 analogue [I-Tyrn ]MCH had only marginal 
activity, further reflecting the importance of the Tyr11 residue.
Replacement of Met3 and Met6 by norvaline (NVa) or propargylglycine 
(Pra) also resulted in reduction of activity, but not drastically so. The two
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Table 3
Structure Activity Studies of Saimonid MCH'*'
Peptide Baker et a'/a  ^ Kawazoe et al^- Hadley et a l ^
MCH 100 100 100
cyclic MCH(5-17) 100 100
cyclic MCH(1-14) 100 10
cyclic MCH(5-14)
















+ values are the % potencies compared with the native hormone which is taken as 100%
(a) tested on scales from Ctenopharynogodon idellus
(b) tested on scales from Sarotherodon mossambicus
(c) tested on skin from Synbranchus mar moral us
Acm = acetamidomethyl; NPS = onitrophenylsulphenyl; Pra = proparglyglycine; NVa = norvaline
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methionine residues may, therefore, not be crucial for biological activity. 
In contrast to the findings of Kawazoe,8 the [Acm-Cys5,14] linear MCH 
was a full MCH agonist, though with a potency of only 0.3%.
Fragment analogues of the native peptide have also been studied by 
Hadley et al13 in an attempt to decipher the differential structural 
requirements for the MCH- and MSH-like activities. In the fish-skin assay, 
MCH(5-17) (5) was equipotent to MCH but MCH(1-14) (6) and 
MCH(5-14) (7) possessed 10% and 1% activities respectively, this in 
contrast to the findings of Kawazoe.
H-Cys5-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Glu-Val17-OH
(5)




In the MSH frog and lizard skin bioassay, where the abilities of 
analogues to effect melanosome dispersion is studied, the 5-17 and 5-14 
fragments of MCH were inactive, whereas the 1-14 sequence exhibited 
minimal MSH activity. MCH is self-antagonised in a dose-response 
manner by higher concentrations of the peptide, as was the activity of 
MCH(1-14) (6). The results indicate that the N-terminal sequence is 
particularly critical to MSH-like activity, whereas MCH activity is more a 
function of the C-terminal exocyclic residues.
Lebl has studied the MCH-like agonist and antagonist activities of ring
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contracted analogues.14 The disulphide cyclised portion was contracted 
from the 5-14, to the 7-14, 8-14 and 10-14 residues with concomitant 
substitution of alanine for cysteine at position 5. Similar substitutions were 
also made in the 5-17 analogue. Contraction of the ring generally resulted 
in loss of MCH-like activity, further reflecting the importance of the 
disulphide bond. However, some analogues still possessed MSH-like 
activity. These, like a-MSH, also antagonised the actions of MCH on fish 
melanosomes. In common with a-MSH, the antagonist activity of these 
analogues were Ca2+ dependent. The evidence suggests that the 
antagonism of MCH activity is related to the intrinsic MSH-like activity of 
the analogue. This indicates that MCH and a-MSH may be structurally and 
evolutionary related. Indeed, sequence homology between the 
a-MSH(4-10) fragment (8) and MCH (1) is evident, as shown in Figure 9, 
and is supported by the demonstration that immunoreactive MCH and 
a-MSH may co-exist in the same neurosecretory granules within the fish 






The nature and physiological significance of the MCH-like substance 
in the mammalian brain is as yet unreported, though it is currently being 
purified and characterised.153 The low bioactivity of the mammalian 
hormone when tested in the fish melanophore bioassay, and relatively poor 
immunoreactivity with antiserum raised against the fish MCH, suggest that 
the mammalian hormone is structurally different.
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The sequence of rat MCH (9) has recently been determined158 and 



















Like other brain neuropeptides, the ubiquitous distribution of cell 
bodies and fibres showing presence of MCH, indicates a modulating action 
on a variety of functions. Indeed, recent developments have suggested that 
peptides of this size possess more structural integrity than was previously 
thought54,66
1.4. AIMS
It is suggested in the previous discussions, that MCH is a potent 
pituitary regulating hormone. Thus, it is highly desirable to learn more 
about its methods of action since potential applications may involve the 
definition of human receptor sites related to those of fish. The control of 
ACTH and growth hormone may also be in prospect.
Some of the techniques already discussed have been applied in a 
structural and conformation study of MCH, where the syntheses of 
rationally designed analogues were performed by the solid phase 
methodology.
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An initial structure-activity study was required to determine the 
essential structural elements. It is possible to predict accessible 
conformations independently by high field n.m.r. and molecular dynamics 
studies of selected analogues. The results from the theoretical study can 
then be used in conjunction with experimental findings to determine the 
conformational features necessary for binding and activity. These might be 
further probed by the analysis of molecules of restricted conformational 
freedom.
Therefore, such a structure-conformation-activity study may lead to 
some understanding of the receptor site requirements. Indeed the ultimate 
aim is the design of an effective non-peptide agonist or antagonist for 
MCH, since this may prove to be extremely useful in a variety of 
pharmacological and physiological applications.




SYNTHESIS. BIOLOGICAL ACTIVITY AND CONFORMATIONAL
STUDIES
» STAGE 1"
The synthesis of each analogue of MCH (1), required for the preliminary 
structure-conformation-activity study, is considered in the following sections. The 
rationale for each preparation is also discussed.
H-Asp^Thr-Met-Arg-Cys-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Glu-Val^-OH
(1)
2.1. GENERAL SYNTHETIC PROCEDURES
Before considering each synthesis in detail, it is necessary to review 
the common methodologies employed.
2.1.1. Solid Phase Strategy and Tactics
All solid phase assemblies were performed using the continuous-flow 
Fmoc-polyamide method.24
Both the conventional Boc-polystyrene and Fmoc-polyamide 
procedures have been applied in previous syntheses of MCH.10,11 We 
opted for the latter since we considered certain intrinsic features of this 
method to be advantageous.
Use of the base labile Na -Fmoc protecting group in combination with 
both acid labile side-chain protection and peptide-resin linkage agent, 
enables the solid phase synthesis to be earned out under milder conditions 
than in the Boc-polystyrene procedure. This chemical selectivity further 
widens the scope of the method. The use of the polyamide gel support 
allows the polar aprotic solvent, DMF, to freely permeate the medium, 
therefore providing an environment within the polymer matrix which is
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substantially optimised for the chemical processes involved. It has been 
reported30 that a peptide was successfully prepared by employing DMF, 
where synthesis had failed using the less polar medium, DCM. The 
composite polydimethylacrylamide-macroporous kieselguhr support 
permits low pressure, continuous-flow operation. This is advantageous 
since removal of excess reactants is inherently more efficient than with 
batchwise washing. Perhaps more importantly, flow systems offer a greater 
opportunity for analytical control. Continuous spectrophotometric effluent 
monitoring is easily achieved through the high u.v. absorption of certain 
chromophores eg. that of Fmoc derivatives. A summary of the general 
strategy adopted is outlined in Scheme 4.
h o c h 2
Y
Fmoc .NHCHR to.O CH2
Y









(i) Fmoc-amino acid : anhydride /  Pfp ester, Dmap (ii) 20% piperidine-DMF
(iii) Fmoc-amino acid: Pfp ester, HOBt / anhydride /  Dhbt ester
(iv) 20% piperidine-DMF (v) TFA, scavengers.
Scheme 4
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2.1.1.1. Resin Support
Each synthesis was performed using the composite resin allowing 
continuous-flow operation. In almost every case we employed the 
4-hydroxymethylphenoxyacetyl-norleucyl-derivatised 
polydimethylacrylamide-kieselguhr support (10). The handle provides 
lability to 95% TFA to afford the C-terminal carboxylic acid of the peptide 
and to effect removal of the majority of side-chain protecting groups. In 
the main, peptides were required in this form. Alternative handles, 
4-hydroxymethyl-3-methoxyphenoxyacetic acid (11) and 
4-hydroxymethylbenzoic acid (12), provide lability to 1% TFA and amines 
respectively.





uocu2 — v  y —  o c h 2c o 2H h o c h 2 —  '  7 — c o 2h
ch3o
(11) (12)
2.1.1.2. First Residue Attachment
The first residue was incorporated using a 4-fold excess of the 
preformed symmetrical anhydride, or Pfp ester, of the Fmoc-amino acid in 
the presence of DMAP as the effective catalyst.
All Fmoc-amino acid anhydrides were prepared in the traditional 
manner from the corresponding Fmoc-amino acid and DCC in DCM 
solution. In general, filtration and evaporation afforded the crystalline 
anhydride directly, contaminated only with traces of DCU. Some
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anhydrides were observed to precipitate during their formation, but the 
majority remained in solution. Slightly less than the theoretical amount of 
DCC required was employed in order to ensure that no excess should be 
present as a contaminant in the isolated anhydride, since this may 
encourage side-reactions or induce base-catalysed decomposition of the 
anhydride. Each derivative was prepared immediately before use.
Conditions have been established for minimising DMAP-promoted 
racemisation during introduction of the first Fmoc-amino acid.27 To this 
end, it was common practise to add DMAP, as a dilute solution in DMF, to 
the resin after the Fmoc-amino acid derivative. This procedure ensured that 
the two reactants were mixed in the presence of the hydroxy component 
and not beforehand. The converse order of addition has been found to be 
less effective since DMAP had the initial tendency to remain at the top of 
the resin bed. The amount of DMAP used was also minimised and in 
general 0.1 molar equivalents of the amino acid derivative were 
satisfactory.
The method of activation used for the first-residue coupling was found 
to depend on the Fmoc-amino acid involved and is considered in the 
following sections 2.2. and 2.3. In general, two consecutive batches of 
reactants were employed and each recirculated for a certain period. Further 
batches were added as required until satisfactory resin coverage had been 
attained. When incorporating the Fmoc-amino acid via Pfp ester activation, 
recirculation periods of 2 hours or longer were used, the time being 
extended for acylations that proceeded more slowly. For anhydrides, 50 
minute periods were employed, since a longer duration was deemed to be 
ineffective as the anhydride is faster reacting yet somewhat less stable in 
the reaction medium.
2.1.1.3. Quantitative Ninhydrin Colour Test
In most cases the extent of resin esterification was monitored by the 
application of the quantitative ninhydrin colour test.45 Since this is an 
assay for free amino groups, the Fmoc group of the coupled amino acid was 
first cleaved with 20% piperidine-DMF. Reaction of ninhydrin, (13), with 
a primary amine is generally believed to result in generation of the 
chromophore Ruhemann’s purple, (14), (Scheme 5), seen as a blue colour 
in solution.












Under the conditions employed, maximum colour is developed within 
5 minutes and remains stable for a further 10 minutes at 100°C. The 
chromophore has maximum absorbance at 410-570 nm, but the 
determination was carried out at 570 nm because this gave the lowest blank 
absorbance. For routine monitoring, an average effective extinction 
coefficient was recommended45 and used to estimate the level of free 
amine.
There are, however, some inherent inaccuracies with this method. For 
an exact value of the percentage resin esterification it becomes necessary to 
establish the effective extinction coefficient, i.e. colour yield of the 
reaction, for the particular amino acid-resin (or peptidyl-resin) under study. 
Moreover, the formation of the chromophore is dependent on an 
equilibrium reaction (Scheme 5). The position of equilibrium determines 
the amount of chromophore detected in solution and thus inaccuracies may
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be introduced by factors affecting this equilibrium process.
2.1.1.4. Quantitative Fmoc Test
In later syntheses, an alternative procedure to the quantitative 
ninhydrin assay was used, which may prove to be more accurate. The 
adduct formed between dibenzofulvene and piperidine on removal of the 
Fmoc group has a strong u.v. chromophore = 275 nm, emax = 10,700). 
This property was used as the basis of the quantitative Fmoc test to 
determine the amount of protecting group liberated from a sample of 
resin-bound amino acid and hence the level of resin coverage achieved. A 
similar analysis has been carried out by Meienhofer et al.67 From 
calibration studies based on Fmoc-Val, the number of nmol equivalents of 
Fmoc per cm3 of 20% piperidine-DMF was correlated to absorbance units. 
The method was applied to a number of Fmoc-amino acid to resin coupling 
reactions and the results were comparable to those obtained by amino acid 
analysis and the quantitative ninhydrin assay. However, the Fmoc 
determination should be independent of the particular amino acid involved 
and hence more accurate than the ninhydrin test In addition the protecting 
group is cleaved rapidly and quantitatively with no dependence on 
equilibrium processes.
In both methods it is vital to wash the acylated resin thoroughly before 
application of the tests, since contaminants may give rise to misleading 
results.
2.1.1.5. Coupling of the Remaining Amino Acids of the Sequence
>
Once a satisfactory resin coverage has been achieved, the synthesis 
proceeds with the usual cycles of Fmoc cleavage and acylation; all Fmoc 
groups were removed by treatment with 20% piperidine-DMF. A 4-fold 
excess of the Fmoc-amino acid derivative was used in each case and was 
added in the minimum volume of DMF. In general, Pfp esters were 
employed, with added HOBt. Until recently, Fmoc-polyamide syntheses 
used symmetrical anhydrides68 as the activated derivative for the majority 
of Fmoc-amino acids. Although very efficient, the use of anhydrides may 
be considered disadvantageous in that preparation is required for each 
derivative, immediately before use, since they can be somewhat unstable. 
The introduction of Pfp esters of Fmoc-amino acids to the polyamide-based
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solid phase method38 combines the high reaction rates and freedom from 
side reactions characteristic of Fmoc-amino acid anhydrides, with the 
crystallinity and stability on storage of active esters. Though it was our 
experience that Pfp esters with added HOBt are less reactive than 
symmetrical anhydrides, this was only problematic in certain cases, 
particularly attachment of the first Fmoc-amino acid to the resin.
The Pfp esters of Fmoc-Ser(r-Bu) and Fmoc-Thr(r-Bu) are 
exceptionally soluble and have not been obtained in a stable crystalline 
form. Early syntheses involving Fmoc-Thr(r-Bu) employed the anhydride. 
Dhbt esters now provide alternative activated derivatives,39 and were 
subsequently employed for coupling of Fmoc-Thr(f-Bu), and also for 
Fmoc-Arg(Mtr), where the Pfp ester was not commercially available at that 
time. Reaction of Dhbt esters with resin bound amino groups results in the 







appears on the resin during the acylation which fades as the reaction 
proceeds. The yellow colour is attributed to ionisation of (15) by resin 
bound amino groups. Thus the Dhbt ester provides both an effective 
acylating agent and a sensitive indicator of the presence of unreacted 
amines. Reactivity parallels that of the Pfp/HOBt coupling.
2.1.1.6. Side-Chain Protecting Groups
The use of the Fmoc group enables the adoption of the acid labile r-Bu 
group for general amino acid side-chain protection. Thus, aspartic acid and 
glutamic acid were protected as r-Bu esters and threonine and tyrosine as 
f-Bu ethers. The intrinsically acid sensitive side chain of tryptophan was 
left unprotected. For cysteine, either the TFA-stable Acm69 derivative or 
the TFA-labile trityl (Trt)70 thioether were employed, depending on the 
permanence of S-protection required following cleavage of the 
peptidy 1-resin. Use of the Acm derivative allowed purification of the linear
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form. Both derivatives provided opportunity for disulphide bond formation 
simultaneously with protecting group cleavage. At the start of this study, a 
highly acid-labile protecting group for arginine was not available. Our 
search for a suitable candidate yielded only the 
NTl-(4-methoxy-2,3,6-trimethylbenzenesulphonyl) (Mtr) derivative,71 
though this required more vigorous conditions for the final cleavage 
(several hours contact with TFA) than were desirable, particularly when 
more than one arginine residue was present. Conflict with unprotected 
tryptophan was problematic. In most cases this was due to trapping of 
intermediates formed during the final deprotection. It has since come to 
our attention, that a more suitable candidate may be the 
A^-(2,2,5,7,8-pentamethylchroman-6-sulphonyl) (Pmc) derivative723 (16), 
as a TFA-labile protecting group for arginine with much enhanced lability 
over the Mtr group. We are yet to employ this derivative, however, it has 
proved successful in peptide syntheses elsewhere 72 Presence of 
unprotected tryptophan could cause problems in an analogous fashion to 
Mtr deprotection, therefore care must be taken to have scavengers present.
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2.1.1.7. Synthesis Monitoring
The progress of each synthesis was monitored continuously, at 330 nm, 
using a u.v. flow-cell in the reagent stream. An absorbance trace for a 
complete cycle of Fmoc-amino acid anhydride addition and deprotection is 
depicted in Figure 11.






Introduction of the activated Fmoc-amino acid and recirculation 
through the resin produces the characteristic oscillating pattern. Progress 
of the acylation reaction can be followed by differences in the area of 
successive peaks as the Fmoc-amino acid anhydride recirculates through 
the resin bed and by the plateau level after a uniform concentration has 
been reached throughout the system. It is only possible to obtain useful 
quantitative information when using symmetrical anhydrides and in 
couplings other than the first-residue attachment, since the only major u.v. 
absorbing species are the Fmoc-amino acid anhydride and the free acid.
The additional u.v. absorption of DMAP, aryl esters and in particular HOBt 
complicates, and reduces the value of, spectrophotometric monitoring. 
Quantitative monitoring of the deprotection reaction is still feasible. In 
normal operation, consistent areas of successive deprotection peaks 
provides assurance that the synthesis is proceeding smoothly. On certain 
occasions it was observed that the deprotection peaks were not consistent in 
shape. This occurred particularly during removal of the Fmoc group from 
proline, where a lower, broader peak was seen corresponding to a slower 
release of the chromophore into solution, most likely due to a reduced rate 
of cleavage of the Fmoc group in this case.
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Routinc monitoring of the acylation reaction was carried out by 
application of the qualitative ninhydrin colour test for residual free amine.43 
If an incomplete reaction was indicated, then recirculation of reactants was 
continued for a further period until a satisfactory test result was obtained. 
When using preformed symmetrical anhydrides however, a fresh batch of 
reactants was added and recirculated, since there was probably an 
insufficient amount of active anhydride remaining in the previous batch. 
This test is markedly less sensitive for the secondary amine group of 
proline and thus extended coupling periods were employed. When using 
Dhbt esters, the progress of the acylation reaction was further assessed by 
observing the resin. The removal of all excess reactants during the washing 
cycles was shown by the rapid fall in absorbance of the column effluent.
2.1.1.8. Apparatus
All solid phase peptide syntheses were performed on a semi-automatic 
microprocessor-controlled apparatus. The synthetic cycles are detailed in 
the Experimental section. The essential features of a continuous-flow 
synthesiser are shown in Figure 12.
The composite resin is placed in the reaction column(s), where the 
peptide assembly is carried out. The solvent/reagent to be passed through 
the resin is selected by a series of solanoid valves and delivered by a pump. 
Therefore, all chemical processes for Fmoc cleavage, washing, and addition 
of the activated Fmoc-amino acid derivative, are easily mechanised using 
the continuous-flow techniques. Use of the recirculation loop allows 
recycling of reactants through the reaction column, u.v. flow cell and 
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On completion of each assembly, the final Fmoc group was removed to 
afford the peptidyl-resin, which was then subjected to 
cleavage/deprotection. A preliminary small-scale cleavage was performed, 
monitored by analytical RPHPLC, to determine the optimum conditions 
e.g. choice of scavenging agents and reaction time. This is a prerequisite 
for successful syntheses.
A mixture of TFA, ethanedithiol (EDT) and phenol, was found to be 
satisfactory for most peptidyl-resins in this study. The TFA effected 
efficient cleavage of peptide from the resin and the removal of acid labile 
side-chain protecting groups e.g. f-Bu based, Trt and Mtr. The EDT was 
added as a scavenger for cations derived from cleaved protecting groups, 
and for the prevention of irreversible back-addition of the detached peptide 
via methionine and tryptophan to benzyl cations derived from the 
resin-bound linkage agent. Cleavage of the Mtr protecting group requires 
prolonged treatment with TFA, but is enhanced by additives. Thioanisole 
promotes the most rapid removal of Mtr but a purer product was obtained 
using phenol.73 Cleavage/deprotection of peptides containing both arginine
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and tryptophan have been found to be problematic, as will be considered 
subsequently. Purging of the cleavage/deprotection mixture with nitrogen 
before leaving to stand was also found to be advantageous. This appeared 
to minimise the presence of impurities, less retained on RPHPLC compared 
to the product, which were probably due to methionine oxidised peptide.
2.1.1.10. Purification Procedures
All peptide analogues were to be subjected to biological testing. Thus, 
it was imperative that each was rigorously purified. It was common 
practise to subject the crude peptides to preliminary purification by gel 
permeation chromatography. This procedure removes low molecular 
weight impurities, such as those arising from cleaved side-chain protecting 
groups, residual scavengers, and any fragmented peptides. During 
cyclisation reactions polymeric material was also successfully separated 
from the required monomer by this technique. Ion exchange 
chromatography was attempted on some occasions but was found to offer 
no significant improvements over procedures already adopted, with higher 
losses of material resulting. However, preparative RPHPLC was found to 
be an extremely useful technique. Gradients were employed, formed 
between 0.1% TFA in water (solvent A) and 0.1% TFA-CH3CN, 9:1 v/v, 
(solvent B). The high resolution achieved enabled us to separate 
diastereomeric peptides. In general, preparative RPHPLC was employed as 
a final purification, following gel permeation chromatography, although, in 
some cases, it was sufficient as the sole purification technique. All 
columns were washed thoroughly before application of the crude samples.
2.1.1.11. Characterisation and Evaluation of Purity
Each compound was characterised by a combination of analytical 
RPHPLC, t.l.c., amino acid analysis and fast atom bombardment (F.A.B.) 
mass spectrometry. Selected compounds were further evaluated by !H 
n.m.r. and the reader is directed to Section 2.5. for a discussion of these 
studies.
The homogeneity of each product was ascertained by a combination of 
analytical RPHPLC, and t.l.c. in two or more solvent systems, therefore 
using the resolving powers of both reverse-phase and normal-phase 
chromatography. A single symmetrical peak by analytical RPHPLC and a
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single spot by t.l.c. were both required before submitting the compound to 
the biological screen.
Analysis of peptides by F.A.B. mass spectrometry was particularly 
informative, since both molecular weight and structural information could 
be obtained. The molecular protonated ion, (M+H)+, was observed for each 
peptide. In some cases, molecular cationised species resulting from 
addition of Na or K were detected.
For linear peptides, structural information is available from a series of 
ions formed by fragmentation at specific sites along the peptide backbone, 
as indicated in Figure 13.
CcoC ,m Calk
77 77 &  77 ^
& £  P
Nx N2 N3
: H2N +=CHR1 
commonly observed 
N2 : H2N-CHR1-GO + 
common
N3 : [ H2N-CHR1-CONH2 + H ] + 
common
Figure 13
Cleavage may occur in the positions shown, giving rise to ions of the 
structural types indicated. In general, peptide fragmentations can result 
from cleavages of NH-Ca  bond, Ca -CO bond or CO-NH bond. In each 
case the charge can be retained on either the amino or carboxyl terminal 
position of the peptide. There are also fragment ions associated with 
various cleavages of side-chain functionalities. However, not all expected 
fragment ions were seen, and some series predominated over others,
c alk : [ CH2R2-C02H + H ] 
rare
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because of favoured fragmentation and/or better charge stabilisation.
Due to the internal cross-link, only limited fragmentation of cyclic 
peptides occurs. Cleavage to generate ion fragments containing amino 
acids from within the cross-linked portion would require the cleavage of 
two bonds, a process much less favourable than the single bond cleavage.
It is possible to assign ions to the molecular protonated species and to each 
of the fragments which result from sequential losses of amino acid residues 
until the cross-link is encountered. This allows definition of certain amino 
acids from each terminus to the position of cross-linking.
2.1.1.12. Cvclisation Reactions
Many syntheses involved subsequent cyclisation reactions. When 
employing oxidising reagents other than molecular oxygen, the use of a 
nitrogen atmosphere during the cyclisation step was found to suppress 
dimer and oligomer formation. To this end all oxidation processes were 
also performed in dilute solution.
Polymeric material was recycled in some cases. Disulphides were 
customarily reduced with mercaptans e.g. 2-mercaptoethanol. Molar 
excesses of 20- to 1000-fold are used in order to drive the equilibrium 
reaction toward the desired products (Scheme 6). Simple organic 
disulphides may be reduced by derivatives of trivalent phosphorus. In 
particular, tri-/i-butylphosphine is a potent and specific reducing agent for 
disulphides, with a non-equilibrium behaviour.74
R^S-S-R2 + (R3-SH)n ^  >  R!SH + HS-R2 + R3-S-S-R3 + (R3-SH)n_2
Scheme 6
The majority of cyclisation reactions were monitored by a quantitative 
thiol test. This procedure involved the use of Ellman’s reagent,75 
5,5'-dithio£/s-(2-nitrobenzoic acid), which in aqueous solution at pH 8 
reacts with free thiol to form a highly yellow-coloured anion Figure 14. 
Therefore, the initial extent of removal of S-protecting groups and 
subsequent disappearance of free sulphydryls on cyclisation could be 
assessed.
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Figure 14
The integrity of the cystine bond is further confirmed by F.A.B. mass 
spectrometry. It is important that a thiol matrix is not used since this has 
been observed to cause reduction of the disulphide.
Having outlined the general procedures applied, the syntheses of linear 
and cyclic analogues of MCH, prepared for "Stage 1" of our study, will be 
considered in detail.
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2.2 SYNTHESES OF LINEAR ANALOGUES OF MCH
The following discussion is concerned with the preparation of linear 
analogues of MCH.
2.2.1. Sequential Fragments of MCH (1)
To commence the synthetic and structure-activity studies of MCH (1), a 
series of sequential fragments (17)-(31) were prepared, as shown in Figure 





[Acm-Cys14] linear MCH(14-17) (18)
[Acm-Cys14] linear MCH( 13-17) (19)
[Acm-Cys14] linear MCH( 12-17) (20)
[Acm-Cys14] linear MCH(11-17) (21)
[Acm-Cys14] linear MCH(10-17) (22)
[Acm-Cys14] linear MCH(9-17) (23)
[Acm-Cys14] linear MCH(8-17) (24)
[Acm-Cys14] linear MCH(7-17) (25)
[Acm-Cys14] linear MCH(6-17) (26)
[Acm-Cys5*14] linear MCH(5-17) (27)
[Acm-Cys5*14] linear MCH(4-17) (28)
[Acm-Cys5’14] linear MCH(3-17) (29)
[Acm-Cys5’14] linear MCH(2-17) (30)
[Acm-Cys5,14] linear MCH (31)
Figure 15
analogues which show increased potency compared to the precursor, due to 
the addition of the next amino acid of the sequence. This could indicate the 
importance of that amino acid for activity. Moreover, such a study may 
highlight synthetic problems which could be encountered in future work.
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The syntheses proceeded relatively smoothly. Valine, the first amino 
acid of the sequence, was introduced by the usual two batch coupling 
procedure, employing the active ester derivative Fmoc-Val-OPfp (with the 
normal amount of DMAP), for 4 h and 15 h respectively. For these initial 
syntheses, neither the quantitative ninhydrin colour test or the quantitative 
Fmoc determination had been fully developed in our hands. Thus, no 
quantification of the extent of resin acylation was obtained, and the 
synthesis proceeded in the customary manner, adding each Fmoc-amino 
acid derivative until the complete MCH sequence had been assembled. 
After each deprotection stage from the tripeptide (17) onwards, a portion of 
the peptidyl-resin was removed to isolate each fragment of the series. 
Fmoc-amino acids were introduced using the Pfp ester derivative except in 
the case of Fmoc-Arg(Mtr) and Fmoc-Thr(r-Bu) where the Dhbt ester was 
employed. The Acm protecting group was used for the cysteine residue. 
Each coupling was complete after the normal 25 min period, except for 
Pro13 (120 min), Arg9 (100 min) and Cys5 (120 min).
A modified cleavage/deprotection procedure was used for the 
peptidyl-resins of compounds (17) - (19), where a mixture of anisole and 
EDT was found to be the most effective in scavenging for tryptophan, with 
a period of only 2 h required to cleave the peptide from the resin and 
remove the O-r-Bu protecting group from the glutamic acid residue.
Cleavage/deprotection of the peptidyl-resin samples of compounds 
(20) - (31) was carried out following the usual protocol, a period of 7 h 
being the optimum in each case. It was found that removal of the Mtr 
protecting groups did not appear to be entirely complete after the 7 h period 
(as indicated by analytical RPHPLC), and it appeared that longer periods 
were required as the number of Arg(Mtr) residues increased. However, if 
cleavage/deprotection was allowed to proceed for extended periods, then 
formation of a by-product occurred, to the detriment of the fully 
deprotected peptide. In each case, the by-product was more retained on 
RPHPLC compared to the desired product. A similar observation was made 
by Eberle and co-workers11 during their synthesis of MCH. Using identical 
protecting groups to those employed in our case, the MCH peptidyl-resin 
was treated with TFA in the presence of anisole and EDT for 5 h. The 
crude material obtained after cleavage was found to contain a contaminant 
possessing anomalous u.v. absorption, which was thought to be a
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by-product of cleavage of the Mtr protecting group and/or containing a 
modified tryptophan residue.
After work-up, the yield of each crude peptide was uniformly low. 
Purification was carried out successfully by preparative RPHPLC alone, to 
afford pure samples of each compound (17)-(31), in yields varying from 
14-26%. It is our opinion that these poor yields are due to low resin 
coverage on the initial esterification reaction with valine, despite 
employing extended coupling periods. Difficulties in acylation reactions 
involving this sterically hindered amino acid have been reported many 
times in the literature. It has since been shown that the esterification 
proceeds in higher yield when the more reactive symmetrical anhydride of 
Fmoc-Val is employed (see Section 2.2.4.1.).
2.2.2. rAcm-Cvss>14.Phe11l linear MCH (32)
Modification of the Tyr11 residue of MCH results in reduced activity, 
as both [N02-Tyrn ]MCH8 and [I-Tyrn ]MCH12 had lower potencies 
compared to the parent peptide; thus emphasising the importance of this 
residue. This finding prompted our synthesis of [Acm-Cys5,14J>he11] linear 
MCH (32), where the Tyr11 residue is substituted by Phe to test the effect 
on activity of the absence of the phenolic OH. A similar substitution was 
carried out in a structure-activity study of oxytocin.**3
The analogue (32) was prepared in a parallel synthesis with that of the 
compounds (17)-(31) (as considered earlier in section 2.2.1.), by the 
addition of Fmoc-Phe-OPfp in place of Fmoc-Tyr(f-B u)-OPfp at the 
appropriate point. A normal coupling time ensued and 
cleavage/deprotection of the peptidyl-resin proceeded as usual with an 
optimum period of 7 h. Purification of the crude peptide was carried out by 
preparative RPHPLC, using 10 p. microparticulate porous silica packing, as 
opposed to the usual 5 \i particle size, with the intention of improving 
product yield. However, the yield was again disappointing at only 14%.
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2.2.3.
2.2.4.
[Acm-Cys141 linear MCH(9-14) (33) and 
[Acm-Cys14] linear MCH(10-14) (34)
The importance of the Tyr11 residue has already been implied. It is 
also a possibility that the residues in the region of Tyr11 may be important 
for molecular activity. Thus, the fragments [Acm-Cys14] linear 
MCH(9-14) (33) and [Acm-Cys14] linear MCH(10-14) (34) containing 





Synthesis was carried out in the usual manner, by employing the
customary protecting groups, with Cys14 protected as the Acm derivative.
Hence pure samples of each compound (33) and (34) were obtained for the ♦
biological assay.
Linear MCH(l-4,15-17) (35) and linear MCH(l-4. Aha,15-17) (36)
To our knowledge, no structure-activity study has yet been carried out 
on the exocyclic fragments of MCH alone. We were therefore interested in 
gaining some understanding of their importance for activity/binding.
The C-terminal tripeptide, linear MCH(15-17) (17), has already been 
prepared and we next turned our attention to the syntheses of the joined 
N-terminal and C-terminal exocyclic sequences, linear MCH(1-4,15-17) 
(35) and linear MCH(l-4,Aha, 15-17) (36).
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however, the inserted Aha unit (7-aminoheptanoic acid, -NH-(CH2)6-CO-) 
spaces the terminal sequences at the same calculated distance apart as in 
the native peptide (Figure 16).
»A|W
c o  n h
(CH2)4 -  '""'•’ccr
Aha unit
Figure 16
2.2.4.1. Linear MCH(1-4,15-17) (35)
The synthesis proceeded relatively smoothly. The first Fmoc-amino 
acid to be coupled to the resin was valine. Experience gained in the 
synthesis of the sequential linear fragments, (17)-(31) and (32), had 
indicated that use of the symmetrical anhydride of Fmoc-Val, as opposed to 
the Pfp ester, may result in higher resin coverage. Thus, two batches of the 
freshly prepared Fmoc-Val anhydride were employed and each recirculated 
for 50 minutes. The quantitative ninhydrin colour test indicated that the 
esterification reaction had proceeded in 91% yield. Therefore, it appears
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that the symmetrical anhydride is the acylating reagent of choice for direct 
attachment of Fmoc-Val to the resin. Low coverage resulted even after 
periods of 4 h and 15 h when using the Pfp ester.
When coupling Fmoc-Arg(Mtr), as its pre-formed anhydride, the 
qualitative Kaiser test indicated that the acylation reaction was incomplete 
even after a 50 minute recirculation period. It is thought that the anhydride 
of this side-chain protected derivative is unstable,76 and does not persist in 
the reaction medium long enough when the acylation becomes sluggish for 
steric or other reasons. However, complete acylation was achieved after 
the addition and recirculation (50 min) of a fresh batch of Fmoc-Arg(Mtr) 
anhydride.
Cleavage/deprotection was carried out in the customary manner with 
an optimum period of 7 h. The crude peptide was obtained in good yield 
(89%), hence validating the use of Fmoc-Val anhydride for the initial 
esterification reaction with the resin bound active sites. Following the 
usual purification procedures, the pure peptide was obtained in 33% yield.
2.2.4.2. Linear MCH(l-4,Aha,15-17) (36)
In order to incorporate the Aha unit it was necessary to synthesise a 
derivative that was suitably functionalised for use in solid phase assembly. 
Thus the compound pentafluorophenyl
Va -(9-fluorenylmethyloxycarbonyl)-7-aminoheptanoate (37) was targeted. 
Preparation was carried out in three steps according to Scheme 7.
The hydrochloride salt of 7-aminoheptanoic acid (38) was first 
obtained by the acid catalysed hydrolysis of 2-azacyclooctanone. 
Neutralisation of (38) with aqueous Na2CC>3 was followed by formation of 
the Fmoc derivative (39) by reaction with 9-fluorenylmethyl 
chloroformate77 in the presence of aqueous Na2C03. The product was 
observed to precipitate out in the reaction mixture. Spectroscopic data 
indicated that the Fmoc group had been successfully incorporated, though 
the carboxylic acid proton of (39) remained undetected by n.m.r. in 
DMSO. Literature precedents validate the use of alternative reagents to 
introduce the Fmoc functionality since 9-fluorenylmethyl chloroformate 
has been shown to afford the product accompanied by the undesired, 
presumably mixed anhydride mediated, formation of significant amounts
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(i) 2N HC1, reflux, 1.5 h (ii) 10% aq. Na2CC>3 , dioxan (iii) Fmoc-Cl, dioxan ; 0°C, 1 h ; 
RT, 18 h Civ) Pfp-OH, DCC , DMF-EtOAc; 0°C , 1 h ; RT, 1 h
(3-20%) of Fmoc-dipeptide.78 The application of 9-fluorenylmethyl 
carbonoazidate78a and mixed carbonates785 have been suggested as 
side-reaction-free alternatives. In our case however, 9-fluorenylmethyl 
chloroformate performed satisfactorily since formation of Fmoc-dipeptide 
could not be detected by chromatographic or spectroscopic means.
The Pfp ester derivative (37) was formed following the procedure of 
Kisfaludy et al,79 by the addition of pentafluorophenol and DCC as the 
activating species. In this reaction it was imperative that DMF used in the 
solvent system was freshly distilled to remove unwanted dimethylamine 
which could cause undesired cleavage of the Fmoc group. Since C-F 
carbons of the Pfp group are strongly coupled in 13C n.m.r. spectroscopy, a 
semi-quantitative comparison with a sample of Fmoc-Leu-OPfp, by 19F 
n.m.r., was used to show the Pfp group to be present as required. In 




It is interesting to note that Fmoc-amino acid pentafluorophenyl esters 
can be prepared by a double utilisation of mixed carbonates. A useful 
reagent is 9-fluorenylmethyl pentafluorophenyl carbonate80 (40), which 
effects efficient side-reaction-free-introduction of the Fmoc protecting 
group and subsequent preparation of the Pfp derivative.
o
(40)
Having successfully synthesised Fmoc-Aha-OPfp (37), the synthesis of 
linear MCH(l-4,Aha,15-17) (36) was performed in parallel with that of 
linear MCH(l-4,15-17) (35). Fmoc-Aha-OPfp was added at the 
appropriate point and successful acylation of Trp15 was achieved after the 
standard 25 min period. However, deprotection of the Aha amino group 
did not take place during the usual ten min reaction time, as no deprotection 
peak was seen and in addition, the Kaiser test showed no development of 
the blue colour characteristic of free amine. Exposure to 20% 
piperidine-DMF for 15 h was required to achieve cleavage. There is no 
obvious explanation for this phenomenon of reduced rate of cleavage. It is 
possible however that intra-chain and/or inter-chain interactions may have 
occurred. Removal of all the subsequent Fmoc-groups was normal.
As discussed earlier in relation to the cleavage/deprotection of the 
peptidyl-resin of compounds (17)-(31), a cleavage period longer than the 
stipulated 7 h resulted in the formation of a by-product. During a trial 
cleavage of the peptidyl-resin of (36), the reaction was allowed to proceed 
for an extended 36 h period, after which time two peaks, (I) and (II), of 
approximately equal heights were detected as shown in Figure 17.
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Absorbance
(214 nm)
2 0  1 5  1 0  5  0
Time (min)
Synthesis of (36) : analytical RPHPLC of the crude product following 
prolonged cleavage / deprotection . showing the desired peptide peak 
(I) , and the by-product peak (II) .
Figure 17
The observed peak (I) was thought to be due to the desired product and 
peak (II) to the by-product. It was our intention to identify this by-product 
and to this end it was isolated by preparative RPHPLC and analysed by 
mass spectrometry (F.A.B.). No separation was effected by the preceeding 
gel permeation chromatography. A major fragment at m/z 1237 was 
detected.
One possibility considered in the case of compounds (17)-(31) was that 
the by-product could be an analogue in which tryptophan has been 
modified by the cleaved Mtr group (41). However, we could suggest no 
such
analogue that would fit the mass spectrometry finding. It came to our 
attention that Sieber81 had carried out studies on the effect of scavengers on 
the modification of tryptophan residues during acidolysis of Mtr groups. 
The formation of the lipophilic by-product (41) was found to occur on 
treatment of a model peptide with TFA-H20 , but was minimised by the 
addition of EDT. However, if the cleavage was left in the presence of this 
scavenger for extended periods then a dithioketal product (42) was formed, 
which was ultimately the sole product. Thus, it appears that the by-product 
obtained in our synthesis could be attributed to an analogue where 
tryptophan has been modified in this fashion during the prolonged cleavage 
period. Such a by-product would give rise to an (M+H)+ peak at m/z 1237, 
as we observed.
Removal of the Mtr group from arginine in the presence of the 
sensitive tryptophan residue is therefore problematic, where Mtr requires 
more vigorous conditions for cleavage compared to the other acid-labile 
protecting groups employed. The nature and extent of tryptophan 
modification is dependent on the scavengers used and the length of the 
reaction period, thus these factors would have affected the type of 
by-products observed in the syntheses of (17)-(31) and (32).
(42)
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Our experiment has therefore confirmed that it is imperative to perform 
trial cleavages and to keep the reaction time to a minimum in the presence 
of sensitive residues. Hence we were able to obtain the desired product 
successfully, adopting a 7 h optimum cleavage period, with the normal 
cleavage/deprotection mixture. Pure material was obtained in 39% yield 
with the presence of the spacer unit readily confirmed by F.A.B. mass 
spectrometry, m/z 1064 (M+H)+.
2.2.5. fAcm-Cvs5’14! linear MCH(5-14) (43)
Having completed syntheses of exocyclic fragments of MCH, a study 
of the substructural unit comprising residues 5-14 of the cyclic portion of 
the peptide was undertaken. The disulphide ring-closed fragment has been 
prepared and will be considered subsequently, however, the linear form 
was also of interest. A comparison of the relative potencies of each 
derivative may give an indication of the importance of the disulphide bond 
for activity.
The fragment [Acm-Cys5,14] linear MCH(5-14) (43) was thus targeted, 
where the cysteine residues were permanently protected as the Acm 
derivatives. Synthesis was attempted following the usual procedures. For 
attachment of the first residue, cysteine, to the resin, the preformed 
symmetrical anhydride procedure was adopted, using the normal amount of 
DMAP. Fmoc-Cys(Acm) anhydride was therefore prepared and was seen 
to precipitate during its formation. The synthesis then appeared to proceed 
in a satisfactory manner.
H-Cys5(Acm)-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys14(Acm)-OH
(43)
The peptide does not possess a tryptophan residue and thus 
cleavage/deprotection of the peptidyl-resin was not accompanied by the 
associated side-product formation. The reaction could be allowed to 
proceed for longer periods with an optimum time of 15 h. However, to our 
dismay, analysis of the crude product by RPHPLC revealed two 
overlapping peaks in an approximate 2:1 ratio (Figure 18). These 
remained unseparated following gel permeation chromatography and thus
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Figure 18
small amounts of each component were isolated by preparative RPHPLC. 
Identical mass spectra (F.A.B.) analyses, compatible with the expected 
product, were obtained in each case and it is postulated therefore that the 
two compounds are diastereomers.
*
The mixture was later cyclised and the two products separated by 
preparative RPHPLC. They were indistinguishable by amino acid analysis 
and F.A.B. mass spectrometry and a comparison of their *H n.m.r. spectra 







Epimerisation of urethane-protected amino acids by DMAP was shown 
to be a significant side reaction during attachment of the first amino acid to 
the resin.27 Therefore, it appears that racemisation of Cys14 has occurred 
during this process where the coupling was carried out in the presence of 
DMAP, known to induce racemisation by proton abstraction.
Amino acids such as cysteine, with electronegative substituents in the 
p-position, are particularly prone to racemisation, where the lability of the 
Ca  proton is enhanced by inductive stabilisation of the resulting anion.
Two different mechanisms can be envisaged for this process and are 
outlined in Scheme 8. One route (a) is via p-elimination-readdition of the 
side chain.82 The second route (b) is by direct abstraction of the a-proton, 
without elimination, known as the isoracemisation or "conducted tour" 
mechanism proposed by Kovacs.83 Moreover, contrary to long held beliefs, 
oxazolone formation and hence racemisation of urethane protected a-amino 
acids is indeed possible.84
It is important to add DMAP to the resin after the addition of the 
Fmoc-amino acid derivative, during attachment of the first residue, in order 
to minimise racemisation. In addition, shortening of the coupling time, and 
particularly reducing the amount of DMAP added, were found by Atherton 
et al27 to be important strategies. Moreover, these workers showed there 
was no evidence for racemisation of the resin-bound species when an active 
ester coupling was employed (under the same conditions used for the 
symmetrical anhydride).
-64-
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In our subsequent attempt to obtain the unracemised product (43) we 
used only 0.025 molar equivalents of DMAP, and the usual anhydride 
method was replaced by a double Pfp ester couple, each of 4 h duration. 
The synthesis then proceeded in the customary manner having achieved 
satisfactory acylation of the resin. All couplings except that of Arg9 (50 
min) were complete after the customary 25 min period. 
Cleavage/deprotection, with an optimum period of 15 h, furnished the 
crude material which now gave rise to virtually a single peak on analytical 
RPHPLC. Thus, it appears that no detectable racemisation has occurred and 
hence procedures adopted to obtain the single diastereomer have been 
successful. Following purification, the homogeneous product 
[Acm-Cys5,14] linear MCH(5-14) (43) was obtained in 69% yield.
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Although racemisation of urethane-protected amino acid derivatives 
may not be a significant problem in the normal processes of solution or 
solid phase peptide synthesis, serious consideration should be made in 
special circumstances, particularly when using basic catalysts, as in 
attachment of the first residue to the resin. Racemisation may be 
circumvented by employing one of the available methods for first residue 
attachment where the use of DMAP is avoided. Slight racemisation is less 
problematic provided that the single unwanted diastereomer can be 
separated.
2.2.6. rAcm-Cvss>14J>hen ] linear MCH(5-14) (45)
To further test the importance of the Tyr11 residue, the Phe analogue of 
(43), [Acm-Cys5’14,Phen ] linear MCH(5-14) (45) was prepared. Synthesis 
was carried out in parallel with that of (43), substituting Fmoc-Phe-OPfp 
(coupling time 25 min) for Fmoc-Tyr(r-Bu)-OPfp at the appropriate point. 
Following cleavage/deprotection (optimum period 15 h), and subsequent 
purification, the homogeneous product was obtained in 65% yield.
2.3. SYNTHESES OF CYCLIC ANALOGUES OF MCH
Having accomplished the preparation of various linear fragments of 
MCH, attention was turned to the syntheses of cyclic analogues. Such 
compounds are inherently of interest, due to their limited conformational 
freedom.
2.3.1. *fAcm-Cvs5,14l cyclic MCH(5-14) 146)
As part of our investigation into the importance of the disulphide bond 
for activity, an analogue comprising the residues 5-14 of the ring portion 
was required, where cyclisation is effected by a bond other than disulphide. 
The homodectic peptide [Acm-Cys5,14] cyclic MCH(5-14) (46), where ring 
closure was achieved via an amide bond between the two Acm protected 
C y s5’14 residues, was targeted.
Studies of the importance of the disulphide group for biological 
activity in other hormones have been carried out, where various carba- 
analogues of hormones which ordinarily contain a disulphide bridge (e.g.
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Cys5(Acm)-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys14(Acm)
(46)
oxytoxin), were synthesised.85 The final cyclisation was effected via an 
amide bond, for which various methods are available, generally based on 
the well known coupling protocols of peptide synthesis e.g. the azide, 
mixed anhydride, active ester and DCC procedures.
It was found that diphenylphosphoryl azide,40* with added HOBt,
provided efficient activation for ring closure. The cyclisation was
accomplished in high yield (42%), both with prior or subsequent, side-chain
deprotection. In the latter case the synthesis was performed using the
4-hydroxymethyl-3-methoxyphenoxyacetic acid handle (11), providing
lability of the peptide-resin linkage to 1% TFA. This yielded the fully
protected peptide with a C-terminal caboxylic acid. The reaction may
involve (a) acyl azide formation in situ, but also seems likely to proceed via
(b) mixed diphenylphosphinic or (c) symmetrical anhydrides. Moreover,
the added HOBt may not only be effective in reducing racemisation, but
could also be involved in the reaction by formation of the HOBt ester. The
*
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2.3.2. Cyclic MCH(5-14) (7)
Having synthesised the linear and amide cyclised compounds 
containing only residues of the ring portion of MCH, we turned our 
attention to the preparation of cyclic MCH(5-14) (7), where cyclisation is 
achieved by a disulphide bond, as in the native molecule. These three 
analogues were required in order that a complete study could be carried out 
on both the importance of the 5-14 subunit and the cystine bridge for




In attempts to synthesise (7), various methods for disulphide bond 
formation were tried, in order to find a suitable procedure that could also be 
readily applied in future syntheses of other cyclic analogues. Reactions 
were carried out on the corresponding linear compound where both the 
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Scheme 11
2.3.2.1. Iodine Mediated Oxidation of the TAcm-Cvs5,14! Protected Peptide
The analogue [Acm-Cys5,14] linear MCH(5-14) (43) was already in 
hand, thus deprotection and simultaneous disulphide bond formation was 
attempted by treatment with iodine.64
The reaction was carried out following essentially the same procedure 
as that described by Minamitake et al.86 The solvent of choice was 90% 
aqueous acetic acid solution. Studies carried out by Kamber87 indicated 
favourable rates in aqueous acetic acid solution, where the addition of 
water enhances the reaction. Dilute hydrochloric acid was added in an 
attempt to safeguard against iodination of tyrosine, though this is 
considered to be much less severe in the solvent system adopted. It is still 
necessary however to keep the reaction time as short as possible. Excess 
iodine (50 equivalents in 90% aqueous acetic acid) was employed, to which 
the peptide solution was added. It has been suggested that the reverse 
mode of addition may result in larger quantities of polymeric material.
Following a 30 minute reaction period, excess iodine was extracted 
with carbon tetrachloride, but following lyophilisation, traces of iodine still 
remained which were quenched by the addition of aqueous ascorbic acid. 
Purification was attempted by ion exchange chromatography, since this 
may enable efficient separation of any remaining Acm protected peptide 
from the desired product. However, only non-volatile buffers and a salt 
gradient were effective in eluting peptidic material, and subsequent 
desalting methods proved unsuccessful. The usual purification procedures
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of gel permeation chromatography, followed by preparative RPHPLC, were 
employed. The product obtained was shown by F.A.B. mass spectrometry 
to correspond to [O-Met6] cyclic MCH(5-14) (47), where methionine has 
been oxidised to the corresponding sulphoxide. There was no evidence for 
Acm protected peptide. It should be noted that a combination of 
ammonium iodide and dimethyl sulphide in TFA has been found to be 
effective in reduction of methionine sulphoxide to methionine, without 
affecting the cystine bond.88
The undesired oxidation of methionine could be suppressed by 
performing the reaction under nitrogen, in purged solutions, with addition 
of methionine as a scavenger. Isolation of the product from this system 
was difficult, particularly in the separation of peptide from involatile salts, 
and recovered amounts of pure product never exceeded 6% yield. 
Alternative methods for disulphide bond formation were therefore 
investigated. In later syntheses of other analogues, we have found iodine 
oxidation to proceed successfully using a slightly modified procedure.
2.3.2.2. Cleavage of Acm Protecting Groups with Mercuric Acetate
Heavy metal salts e.g. of silver and mercury, have been used to remove 
the Acm protecting group. This method is of value because reaction 
conditions are mild. The formation of disulphide is then accomplished in a 
separate oxidation step.
Cleavage of the Acm protecting group from [Acm-Cys5,14] linear 
MCH(5-14) (43) was effected by exposure to aqueous mercuric acetate 
solution at pH 4 for 4 h.89 The cleavage proceeds more slowly both above 
and below pH 4; at higher pH mercuric ion is precipitated as HgO. The 
reaction was carried out under nitrogen to prevent oxidation of methionine 
and premature disulphide formation. Monitoring by analytical RPHPLC, at 
hourly intervals, showed an initial peak (I), due to the starting material, 
which diminished with time as a broad peak (II), corresponding to the 
mercuric salt of the peptide, appeared (as illustrated in Figure 19). After 4 
h, only the product peak was evident. Removal of Hg2+ was accomplished 
by addition of hydrogen sulphide. Scrupulous removal of excess H2S, by a 
nitrogen purge, was subsequently required to prevent the formation of
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Figure 19
S-sulphonates resulting from the oxidation of H2S to S02- Having removed 
the precipitated mercuric sulphide, treatment with 2-mercaptoethanol-acetic 
acid ensured total removal of Hg2+ and reduction of any preformed 
disulphide. Gel permeation chromatography was performed under nitrogen 
in presence of the reducing agent. The crude dihydro peptide was isolated 
in 44% yield. A portion of the crude material was rapidly purified by 
preparative RPHPLC. The assay using Ellman’s reagent determined a 61% 
yield of free thiol groups.
Mercuric acetate was therefore successful in causing cleavage of the 
Acm protecting groups. The reaction was readily monitored by analytical 
RPHPLC, unlike in the iodine oxidation method. However, low yield of 
product was again problematic. Some losses may have occurred by 
adsorption of the peptide on mercuric sulphide. Alternatively, treatment 
with excess 2-mercaptoethanol and removal of mercurimercaptoethanol by 
gel permeation may be the method of choice.
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The crude dihydro peptide was used without further purification in the 
following cyclisation reactions, mediated by (a) aeration, and (b) potassium 
ferricyanide.
(a) Air Oxidation
Molecular oxygen90 has been used to synthesise disulphide-cyclised 
peptides from the corresponding disulphydryl compound in dilute aqueous 
solutions. Steps can be taken to minimise the production of polymeric 
material. The solution should be degassed by a nitrogen purge before 
leaving to stand. The reaction is best carried out in a conical flask such that 
the surface area in contact with the atmosphere is minimised. These 
precautions allow the slow diffusion of oxygen through the system and 
hence favour the production of monomer over dimer and oligomer.
The crude dihydro peptide, linear MCH(5-14) (48), was thus subjected 
to air oxidation in degassed, neutral buffered water in a narrow necked 
flask open to the atmosphere for 15 h at RT. During this period a small 
amount of precipitate developed, presumably polymeric material. 
Following confirmation of the absence of free sulphydryls, the crude 
material was purified to yield the desired product (7) in only 21% yield 
(from the crude disulphydryl peptide). Gel permeation chromatography 
had indicated a relatively large quantity of polymeric material to be 
present.
(b) Potassium Ferricyanide Oxidation
Formation of intra-molecular disulphide bonds from sulphydryl group 
containing peptides can be accomplished in dilute, neutral solutions, by 
potassium ferricyanide. This oxidising agent has proved to be effective in 
the preparation of the cystine bond of MCH,10 and related analogues, from 
the corresponding dihydro peptides. Potassium ferricyanide does not 
appear to oxidise thiols beyond the disulphide stage or to affect the 
phenolic function of tyrosine.
Thus the crude dihydro peptide, linear MCH(5-14) (48), as a dilute 
aqueous solution in degassed, neutral buffer, was treated with an aqueous 
solution of potassium ferricyanide. The "end-point” of the reaction is 
indicated by a permanent yellow colour of the solution due to the presence
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of excess ferricyanide reagent. However, since a faint yellow colour 
appeared in the solution after the addition of only a small portion of the 
theoretical amount of ferricyanide required, a small excess (10%) of the 
reagent was employed to ensure complete absence of traces of thiol. 
Work-up proceeded after a 2 h reaction period and following purification, a 
product homogeneous to that from the air oxidation process was obtained in 
22% yield (from the crude disulphydryl peptide). A large portion of 
polymeric material was again separated by gel permeation chromatography.
Our results indicate that both air and ferricyanide are effective in 
causing oxidative ring closure. The yield of product from each process was 
very similar (ca. 22%). However, the reaction is faster when using 
ferricyanide, the more potent oxidising agent, though formation of 
polymeric material is more likely. It is vital that the ferricyanide reaction is 
performed under nitrogen in order to suppress the production of dimer and 
oligomer.
The yield of cyclised product from the Cys(Acm) protected peptide 
was disappointing in each case, being ca. 9%. It is our perception that some 
losses have occurred by adsorption of the peptide onto mercuric sulphide. 
Moreover, it is likely that premature disulphide bond formation has 
occurred during handling, before the controlled oxidation processes were 
employed. This resulted in production of the polymeric by-product as was 
detected by gel permeation chromatography. It has been found that the 
linear dihydro peptide (48) polymerises on standing. The oxidation step 
must therefore be employed as soon as this compound is isolated.
2.3.2.3. Acidolytic Treatment of rTrt-Cvs5,141-Peptidyl Resin followed by Air 
Oxidation
Our previous attempts at the synthesis of cyclic MCH(5-14) (7) have 
been successful, yet yields have remained low. An alternative method was 
still desirable and to this end a relatively simplistic approach was adopted, 
where cysteine protecting groups were more conveniently removed 
(Scheme 11).
The S-Trt group in both cysteine and cysteine peptides is readily 
cleaved at RT by TFA.70 Thus, we employed Trt protected cysteines in the 
synthesis, such that the trityl groups could be removed during TFA
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mediated cleavage/deprotection of the peptidyl-resin. Oxidation by 
aeration or ferricyanide of the disulphydryl peptide obtained should provide 
an accessible route to (7).
The [Trt-Cys5,14]-peptidyl-resin was therefore required. In order to 
suppress racemisation, Fmoc-Cys(Trt) was esterified to the resin by 
employing the Pfp ester couple in the presence of the reduced amount of 
DMAP (0.025 molar equivalents). It has been suggested that the S-Trt 
derivative of cysteine is highly lipophilic and conflicts with the generally 
polar character of the Fmoc-polyamide system.11 Thus, three batches of 
reactants were employed, applying recirculation periods of 2 h, 15 h and 2 h 
respectively. The quantitative ninhydrin assay indicated a reasonable resin 
coverage of 74%. The synthesis was then continued in the usual manner, 
with all couplings complete after 25 min except for Val10 (60 min), Arg9 
(60 min) and Val7 (90 min).
The removal of S-Trt by TFA is an equilibrium reaction, which is 
displaced during the removal of TFA so that retritylation of the SH group is 
favoured. It has been found70 that the reaction conditions and work-up 
must therefore be carefully controlled. The peptidyl-resin was subjected to 
the usual cleavage/deprotection mixture for 15 h, and a yellow colour was 
seen instantly on addition of the peptidyl-resin, due to the cleaved trityl 
cations in solution. A modified work-up procedure was then employed so 
as to avoid retritylation. Thus TFA, usually removed totally, was reduced 
in volume to about one sixth of the original. The resulting solution was 
then added to a large volume of water, to quench the trityl cations, before 
washing with r-butyl methyl ether. The crude product obtained was shown 
to contain 70% of free thiol groups. It was used in the following 
cyclisation reaction immediately without further purification, since we 
intended to minimise losses of material where possible. Simple air 
oxidation was the method selected, and no free thiol groups were detected 
after a period of 15 h. Initial purification by gel permeation 
chromatography indicated a minimum amount of polymeric material had 
been formed. Following preparative RPHPLC, the pure product (7) was 
obtained in 68% yield (from the crude disulphydryl compound). The 
overall yield was 28%.
This method has therefore resulted in a much improved yield of 
product. The advantage of the procedure is its relative simplicity, where
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the cysteine protecting groups were cleaved very easily as part of the 
cleavage/deprotection process. The crude dihydro peptide (48) was 
subjected to oxidation as soon as it had been isolated and any purification 
delayed until cyclisation had been achieved. The alternative methods that 
were applied still have scope, once the work-up procedures have been 
optimised.
2.3.3. Cyclic MCH(5-17) (5)
Exocyclic, and ring subunit, analogues of MCH have been successfully 
synthesised. The importance of the exocyclic residues for binding/activity 
would be further tested by syntheses of analogues where either the C- or 
N-terminal residues are absent. Activity studies carried out by other 
workers133 on compounds of this nature have indicated that the C-terminal 
residues are more critical to MCH activity in teleosts compared to the 
N-terminal sequence. Therefore, the synthesis of cyclic MCH(5-17) (5) 
was attempted to test the effect on activity of the introduction of the 
C-terminal fragment. Thus the [Trt-Cys5,14]-peptidyl-resin was required.
H-Cys5-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Glu-Val17-OH
(5)
Solid phase synthesis proceeded in the usual manner. The first residue 
to be introduced was valine and this was achieved using the preformed 
anhydride double-couple procedure, with the usual amount of DMAP. The 
quantitative ninhydrin colour test indicated that a resin coverage of 77% 
had been attained and the synthesis was continued. All couplings were 
complete after 25 min except for Arg9 (60 min) and Cys5 (90 min).
The peptidyl-resin was then subjected to a trial cyclisation adopting the 
same procedure as that found to be most successful in the synthesis of 
cyclic MCH(5-14) (7). The optimum period for cleavage/deprotection was 
7 h since the troublesome combination of arginine and tryptophan was 
again present. However, the crude linear dihydro peptide isolated was 
found to be fairly insoluble in the aqueous buffer used for the air oxidation 
process. Yields of the cyclic product subsequently isolated were very low
- 7 6 -
and a large amount of polymeric material was isolated. Therefore the 
procedure was modified slightly, where the crude disulphydryl compound 
was not actually isolated but air oxidation was allowed to proceed in the 
combined aqueous layers obtained from work-up of the 
cleavage/deprotection. The aqueous medium was adjusted to pH 7.6 by 
addition of ammonium hydroxide solution and was left to stand for 30 h. 
Following lyophilisation, the crude product was obtained in the presence of 
a large quantity of ammonium trifluoroacetate since the air oxidation 
solution was contaminated with TFA. Removal of the salt was easily 
accomplished by solid phase extraction using a small Cjg silica cartridge, to 
yield the crude cyclic peptide. At low concentration of acetonitrile, the 
peptide remains bound to the column while the salt is not retained and 
removed by washing. The peptide can then be eluted at higher 
concentrations of acetonitrile.
The yield of product following gel permeation chromatography was 
28% overall. Only a small portion was further purified by preparative 
RPHPLC since analytical RPHPLC indicated good purity of material 
following gel permeation chromatography. The modified air oxidation 
procedure minimised the risk of polymerisation occurring, since cyclisation 
was achieved before any lyophilisation process, during which premature 
and uncontrolled disulphide bond formation can occur.
2.3.4. MCH (1)
The synthesis of MCH (1) was the ultimate target in the first stage of 
the synthetic program. Bioassay of the product obtained would be a true 
test of integrity and of the synthetic methods so far employed.
H-Asp^Thr-Met-Arg-Cys-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Glu-Val^-OH
(1)
The solid phase assembly was accomplished in parallel to that of cyclic 
MCH(5-17) (5) where the synthesis was continued until the complete MCH 
sequence had been assembled. Each remaining coupling was complete 
after 25 min.
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Following cleavage/deprotection (7 h optimum), the cyclisation 
procedure adopted was identical to that employed in the synthesis of cyclic 
MCH(5-17) (5) (see Section 2.3.3.), where a higher yield of product was 
obtained than if the dihydro peptide was isolated before air oxidation. The 
crude peptide was subjected to the usual vigorous purification procedures 
to afford the homogeneous product (1). The overall yield was only 13% 
but the crude product had not been as pure as would have been hoped.
A sample of synthetic MCH from another source (Peninsula 
Laboratories) was generously provided by Dr. Bridget Baker and shown to 
give rise to a peak corresponding in elution position exactly with that of our 
synthetic product. All spectral data indicated that the synthesis had been 
successful.
2.3.5. Synthesis of MCH (1) by Cyclisation on the Solid Support
Disulphide cyclisations performed on polystyrene and polyamide solid 
supports have been cited in the literature, and the reader is referred to some 
examples.91 The utilisation of the pseudo-dilution properties of peptides 
linked to polymers, on the synthesis of disulphide bonds, should favour the 
desired intra-molecular reaction over the inter-molecular process. Thus, if 
the polymer-attached molecules are sufficiently distant from one another, 
then the intra-molecular cyclisation should predominate since it is rapid 
relative to the competing inter-site reaction. Solubility problems, which 
can lead to poor yields in solution, are also circumvented.
As part of our synthetic studies, an alternative preparation of MCH was 
attempted, by cyclisation on the solid support. The 
[Trt-Cys5,14]-peptidyl-resin of MCH was used for this synthesis, as 
depicted in Scheme 12. In previous syntheses, Trt groups had been 
removed by TFA, however, in this case, undesired cleavage of peptide from 
the resin would also occur. Iodine was used to cause successive 
deprotection and disulphide bond formation. The medium of choice for the 
reaction was DMF. This solvent freely permeates and solvates the 
peptidyl-resin. Tryptophan was added as a scavenger to guard against 
iodination of this residue. To suppress oxidation of Met3,6 the reaction was 
performed under nitrogen and methionine added. Iodination of tyrosine 
was not problematic since the phenolic hydroxyl was protected as the f-Bu
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(1) 10%
(i) I2 , DMF, RT, 25 minutes (ii) TFA, phenol, RT, 7 h
Scheme 12
ether. Following a 25 min reaction period, the removal of excess reactants 
was easily accomplished by various washing procedures. 
Cleavage/deprotection of the peptidyl-resin was achieved by treatment with 
a TFA-phenol mixture containing methionine and tryptophan as scavengers 
for these residues. It would also have been possible to use ethyl methyl 
sulphide in place of methionine. The usual TFA-EDT-phenol mixture 
could not have been used since EDT could cause reduction of the 
preformed disulphide bond. The characteristic yellow colour due to trityl 
cations in solution was not evident, indicating that they had been removed 
by the iodine treatment.
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Cleavagc of the peptide from the resin and removal of f-Bu protecting 
groups should be complete after 2 h. Therefore, the resin was removed at 
this stage to further prevent any back-addition of the detached peptide to 
the resin. The filtrate was left to stand for a further 5 h deprotection period 
before work-up, to isolate the crude peptide, which was satisfactorily 
purified to furnish a homogeneous product in 10% overall yield. The thiol 
test indicated the absence of free sulphydryls. The product was identical to 
that prepared by the previous methodology.
Thus it appears that disulphide bond formation has been achieved 
successfully by cyclisation on the solid support. Biological assay of the 
product will be a further test that MCH has been synthesised by this 
method. The crude material gave rise to a peptide peak on analytical 
RPHPLC that did not show broadening, as is characteristic of polymeric 
material. Purification, by preparative RPHPLC alone, was found to be 
satisfactory. In the previous synthesis of MCH the peptide peak of crude 
material was much less sharp though it improved dramatically on gel 
permeation chromatography using Sephadex LH20. All the indications are 
that the intra-molecular reaction has been favoured by cyclisation on the 
solid support
Loss of peptide may have occurred during the cleavage/deprotection 
stage, due to irreversible attachment to the resin, leading to the 
disappointingly low yield. The Mtr protected/modified tryptophan peptide 
was also a contaminant.
With further optimisation, the advantages associated with the use of 
polymers as supports for cyclisation reactions may lead to greatly improved 
synthetic procedures, indeed this has been an area of much fruitful study.92
Homogeneous samples of each peptide, whose synthesis has been 
discussed, were submitted for bioassay. The analogues [DCys14] cyclic 
MCH(5-14) (44) and [O-Met6] cyclic MCH(5-14) (47) were also included 
out of interest, though they had not been intentionally prepared.
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2.4. *STRU CTURE-ACTrVIT Y STUDIES
The structure-activity studies may provide an important insight into the 
receptor regulating pigment granule movements within melanophores.
Rigorously purified samples of all peptides, whose synthesis has been 
considered thus far, were tested for agonist MCH bioactivity in the in vitro 
melanophore assay,4 using scales of the Chinese grass carp 
Ctenopharyngodon idellus. Addition of MCH to the scales of teleost fish 
results in a lightening effect, due to melanosome aggregation within 
melanophores; such is the basis of this assay which has so far proved to be 
the most sensitive for MCH, though several have been utilised.93 The EC50 
(concentration required for half maximal pigment aggregation) was 
measured for each sample peptide. Thus the percentage potency relative to 
the reference synthetic salmonid MCH (100% activity) was calculated 
using the relationship:
EC50 MCH
% potency = ------------------ x 100
EC50 sample
The % MCH activities are shown in Table 4. Parallelity of the 
dilution curves for each fragment with that of MCH itself is also indicated. 
These are effectively dose-response plots and an example is given in 
Figure 20 for selected analogues. Dilution curves that were observed to be 
parallel to that of MCH may be an indication that the respective fragments 
interact similarly at the receptor site to the parent peptide.
Table 4





[Acm-Cys14] linear MCH(14-17) (18) 
[Acm-Cys14] linear MCH( 13-17) (19) 
[Acm-Cys14] linear MCH(12-17) (20) 
[Acm-Cys14] linear MCH(11-17) (21) 
[Acm-Cys14] linear MCH(10-17) (22) 
[Acm-Cys14] linear MCH(9-17) (23) 
[Acm-Cys14] linear MCH(8-17) (24) 
[Acm-Cys14] Unear MCH(7-17) (25) 
[Acm-Cys14] Unear MCH(6-17) (26) 
[Acm-Cys5-14] linear MCH(5-17) (27) 
[Acm-Cys5-14] linear MCH(4-17) (28) 
[Acm-Cys5-14] linear MCH(3-17) (29) 
[Acm-Cys5-14] linear MCH(2-17) (30) 
[Acm-Cys5,14] linear MCH (31) 
[Acm-Cys5-14, Phe11] Unear MCH (32) 
[Acm-Cys14] linear MCH(9-14) (33) 
[Acm-Cys14] Unear MCH(10-14) (34)
Unear MCH(l-4,15-17) (35) 
linear MCH(l-4,Aha,15-17) (36) 
[Acm-Cys5,14] linear MCH(5-14) (43) 
[Acm-Cys5,14J ’he11] linear MCH(5-14) (45) 
[Acm-Cys5-14] cyclic MCH(5-14) (46) 
cycUc MCH(5-14) (7)
[DCys14] cycUc MCH(5-14) (44)




% MCH Activity Parallelity
2.1 x 10-4 P
1.0 x 10^ P
2.0 x 10^ P
2.2 x 10-4 P
2.0 x 10^ P
2.7 x lO 3 P
5.8 x 10'3 P
5.0 xlO '3 P
4.3 x lO 3 P
9.0 x 10'3 P
1.7 x lO 2 P
2.0 x 10'1 P
3.2 x lO 1 P
5.2 x lO"1 P
3.5 x 101 P
1.0 x 101 P
ND
ND
4.4 x 10-4 P
3.8 x 104 P
1.7 x 10A NP
7.0 x lO 5 NP







Aha = -NHfCH^CO-; ND = not detected; P = parallel; NP = non-parallel
aEach assay was performed at least twice, usually with periods of several 
months intervening, and procedures already described.4 The % MCH activities 
quoted are therefore mean values.















* In teleost melanophores , melanosomes are generally in the dispersed state , (5). 
MCH causes movement of melanosomes toward the cell centre , (1).
-82-
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2.4.1. Importance of Individual Amino Acids
The bioactivities of the sequential linear sequences (17)-(31) of MCH 
(1) will first be considered. It is evident from Table 4 that there is a general 
trend of increasing potency as the MCH sequence is compiled from 2.1 x 
10*4% - 3.5 x 10"1%, however, marked rises occur on the introduction of 
certain residues. From linear MCH(15-17) (17) to [Acm-Cys14] linear 
MCH(11-17) (21) the MCH activity is fairly constant at ca. 2 x 10'4%. 
However, on the introduction of Val10 an approximate 10-fold increase in 
activity occurs to 2.7 x 10'3%. Further significant rises are seen on addition 
of Arg9 (5.8 x 10'3%), Met6 (9.0 x 10‘3%) and Cys5(Acm) (1.7 x 10'2%) 
where activity roughly doubles each time. On introduction of the 
N-terminal exocyclic Arg4 residue the potency again shows a significant 
10-fold increase to 2.0 x 10_1%. An obvious conclusion to be drawn is that 
these amino acids may be particularly important for activity. The 
sequences studied were compiled from the C-terminus of MCH. It would 
indeed be of interest to study the relative activities of sequential fragments 
increasing in one amino acid at a time but from the N-terminus of MCH.
To test the importance of the Tyr11 residue, this amino acid was 
replaced by Phe in the linear MCH and 5-14 fragments. Unfortunately the 
activities of (43) and (45) were too low for any firm conclusions to be 
drawn about their relative potencies, and only a slight decrease in activity 
occurred for the Phe substituted linear MCH (32) compared to (31).
During trial cyclisation reactions for the formation of the disulphide 
bond in the 5-14 subunit, we isolated [O-Met6] cyclic MCH(5-14) (47). 
Although the bioactivity study of the sequential fragments of MCH 
indicated the importance of Met6, a comparison of the relative potencies of 
cyclic MCH(5-14) (7) and [O-Met6] cyclic MCH(5-14) (47) shows that the 
oxidative modification of Met6 has had no effect. A similar finding 
resulted from studies by Baker et al12 where the Met3/Met6 sulphoxide 
analogues of MCH exerted virtually full bioactivity.
2.4.2. The Role of the N- and C-Terminal Sequences
Exocyclic fragments have been tested. These were the C-terminal 
tripeptide linear MCH(15-17) (17) and the sequences composed of the 
joined exocyclic sequences linear MCH(1-4,15-17) (35) and linear
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MCH(l-4,Aha, 15-17) (36), in which the inserted Aha unit 
(-NH(CH2)6CO-) spaces the terminal sequences the same distance apart as 
in the native peptide.
Each of the three peptides elicited full intrinsic activity and although 
the potency was very low, the dose response plots appeared parallel to that 
of the reference parent peptide (Table 4 and Figure 20), which may 
suggest a similar interaction with the receptor. The ring structure, cyclic 
MCH(5-14) (7), had a markedly higher potency on carp melanophores, 
which was not affected by the addition to the incubation medium of the 
exocyclic residues assembly (35) at a concentration of 10'6 Af. Therefore, 
although the terminal sequences possess some intrinsic activity, their main 
role is possibly to assist in the positioning/binding of the ring sequence, to 
achieve optimal interaction with the active site of the receptor molecule.
The importance of the exocyclic sequences was also indicated by the 
relative bioactivities of the linear fragments [Acm-Cys5,14] linear 
MCH(5-14) (43), [Acm-Cys5,14] linear MCH(5-17) (27) and [Acm-Cys5,14] 
linear MCH (31) which show a progressive increase from 1.7 x 10^% to 
l , lxlO-2%io3 .5xWl%.
The same conclusions may also be drawn by a consideration of cyclic 
MCH(5-17) (5) and cyclic MCH(5-14) (7). The analogue (5) possessing 
the C-terminal sequence is more potent than (7) where both the N- and 
C-terminal residues are absent. It would be interesting to test the activity 
of the cyclic MCH(1-14) (6) fragment in our assay to determine the relative 
importance of each exocyclic sequence. However, of the analogues 
prepared in our study, full bioactivity has so far only been elicited by the 
synthetic MCH (1), prepared by cyclisation both in solution and on the 
solid support. Earlier bioactivity studies have been carried out by other 
workers on cyclic MCH(5-14) (7), cyclic MCH(5-17) (5) and cyclic 
MCH(1-14) (6). The results of these investigations, displayed in Table 5, 
are apparently at variance with one another, and with our results. In 
independent studies, full MCH bioactivity was found to be exerted either 
by (a) each analogue8 or by (b) cyclic MCH(5-17) (5) alone,13 where the 
C-terminal sequence was more important than the N-terminal residues. 
Each bioassay however used melanophores from different fish species and 
it is possible that the discrepant results reflect differences in the 
melanophore receptor requirements of the species in question.
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Table 5
%Activities of MCH Fragment Analogues
cyclic MCH(1-14) cyclic MCH(5-17) cyclic MCH(5-14)
(6) (5) (7)
(a) 100 100 100
(b) 10 100 1.0
(a) Tested on scales from Sarotherodon mossambicus?
(b) Tested on skin from Synbranchus marmoratus13
It is of interest that [Acm-Cys5,14] linear MCH(5-14) (43) and 
[ Acm-Cys5,14,Phe11] linear MCH(5-14) (45) were the only analogues tested 
whose dilution curves were, by visual inspection, clearly not parallel with 
that of MCH itself, suggesting that they do not interact normally with the 
receptor. The derivatives [Acm-Cys5,14] linear MCH(5-17) (27) and 
[Acm-Cys5,14] linear MCH (31), however, do show parallel dilution plots, 
which again suggest the importance of the exocyclic residues in correctly 
positioning/binding the molecule to its receptor site.
2.4.3. The Requirement of the Cystine Bridge
The finding that [N02-Tyrn ]MCH and [I-Tyrn ]MCH both have 
reduced activity8*12 suggests that the residues in the region of Tyr11 may be 
important. However, the fragments [Acm-Cys14] linear MCH(9-14) (33) 
and [Acm-Cys14] linear MCH(10-14) (34) showed no detectable activity 
when tested up to a concentration of 10^ Af, indicating that this sterically 
crowded site may require the restraint of the 5-14 cystine bridge to adopt 
the active conformation. The requirement of the cystine bond for activity
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was therefore rationalised by a consideration of the relative potencies of 
[Acm-Cys5,14] linear MCH(5-14) (43), [Acm-Cys5,14] cyclic MCH(5-14) 
(46) and cyclic MCH(5-14) (7). These are the linear, Cys-Cys amide bond 
cyclised and Cys-Cys disulphide ring closed analogues of the subunit 
residues 5-14. Both the linear and amide bond cyclised fragments had very 
low % MCH activities of the order of 10~4. In contrast, the cyclic cystine 
bridged fragment (7) was exceedingly more potent at 1.5%, indicating that 
the disulphide linkage is essential to maintain the biological activity, 
promoting the active conformation. The amide bond of the corresponding 
fragment [Acm-Cys5,14] cyclic MCH(5-14) (46), would profoundly alter the 
spatial arrangement of the adjacent amino acid residues. It is interesting to 
note that the diastereomeric form [DCys14] cyclic MCH(5-14) (44) had a 
very similar activity to the unracemised product (7); thus, change of 
chirality of Cys14 in the disulphide bond has had little affect
2.4.4. Conclusions of the Structure-Activity Studies
Structural features thought to be essential for receptor binding and 
activity have arisen from the studies carried out so far.
It is evident that both the N- and C-terminal sequences are important 
for MCH bioactivity, and it is proposed that the exocyclic residues assist 
the positioning/binding of the molecule to achieve maximal receptor site 
interaction. In addition, the active conformation, probably a property of the 
5-14 ring sequence, is promoted by the cystine bridge (Table 6). This 
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2.5 *HIGH-FIELD *H N.M.R. STUDIES
On consideration of our results from the structure-activity studies, the 
cyclic MCH(5-14) (7) subunit was chosen for independent n.m.r.
H-Cys5-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys14-OH
(7)
analysis on the basis that it was one of the more potent analogues in the 
biological screen and in addition would give simpler spectra than the parent 
peptide. The linear analogue [Acm-Cys5,14] linear MCH(5-14) (43) was 
also studied by n.m.r. as a comparison.
H-Cys5(Acm)-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys14(Acm)-OH
(43)
It was our intention that primary structural confirmation of cyclic 
MCH(5-14) (7) would arise from the necessary, preliminary, high-field !H 
n.m.r. studies required to give information on preferred conformations in 
solution. Thus, resonance assignments for all peaks were required. To 
this end ID, COSY, LRCOSY94 and NOESY measurements were made.
To locate higher structural features, a combination of NOESY and ID 
difference NOE measurements were applied to locate short and long range 
through-space connectivities and enable some gross conformational 
characterisation to be made. In addition, variable temperature studies of 
the chemical shifts of backbone amide and arginine NeH protons were 
performed to assess the extent of conformational 
homogeneity/heterogeneity.
Both cyclic MCH(5-14) (7) and [Acm-Cys5,14] linear MCH(5-14) (43) 
were soluble in H20  and DMSO. Spectra of each were measured in H20  
(containing not more than 20% D20), D20  and DMSO. Very sharp signals 
were obtained in the first two solvents but broader spectra were observed in 
DMSO and in DMSO/CDCI3 solutions (1:1 v/v).
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2.5.1. Assignments
In our attempts to assign these spectra, attention was focused upon the 
characteristic proton resonances.
All residues, excluding the terminal Cys5 and Pro13, possess an 
exchangeable backbone amide NH proton, hence giving a total of eight for 
the peptide. In addition eleven backbone CaH’s were expected, where 
Gly8 possesses two such protons. Each member is further characterised by 
the proton resonances of its side chain.
2.5.1.1. Assignments in HoO and D?Q
The n.m.r. spectra of cyclic MCH(5-14) (7) and [Acm-Cys5,14] linear 
MCH(5-14) (43) were obtained at 400 MHz in H20  and D20  at 25°C. For 
each compound identical spectra resulted from both their H20  and D20  
solutions with respect to the non-exchangeable protons. In H20 , all eight 
exchangeable amide protons and two Arg9,12 imide protons were resolved. 
Therefore COSY measurements were carried out to identify each NH - 
CaH pair and from these all eleven Ca  protons were successfully located. 
These relationships established, the subsequent COSY measurements were 
made in a D20  solution of cyclic MCH(5-14) (7). The corresponding ID 
and 2D spectra are shown in Figure 21 a-c and Figure 22. Assignments 
are displayed in Table 7, which were made with the aid of COSY (Figure 
22), LRCOSY and NOESY. Assignments using similar measurements 
were made for [Acm-Cys5,14] linear MCH(5-14) (43) in D20  solution and 
are shown in Table 8.
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400 Mz spectrum of cyclic MCH(5-14) (7) in D2O
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Cyclic MCH(5-14) (7), D20  , 25°C
Figure 22
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Table 7
Chemical shift assignments for cyclic MCHC5-14) (7) 
in D?Q solution at 25°C
Residue *NH J a P Y 8 €
5 Cys 4.55 3.24
3.10
6 Met 8.84 7.9 5.04 1.95 2.39 1.97
1.91 2.49
7 Val 8.73 7.9 4.14 2.05 0.87
0.91
8 Gly 8.90 5.7 3.98
3.76
9 Arg** 7.88 7.6 4.47 1.48 1.48 3.13 7.18
1.65 1.7 3.18
10 Val 7.82 7.6 4.23 2.17 0.92
11 Tyr 8.47 5.7 4.87 2.85 7.09 6.78
3.06
12 Arg** 8.72 7.6 4.27 1.79 1.48 3.13 -7.1
2.08 1.70 3.18
13 Pro 4.35 2.36 2.10 3.53
1.90 1.90 3.61
14 Cys 8.63 6.6 4.45 3.23
3.21
* Values obtained in H20  at 25°C. 
**Assignments interchangeable.
Table 8
Chemical shift assignments for TAcm-Cvs5,14! linear MCH(5-14) (43)
in D?0  solution at 25°C
Residue *NH a P y 8 €
5 Cys 8.10 4.58 3.20
3.02
6 Met 8.55 4.41 2.30 2.58
2.02
7 Val 8.15 4.08 2.01 0.89
8 Gly 8.52 3.95
9 Arg 8.15 4.56 1.62 7.14 or 7.16
1.77
10 Val 8.31 4.12 2.05 0.95
11 Tyr 8.78 4.58 2.92
2.96
12 Arg 8.11 4.36 1.58 7.14 or 7.16
1.74
13 Pro 4.63 2.02 2.29 3.51
2.08 3.61
14 Cys 4.31 3.08
3.20
*Values obtained in H20  at 25°C.
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Inspection of Table 7 reveals that all the C^, C7, C^and C6 protons 
have been assigned for each residue. The relative integrals in the ID 
spectra showed agreement with the number of protons expected in each 
case. A comparison of the chemical shifts for cyclic MCH(5-14) (7) with 
the assignments made for the linear analogue, shows the greater dispersion 
of individual proton signals in the cyclic molecule. Of particular note is the 
differentiation of the Gly8 Ca  protons and the complete resolution of all the 
NH and C^H protons for cyclic MCH(5-14) (7). This is consistent with the 
greater conformational restraints expected in the cyclic molecule. In 
addition, another difference of interest was the shift of the Met6 Ca H from 
5 4.41 ppm, for the linear analogue, to 5 5.04 ppm for the cyclic molecule, 
indicating possible deshielding of the Met6 Ca  proton in cyclic MCH(5-14)
(7) compared to the linear peptide.
Hence assignments of proton resonances of cyclic MCH(5-14) (7) were 
made following the network of COSY cross-peaks for each residue. An 
example is depicted in Figure 22 of the network of connectivities for the 
Pro13 residue, showing the coupling of the C^H to c f e ’s, of c f e ’s to 
C?H’s and of C?H’s to C^H’s, as indicated by the cross-peaks. All the 
Ca H assignments are also displayed. Certain resonances were instantly 
worth noting from the ID spectrum that were readily assigned. These 
included the Gly8 AX system as a doublet of doublets due to 
non-equivalence of the C01 protons of this residue. In addition the methyl 
resonances of the two Val7,10 residues at 5 0.87-0.92 ppm and the methyl 
singlet of Met6 at 5 1.97 ppm were also characteristic, as were the aromatic 
C^and C6 protons of the Tyr11 residue.
The sequencing of the individual members of the three pairs of like 
residues were made as follows:
(i) Cysteines5,14
The cysteine resonances were identified by their networks of COSY 
connectivities and were clearly differentiated, since only one (Cys14) 
possessed an amide NH. Thus, the COSY spectrum that was obtained in 
H20  linked an NH at 5 8.63 ppm with a C^H-Cys at 5 4.45 ppm, therefore 
identifying this residue as Cys14 rather than Cys5 (Table 7).
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(ii) Valines7,10
The valine residues were recognised by their network of COSY 
cross-peaks. It was interesting to note that the characteristic methyl 
resonances appeared to exhibit non-equivalence for Val7 (as two doublet of 
doublets, coupling to C^H), but not for Val10 (only seen as a doublet). The 
two valines were distinguished by the one, strong, inter-residue cross-peak 
in the NOESY spectum run in H20 , which linked the NH of Gly8 at 5 8.90 
ppm to the CaH of Val at 5 4.14 ppm (Table 7), identifying this residue as 
Val7. The chemical shift values of the non-exchangeable protons were 
unchanged between samples in D20  and H20.
(iii) Arginines9,12
Using COSY, the network of connectivities for the protons of each 
arginine residue were established. However, no inter-residue connectivity 
was observed to allow assignment of the individual arginines to positions in 
the amino acid sequence, nor any NOE enhancements clear enough for this 
purpose.
One further correlation is worth noting. A LRCOS Y measurement 
associating a c f e  of the Tyr11 AMX system with its aromatic C^H 
confirmed the chemical shift assignment made to this residue.
2.5.I.2. Assignments in DMSO
The n.mj. spectra were obtained at 400 MHz in DMSO at 25°C. 
Solutions of the two peptides (7) and (43) gave rise to broader signals and 
to a number of coincidences in 5 values. Hence, only unambiguous or high 
probability connectivities established by NOE measurements were 
considered. The assignments of the protons of the cyclic analogue (7) in 
DMSO (Table 9) were based on a combination of COSY, NOESY and ID 
difference NOE measurements. The Val7,10 and Cys5,14 pairs of residues 
were distinguished as before by the Val7-Ca H to Gly8-NH connectivity 
detected by NOESY measurements and the Cys^-C^H to Cys14-NH 
cross-peak in the COSY spectrum. The Arg9,12 residues were assigned 
with less certainty by inter-residue NOESY cross-peaks between the Ca H 
of Arg9 and the NH of Val10.
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Table 9
Chemical shift assignments for cyclic MCH(5-14) (7) 
in DMSO solution at 25°C
Residue NH a
5 Cys 4.54 -3.0
6 Met * 4.52 1.90 2.96
2.09 2.56
7 Val 7.73 4.12 1.90 0.84
8 Gly 8.41 3.90
3.65
9 Arg** 7.83 4.55 1.78 2.40 -3.1
1.55
10 Val 8.10 4.10 1.92 0.70
11 Tyr 8.16 4.52 2.90
2.78
12 Arg** 8.12 4.17 1.77 2.43 -3.2
1.52
13 Pro 4.33 2.02 2.40 -3.5







Having rigorously confirmed the primary structure of the cyclic 
MCH(5-14) (7) fragment, we turned our attention to the study of 
conformation.
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2.5.2. Conformation
An initial conformational analysis was carried out by performing two 
separate studies. One such experiment was concerned with the 
determination of the temperature coefficients of the backbone amide and 
arginine N€H protons of cyclic MCH(5-14) (7). It was our intention to gain 
some understanding of the extent of conformational flexibility or 
constraint. In the second study ID difference NOE studies were utilised, 
with the hope of indicating conformational features by locating long-range 
connectivities.
2.5.2.1. Temperature Coefficients Study
The variations with temperature of the chemical shifts of the backbone 
amide and Arg NeH protons of (7), in H20  and in DMSO, are disclosed in 
Tables 10 and 11 respectively. In H20 , the shallowest slopes were shown 
by the Arg N6H protons, which is usually indicative of protection from 
solvent molecules. The remaining coefficients were large, indicating 
generally easy access by solvent molecules and little internal hydrogen 
bonding. However, in DMSO solution the arginine guanidinium NH’s 
possessed the largest temperature coefficients, with uniformly low 
coefficients for the amide NH’s; the noteworthy exceptions being the 
terminal Cys14 and Gly8 NH’s. Changes with temperature of amide-proton 
chemical shifts of around 3 ppb/°C are regarded as being indicative of 
non-rigid peptide assemblies. In comparing the ratios cited in Tables 10 
and 11, it is suggested that no major, rigid, hydrogen-bonded conformation 
exists in either of the solvents used. However, there appears to be a 
possibility of less molecular flexibility in DMSO solution. It is also 
interesting to note that the temperature coefficients of the NH amide 
protons of Gly8 are the largest of those in H20  and are also relatively large 
compared to the other values in DMSO solution. This could be evidence 
for the flexibility of the Gly8 residue.
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Table 10
Chemical shift of NH protons vs temperature (°C) 
for cyclic MCH(5-14) (7) in H?Q solution
Residue 20° 30° 40° 50° 60° A5/ATxl(
5 Cys
6 Met 8.84 8.78 8.72 8.66 8.58 6.5
7 Val 7.83 7.78 7.72 7.68 7.64 4.8
8 Gly 8.90 8.78 8.67 8.56 8.46 11.0
9 Arg 7.88 7.83 7.78 7.74 7.69 4.8
10 Val 8.72 8.62 8.53 8.43 8.35 9.3
11 Tyr 8.47 8.37 8.29 8.20 8.13 8.5
12 Arg 8.72 8.65 8.58 8.49 8.41 7.8
13 Pro
14 Cys 8.63 8.52 8.43 8.33 8.26 9.3
9 Arge* 7.18 7.15 7.12 3.0
12 Arge* 7.1 7.06 7.04 7.02 2.0
*Obscured by Tyr C5H.
Table 11
Chemical shift of NH protons vs temperature (°C) 
for cyclic MCH(5-14) (7) in DMSO solution
Residue 20° 30° 40° 50° a8/aTx1
5 Cys
6 Met
7 Val 7.70 7.68 7.64 7.62 2.7
8 Gly 8.41 8.38 8.30 8.28 4.3
9 Arg* 7.83 7.78 7.75 7.74 3.0
10 Val 8.10 8.12 8.07 8.05 3.3
11 Tyr 8.15 8.12 8.07 8.05 3.3
12 Axg* 8.12 7.78 7.75 7.73 3.3
13 Pro
14 Cys 8.08 8.03 7.97 7.93 5.0
9 Arge* 9.21 9.15 9.10 9.06 5.0
12 Arge* 8.73 8.68 8.63 8.57 5.3
*Assignments not certain.
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2.5.2.2. NOE Data
In D20  solution, only intra-residue and a few inter-residue 
connectivities were observed. In contrariety, a number of longer range 
connectivities were detected in DMSO solution and are shown in Table 12. 
The most interesting of these involved the Tyr11 residue. Hence, by ID 
Difference NOE, connectivities were indicated from Tyr11-CeH to 
Pro^-C^H (1.5%), from Tyr11-C6H to Val10-C“ H (1%) and from a CP 
proton of one of the Cys residues to Tyrn -C€H (0.5%). These small but 
reproducible connectivities suggest an accessible conformation in which 
the Tyr11 aromatic ring occupies the centre-space of the peptide ring.
Table 12
Inter-residue NOE enhancements for cyclic MCHC5-14) (7) 
in DMSO solution
Interacting atomsa % enhancement interatomic interatomic
distances* distances*
Conformer 1 Conformer ^
1 c 5„ h C“ ioH 1 6.6 3.9
2 C«,iH Ca 13H 1.5 3.1 2.9
3 C«iiH cP5o rcP 14H 0.5 4.1** 3 2**
4 n 8h ct7h 3 3.5 2.1
5 N8H Ca 7H 15 2.1 2.4
5a Ca 7H n 8h 20 2.1 2.4
6 N iqH CTjH 4 4.0 2.7
7 N10H Ca9H 6 2.1 2.3
8 Ca 5H C?7H 2 6.0 5.6
Subscripts refer to residue numbers.
* The interatomic distances (A°) are obtained from conformations observed in simulations, 
and where more than one hydrogen is designated represents the smallest value.
** N.m.r. assignments ambiguous; distances based on cP 14H.
Such a conformation may require a transannular hydrogen bond for 
stabilisation. No signal which could have been assigned to the Tyrn -OH 
proton was observed in either H20  or DMSO. This may have been the 
result of rapid exchange with the terminal NH2 and COOH protons (under 
the broad unresolved signal centred at 5 6.65 ppm in H20  and 8 7.54 ppm 
in DMSO) or by severe broadening due to hydrogen bonding.
Conclusions from the *H N.M.R. Studies
The assignment of the various n.m.r spectra has confirmed the primary 
structure of the cyclic MCH(5-14) analogue (7). The most useful solvents 
of those employed were H20  and D20 . Moreover some interesting 
conformational features have arisen from our studies.
Temperature coefficients of backbone amide and Arg9,12 N€H protons 
revealed:
no indication of the existence of a particular constrained conformation, 
though less flexibility was inferred in DMSO solution,
possible flexibility of the Gly8 residue.
NOE studies carried out in DMSO solution indicated:
a number of long range connectivities,
the spatial position of the Tyr11 residue to be in the centre-zone of the ring 
portion, hence inferring that Tyr11 could be involved in a cross-ring 
hydrogen bond for stabilisation of such an arrangement.
It is interesting to note that the Me^-C^H was notably deshielded in 
the cyclic analogue compared to the linear fragment. If the aromatic ring of 
Tyr11 occupied the centre-ring position in close proximity to Met6 then 
such a deshielding effect could occur. This however must be treated 
tentatively, since a carbonyl group adjacent to the Me^-C01!! in the cyclic 
analogue would also have this effect.*
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2.6. * ANALYSIS OF CONFORMATION - A MOLECULAR DYNAMICS
APPROACH
As the first stage is elucidating the shape and charge characteristics of 
MCH receptors, we have performed molecular dynamic simulations to 
search for accessible conformations of the hormone, in order to investigate 
the determinants for binding and activity. The results of these initial 
analyses could be used to suggest new analogues which will modify the 
conformational features of the peptide and further define the 
conformational requirements for activity.
Molecular dynamics methods have been employed recently to reveal 
accessible conformations and to characterise dynamic conformational 
transitions of proteins and peptide hormones.95 In simulations the atoms 
follow a trajectory according to Newton’s laws of motion with mobility 
determined by the temperature (or kinetic energy) of the system. Thus such 
a simulation could reveal a range of conformations which are accessible to 
the molecule at a chosen temperature, and when used in conjunction with 
energy minimisation, molecular dynamics becomes a powerful tool to study 
both the distinct conformational energy minima through which a system 
passes as well as the transitions between these low energy conformations.
In this initial study, the characteristic conformational features of the 
native peptide (1) were investigated, by applying molecular dynamics 
simulations and energy minimisation procedures. In addition, the 
importance of the disulphide bridge in determining the structural properties 
of the peptide and the effect of the terminal residues on the structure have 
been studied. Simulations were also carried out on two analogues, cyclic 
MCH(5-14) (7) and linear MCH(5-14) (48). Both contain residues 5-14 of 
the ring portion, however in the cyclic fragment the disulphide bridge is 
present as in the native molecule whereas in the linear fragment cyclisation 
was removed resulting in loss of the cystine bond. These studies have been 
complemented by independent structure-activity (Section 2.4) and 
spectroscopic studies (Section 2.5). The comparisons and conclusions will 
be considered in subsequent sections.








The molecular dynamics and energy minimisation techniques were 
applied using a valence force field software package enabling a detailed 
description of the energy surface of the molecule. In the valence force 
field96 the potential energy of a molecular system is represented as an 
empirical function of the internal (valence) degrees of freedom and the 
interatomic distances. The analytical expression of the potential energy57 
includes, (a) strain energies which arise from deformations of internal 
coordinates like bond length, bond angle and torsion angle, and "cross 
terms" caused by coupling between deformations of two or more intervals, 
and (b) interaction energies which are a result of the exchange repulsion, 
dispersion and coulomb interactions between the non-bonded atoms. The 
parameters included in the various energy terms have been determined by 
fitting experimental crystal structure data, sublimation energies, molecular 
dipole moments, vibrational spectra and strain energies of small organic 
compounds. Ab initio molecular orbital calculations have also been used in 
conjunction with experimental data to give information on charge 
distribution, energy barriers and coupling terms. The effect of solvent has 
not been modelled.
Given the potential energy of the molecular system, the force exerted
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on each atom by all other atoms in the system is defined and consequently 
the equations of motion are solved, yielding a detailed description of the 
dynamic behaviour of the system. The conformations accessed at different 
instances in the dynamics trajectory are then minimised and studied.
2.6.2. Method
The valence force field software package57 was used to run the 
molecular dynamics simulations and energy minimisations. Extensive use 
was also made of the E and S PS300 picture system with the molecular 
graphics software package INSIGHT, to visually display and study the 
dynamics and minimum energy conformations.
The initial conformation of MCH (1) was built on the picture system. 
The residues 1-4 and 15-17 of the two exocyclic sequences were removed 
from this initial structure to generate the cyclic MCH(5-14) (7) fragment. 
The disulphide bond in this structure was then removed to generate the 
linear MCH(5-14) (48) structure. The initial backbone conformations of 
the two fragments were similar to the starting conformation of the full 
MCH (1) peptide.
To start the simulations, the initial conditions i.e. coordinates and 
velocities need to be specified. The three structures were minimised to 
relieve excessive strain and eliminate unrealistic motion before the 
molecular dynamics simulations were performed. These minimised 
conformations are shown in Figure 23. Initial
random velocities consistent with a Maxwell-Boltzmann distribution for an 
average temperature of 300K were assigned to each of the atoms. 
Molecular dynamics simulations with a time step of 10'15 s, were 
performed for a total time period of 50 picosecond (50 x 10'12 s).
Chain torsion angles of energy-minimised conformations were 
analysed at 1 picosecond intervals along the dynamics trajectory of 50 
picoseconds. To ensure convergence, each conformation was minimised 
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2.6.3. Backbone Conformations
In the first stage of the analysis of conformations accessed in the 
simulations, the general structure of the molecules, as determined by the 
conformation of the backbone, was focused upon. For each residue, (<|>,y) 
values and the time periods during which they exist in the simulations were 
analysed. It is evident that MCH as well as the two analogues undergo a 
range of conformational changes. One of the most striking results revealed 
is the variability in conformational flexibility in different regions of the 
molecules.
The overall structural features of conformations accessed during these 
simulations are discussed in detail in the following sections in terms of 
backbone conformations, side-chain interactions and orientations of the 
disulphide bridge.
2.6.4. Regions of Conformational Flexibility
The major conformational flexibility of all three peptides is in the first 
half of the disulphide bridged loop (residues 5-14 of native MCH).
Frequent and large conformational changes occur in the Gly8-Arg9 region 
of the peptide in all three systems. The Gly8 residue exists mainly in either 
a y-tum (-80,50) or an a-helical (-70,-40) type of conformation (Figure 
24). The Arg9 residue also occurs in two conformational states, which 
could be described as quasi-extended (-155,100) and a y-tum (-80,100).
The <|) of Gly8 and the y  of Arg9 show little change while conversely the y  
of Gly8 and the (J) of Arg9 undergo concerted transitions. This tandem 
motion is illustrated in Figure 25, which shows the trajectories of y  of Gly8 
and (j) of Arg9 in the native peptide over the 50 picosecond simulation 
period. Thus transitions between the conformational states persists 
throughout the simulations involving a simultaneous change in these 
torsion angles. In essence the transitions involve movement of the amide 
group connecting the two residues as a nearly rigid moiety, with the NH of 
Gly8 and the CO of Arg hardly affected. This is also evident from Figure 
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Figure 25
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The other mobile residues in this region are Val7 and to some extent 
Met6. They exist mainly in a y-tum or a quasi-extended p-sheet structure.
Additional regions of structural flexibility are the exocyclic residues of 
native MCH. These regions are free to undergo conformational changes, 
since they are not constrained by cyclisation. However, the C-terminal 
residues (15-17) are much more mobile than the N-terminal residues (1-4).
the region from Tyr11 to Cys14 is in a stable helical arrangement (near the 
poly-proline helix) in all three peptides, as shown in Figure 26.
2.6.5. Constrained Regions
The region from Val10 to Cys14 shows very little change. In particular
1 3
C o n s t r a i n e d  r e g i o n  o f  t h e  p e p t i d e  n e a r  P r o  .
Figure 26
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The rigidity of the Arg12-Pro13-Cys14 tripeptide can be explained in 
terms of conformational restrictions imposed by cyclisation and the 
presence of the proline residue. The disulphide bridge between Cys5 and 
Cys14 imposes restriction on the (J) of Cys. The pyrrolidine ring of the 
proline residue (with the side chain folded onto the backbone) imposes 
restrictions not only on the (j) angle of proline but also on the conformations 
of the preceding amino acids.
Interestingly, although proline is known to be an initiator of P-tums, it 
does not participate in one in any of the peptides studied. Also, no p-tums 
were found in the proximity of Pro13. A Tyrn -Arg12 P-tum is ruled out as 
this also requires a hydrogen bond to the Pro13 amide nitrogen. In addition 
the cyclisation requirements of Cys14 prevent P-tums at Arg12-Pro13 or 
Pro13-Cys14.
2.6.6. B-Turns
Given the cyclic nature of the peptides being studied, p-tums could be 
expected to play a major role in the conformational characteristics. Three 
"near" p-tums were located. Two of these, Gly8-Arg9 and Arg9-Val10, are 
in the cyclic segment of MCH and occur in all three peptides. The final 
one, involving Thi^-Met3 is found in the N-terminal sequence of MCH.
The major difference between the (<|>,y) angles characterising these turns 
and those expected for standard P-tums97 is the value of the \jf3 torsion 
angle. While the standard value of this angle in type I and II p-tums is near 
0°, here the values are around 80° and hence the associated 4—>1 hydrogen 
bond is not found in any of the conformations.
Interestingly, the two p-tums in the cyclic region of the molecule occur 
simultaneously i.e. whenever a near type I Gly8-Arg9 p-tum occurs, the 
Arg9-Val10 forms a near type II p-tum. This region of the peptide is shown 
in Figure 27. The p-tum in the N-terminal sequence of MCH is a near type 
I turn.
The region Gly®-Arg9- V a l^ , showing the simultaneous occurrence of two P-tums .
Figure 27
Side-Chain Interactions
A regular feature in most of the conformations was a Tyr11-OH to 
Cys5-CO or Tyrn -OH to Met6-NH cross-ring hydrogen bond (see Figure 
23 for example). This was found in almost all the minimised 
conformations. The overall preference for this constraining feature was 
most significant. An additional simulation was carried out in which the 
Tyr11 side chain was moved away from the peptide ring. The cross-ring 
hydrogen bond was re-established in this additional simulation, even 
though it did not exist in the initial structure.
Another commonly found side chain-backbone hydrogen bond was 
between the Arg12 NeH and the C=0 of Pro13, especially in cyclic 
MCH(5-14) (7). Other noticeable features were the stretching out of the 
Met6 side chain at regular intervals and interaction of the N6H of Arg9 with
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the NH of Val10.
These interactions are likely to be modified by solvent when the 
intra-molecular processes noted above may be replaced by inter-molecular 
interactions with the solvent
Another very important side-chain feature in cyclic peptides containing 
disulphide bridges is the orientation of the cystine bond as determined by 
the torsion around the S-S bond (0). In the present studies, the value of 0 
in cyclic MCH(5-14) (7) and the parent peptide was » +90° in the initial 
structures, and it remained near this value during the simulation, with no 
transitions to the other possible value, -90°. This is due to the high 
rotational barrier around the S-S bond (>10 kcal/mol) and consequently a 
very rare occurrence of transitions. However, this does not rule out 
existence of conformations with the other 0 value. An exploration was 
carried out by removing the bridging atoms (CP and S^) and inserting a 
new bridge with a conformation of 0 = -90° in cyclic MCH(5-14) (7). It 
was found that the orientation of the cystine bridge had little effect on the 
overall conformation of the rest of the peptide.
2.6.8. Comparison of the Conformations of the Three Peptides
The overall backbone conformations of cyclic MCH(5-14) (7) and of 
the cyclic fragment of native MCH (1) are apparently similar. Our 
simulation reveals that the overall conformations and transitions of the 
linear MCH(5-14) (48) peptide fragment resemble those of the other two 
peptides. However, some conformational features were observed only for 
the linear fragment. In order to quantitatively evaluate the similarity in 
conformation between residues 5-14 of the full MCH system, cyclic 
MCH(5-14) and linear MCH(5-14), each of the conformations of one 
peptide was superimposed on each of the conformations of the other two. It 
was quite clear that the cyclic MCH(5-14) analogue is conformationally 
more closely related to the parent peptide than the linear analogue.
The comparison suggests a possible explanation for the lack of activity 
of the linear molecule. Although this analogue can adopt apparendy 
similar conformations to those of the parent peptide, the deviation between 
them may be too large for effective binding and activity. In addition, the 
entropic factor arising from the need to select the binding conformation
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from the many more available to the linear molecular will also contribute to 
its inactivity.
2.6.9. Conclusions
Molecular dynamics simulations and energy minimisation studies on 
the MCH systems have shown that there are two regions in the cyclic part 
of the peptide with very different conformational properties. These are the 
region around Gly8 which shows mobility, and the region around Pro13 
which is quite stable and rigid. The two conformations which the Gly8 
residue adopts suggests that two major families may be accessed.
Moreover, a persistent feature was the Tyr11 phenolic cross-ring hydrogen 
bond. Thus, these analyses have led to a small set of key residues which 
are prime candidates for substitution, aimed at defining the conformational 
requirements for activity and consequently designing more active 
analogues. The similarity between MCH and cyclic MCH(5-14) 
conformations, suggests that the effect of the tail fragments on the ring 
conformation of MCH is marginal. The disulphide bridge appears to be of 
importance since conformations are adopted by the linear fragment which 
are significantly different. However, the orientation of the bridge is shown 
to have only a marginal effect on the overall conformation.
The results obtained so far have therefore established some
*
conformational preferences for the hormone.
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2.7. CONFORMATIONAL ANALYSES - A COMPARISON OF MOLECULAR 
DYNAMICS STUDIES WITH N.M.R. RESULTS
Investigations of the conformations of MCH and its analogues have been 
performed by independent theoretical and experimental studies, using molecular 
dynamics and high-field n.m.r. analyses respectively. To a great extent the results 
of NOE experiments (see Table 12, Section 2.5), carried out on cyclic MCH(5-14) 
(7), are consistent with accessible conformations obtained from simulations of the 
cyclic MCH(5-14) molecule. Four backbone-side chain NOE’s have been found:
(a) Gly8-NH to Val7-CaH
(b) Val10-NH to Arg9-C“ H
(c) Gly*-NH to Val7-CTH
(d) Val10-NH to Arg9-C^H
The first two NOE’s, (a) and (b), are diagnostic98 of a y  value of 120° for Val7 and 
Arg9. This is in agreement with values obtained from the modelling studies. The 
connectivities indicated by (c) and (d) above are also consistent with the minimised 
conformations accessed by the dynamics simulations. In addition, of the four side 
chain-side chain NOE’s, two are in accordance with most of the cyclic MCH(5-14) 
minima:
(i) Tyr11-C€H to Cys5-CpH
(ii) Tyr11-C€H to Pro13-C«H
These connectivities, (i) and (ii), were of particular interest since they indicated the 
presence of a significant population of conformations in which the Tyr11 side chain 
occupies the centre space above the peptide ring.
All the NOE enhancements obtained on cyclic MCH(5-14) (7) in DMSO solution 
(given in Table 12, Section 2.5) are for convenience indicated on the conformers, 1 
and 2, shown in Figure 28. These conformers are typical representations of the two 
families of accessible minimised conformations generated from the molecular 
dynamics simulation, characterised by the a-helical (conformer 1) or y-tum 
(conformer 2) conformation of Gly8. All minimised conformations from each family 
featured the transannular interaction involving the Tyr11 residue. The NOE 
enhancements observed are largely consistent with the simulated spatial 
arrangements. The great majority of these minimised conformations satisfied the 





C y c l i c  M C H ( 5 - 1 4 ) ,  s h o w i n g  N O E  e n h a n c e m e n t s  .
Figure 28
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effects, depending upon the family. In these, the Tyr11 phenolic OH hydrogen is close 
to the Cys5 and to the Met6 carbonyl oxygens. This could provide the hydrogen bond 
which may be necessary to stabilise such an arrangement The existence of this 
feature is therefore suggested by the independent n.m.r. analyses and molecular 
dynamics simulations.
Apart from consistences of measured NOE enhancements with the simulated 
conformations, the region of conformational flexibility around Gly8 has also been 
determined by molecular dynamics and separately by the n.m.r. studies of temperature 
coefficients.
It should be emphasised that no explicit constraints were incorporated in the 
molecular dynamics simulations. Considering the limited number of observed NOE 
enhancements, and consequently the small number of proximity constraints revealed 
by the experiments (relative to all possible proton pairs in the peptide), it is 
noteworthy that the simulations produced conformations which are compatible to 
such a degree with the n.m.r. experiments. Thus, this agreement lends credibility to 
the results of the simulations and indicates that important accessible conformations 
have been successfully generated.
It is important to mention recent findings of other workers151* which add further 
credence to our results. In attempts to determine the conformational structure 
requirements for MCH at its receptor, analyses have been carried out by applying *H 
n.m.r. assignments and conformational studies of MCH in water using NOE 
constraints and molecular modelling algorithms. A total of 69 NOE’s were 
established in 90% H2O-10% D20.
In agreement with our studies, molecular dynamics indicated a Gly8-Arg9 type I 
p-tum. In addition, a transannular NOE was observed between the Tyr11 aromatic 
protons to the Ca H of Met6 and the NH of Val7. There appeared to be no 
convergence upon a common structure, suggesting some flexibility in other parts of 
the molecule.
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2.8. CONCLUSION OF THE STRUCTURE-CONFORMATION-ACTIVITY
STUDY -"STAGE 1”
The preliminary, independent, experimental and theroretical studies have located 
salient conformational features and potentially active sub-structural units of the 
hormone. Moreover, conclusions reached from the separate structure-activity, 
high-field n.m.r. and molecular dynamics analyses have shown a marked 
compatibility.
The results of the "Stage 1" study are summarised as follows:
(1) Structure-activity studies suggest that the active conformation is probably a property 
of the 5-14 sequence and is promoted by the cystine bridge. The importance of the 
disulphide bond was also indicated by molecular dynamics simulations, where 
conformations were adopted by the linear MCH(5-14) (48) fragment which were 
markedly different to those of the native peptide.
(2) The importance of the N- and C-terminal sequences was shown by the
structure-activity studies. It is suggested that they may assist in molecule binding, to 
elicit maximal receptor site interaction. Analysis of the bioactivities of the sequential 
linear sequences of MCH (17) - (31), showed a marked increase in activity on 
introduction of the first of the N-terminal residues, namely Arg4. Molecular dynamics 
simulations indicated that the exocyclic sequences do not influence the conformation 
adopted since their effect on the cyclic ring portion is marginal.
(3) Regions of conformation flexibility have been defined, together with constrained 
regions. The flexibility of the Gly8 residue has been indicated by both molecular 
dynamics and n.m.r. analyses. The simulations revealed that Gly8 adopts either a 
y-tum or an a-helical conformation. Thus it is suggested that two major families of 
conformations may exist.
The molecular dynamics simulation indicated a particularly strained region 
around Pro13. In addition, the Val10 residue showed little mobility and induced an 
increase in activity on its introduction in the structure-activity study of the linear 
sequential MCH fragments.
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(4) The existence of S-turns and key residues involved in conformational determination 
has been predicted by molecular dynamics studies.
(5) There was remarkable agreement between the experimental NOE constraints 
determined by n.m.r. analyses and the accessible conformations obtained from the 
simulations. A dominant transannular tyrosine phenolic hydrogen bond has emerged 
from different dynamics starting points. Independent n.m.r. analyses have provided 
possible experimental validation of this feature. These findings strongly support the 
suggested importance of the Tyr11 side chain in stabilising the biologically active 
conformation.
The results obtained thus far have established a fundamental knowledge of the 
hormone and given some indications regarding the direction of further experimental 
and theoretical studies, as will be considered in the following Chapter.
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Chapter 3
SYNTHESIS. BIOLOGICAL ACTIVITY AND CONFORMATIONAL
STUDIES
11 STAGE 2"
The major sub-structural conformational features defined by the "Stage 1" 
studies, have enabled certain amino acid substitutions to be predicted, which should 
result in definable conformational constraints. Thus, structure-activity and 
conformational studies can then be performed on the resulting fragments to further 
investigate these features.
The Tyr11 residue has been indicated to play a key role in determining the 
conformation of MCH. A dominant transannular phenolic hydrogen bond has 
emerged from both molecular dynamics and high-field n.m.r. studies. A simple 
substitution of Tyr11 by Phe enables further investigation of the importance of the 
Tyr11 side-chain conformation in determining the activity of MCH.
The importance of Tyr11 for activity was suggested by other workers,8,12 and 
this prompted our earlier syntheses of [Acm-Cys5,14J>he11] linear MCH (32) and 
[Acm-Cys5,14,Phen ] linear MCH(5-14) (45). Unfortunately, no meaningful 
conclusions could be formed from comparisons of potencies with those of the 
corresponding Tyr11 peptides. The significance of Tyr11 for activity, may be tested 
more effectively, by a comparison of the relative potencies of disulphide cyclised 
analogues. To this end, [Phe11] cyclic MCH(5-14) (49) was targeted, being the 
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In the regions of conformational flexibility, the purpose of the substitutions 
will be to reduce the conformational space which is most important for activity. 
Hence, Gly8 is an obvious candidate for substitution. As is well known, the glycine 
residue has considerable freedom owing to the absence of a constraining group in its 
side chain. This is well reflected in the dynamics simulations, where the Gly8 residue 
adopts y-tum, and a-helical conformations, alternately. It is of interest, that the two 
main conformations adopted by Gly8, are both favourable for L-residues. Substitution 
of Gly8 by an a,a-dialkylated residue, or a D-residue, may show preference for one of 
these conformational types over the other, and throw more light on the biologically 
active conformation of MCH. To this end, the synthesis of the analogue [DAla8] 
cyclic MCH(5-14) (50) was required, where Gly8 is substituted by DAla. The 
corresponding Phe analogue, [DAla8JPhen ] cyclic MCH(5-14) (51) was also targeted, 
so that a comparison of the relative potencies of (50) and (51) may provide further 





3.1. SYNTHESES OF CYCLIC ANALOGUES OF MCH WITH AMINO 
ACID SUBSTITUTIONS
3.1.1. fPhe11! cyclic MCH(5-14) (49)
The synthesis was accomplished by treatment of [Acm-Cys5,14,Phen ] 
linear MCH(5-14) (45) with iodine, to effect the cyclisation. A similar 
procedure was used, as in the synthesis of cyclic MCH(5-14) (7), with some 
alterations. Both a larger quantity of iodine and a much longer reaction 
time were required. The synthesis of (7) posed problems with removal of 
iodine, but it has since been found that treatment with zinc dust is 
extremely effective,99 which can be removed by simple filtration. The 
pure peptide (49) was obtained in 14% yield from (45).
- 1 1 8  -
3.1.2. fPAIa8! cyclic MCH(5-14) (50)
Synthesis of [DAla8] cyclic MCH(5-14) (50) was accomplished in a 
similar manner to the preparation of cyclic MCH(5-14) (7), where Trt 
groups were employed for the protection of Cys5,14 (see Section 2.3.2.3.). 
The first residue was introduced by three consecutive batches of 
Fmoc-Cys(Trt)-OPfp, with the reduced amount of DMAP. The quantitative 
Fmoc determination was carried out and indicated that 73% resin 
esterification had occurred. The synthesis was then continued, coupling the 
Fmoc-DAla residue as the preformed symmetrical anhydride. All 
couplings were complete after 25 min, apart from Val7 (45 min).
Following cleavage/deprotection of the peptidyl-resin and subsequent 
cyclisation by air oxidation, the crude peptide was subjected to gel 
permeation chromatography on Sephadex LH20. A product of excellent 
purity was obtained in 19% overall yield.
3.1.3. rDAla^Phe11! cyclic MCH(5-14) (51)
In a parallel synthesis to that of (50), the Phe analogue was prepared, 
substituting for Tyr11 at the appropriate point. An identical cyclisation and 
purification procedure was employed, to afford the desired compound in 
44% overall yield.
In attempts to increase yields, the alternative aeration process was 
applied, where the aqueous solution from extraction, following 
cleavage/deprotection, was left to air oxidise, as in the synthesis of cyclic 
MCH(5-17) (5) (see Section 2.3.3.). However, a by-product (II) was 
formed during the aeration process, that was more retained on RPHPLC 
than the required product (I) (Figure 29). The contaminant was isolated by 
preparative RPHPLC, and analysis by F.A.B. mass spectrometry, revealed 
a peak at m/z 1272 (M+H)+, compared to m/z 1180 (M+H)+ for the desired 
product. It is proposed that the secondary product is the desired peptide, 
with the usual disulphide bridge interspersed by an ethanedithiol spacer 
(52). This would account for the observed mass difference. Formation of 
the by-product has most likely occurred during the aeration process, since 
residual amounts of EDT would be present in solution. No such by-product 
was isolated in the syntheses of cyclic MCH(5-17) (5), or MCH (1), where 
the same oxidation procedure was employed.
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It was decided to treat the by-product with sodium borohydride in 
neutral buffered solution. If the EDT unit had been incorporated, then 
reduction should occur to afford the free dihydro form of (51), which would 
then be allowed to undergo air oxidation to render the desired product. 
Indeed, analysis of this reaction by RPHPLC, revealed the by-product to be
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no longer present, only the desired product (I) being evident This added 
confirmation to our suggestion that the by-product had resulted from 
incorporation of EDT into the desired peptide.
It can therefore be concluded, that both DAla analogues, (50) and (51), 
have been successfully prepared. A much higher yield of the Phe analogue 
was obtained, since less polymeric material appeared to have formed 
during the air oxidation process. The incorporation of EDT into the peptide 
was an unexpected yet interesting phenomenon.
3.2. ^STRUCTURE-ACTIVITY STUDIES
The analogues (49), (50) and (51), were subjected to the in vitro 
melanophore assay,4 in the same manner as has been previously applied 
(see Section 2.4.). The % MCH activities are shown in Table 13. The 
potency of the corresponding unsubstituted compound, cyclic MCH(5-14) 
(7), is also indicated as a comparison.
3.2.1. Effect of the Substitution of Tyr11 by Phe
It is evident from Table 13, that substitution of Tyr11 by Phe, in the 
cyclic MCH(5-14) fragment, has resulted in a marked decrease in activity 
from 1.5% to 1.9 x 10'2%. This reduction in potency is clear evidence for 
the importance of the Tyr11 side chain functionality in determining the 
biologically active conformation. This is shown from the relative potencies 
of [DAla8] cyclic MCH(5-14) (50), and [DAla8,Phe11] cyclic MCH(5-14)
(51), where the Phe analogue is less active.
3.2.2. Effect of the Substitution of Gly8 by DAla
The replacement of Gly8 by DAla in the cyclic MCH(5-14) fragment 
has effected a significant reduction in activity from 1.5% to 8.0 x 10 3%. 
This substitution has given rise to a similar decrease in activity for the 
corresponding Phe analogues (49) and (51).
It therefore appears that the biologically active conformation has been 
disrupted by this substitution. Moreover, the DAla8 residue may have 
elicited a preference for one of the conformations (either y-tum or 
a-helical) previously indicated to be equally possible for the Gly8 residue.
Table 13
Melanin Concentrating Hormone in vitro Bioassav 
Fragment % MCH Activity Parallelitv
H-Cys5-Met-Val-Gly-Arg-Val-Tyr-Arg-Pro-Cys14-OH (7)
H-Cys5-Met-Val-Gly-Arg-Val-Phe-Arg-Pro-Cys14-OH (49) l - 9x l0 '2 P
H-Cys5-Met-Val-DAla-Arg-Val-Tyr-Arg-Pro-Cys14-OH (50) 8 0 x l 0 ' 3 P




If this is indeed true, then the biologically active conformation is unlikely 
to be that inferred by the DAla substitution.
A molecular dynamics analysis is therefore required to determine the effect 
of the modification on the conformational flexibility.
3.3. MOLECULAR DYNAMICS SIMULATION
The effect of the substitution of Tyr11 by Phe, in the cyclic MCH(5-14) 
fragment, has yet to be analysed by molecular dynamics. However, the 
replacement of Gly8 by DAla in this analogue has been simulated, for each 
of the geometries (y-tum and a-helical) that Gly8 has been shown to adopt. 
The resultant plots are shown in Figure 30. It is initially evident that an 
a,a-dialkylated residue, or a D-residue, is required to enforce a preference 
in the regional conformation of the cyclic fragment, since for an L-residue 
the side chain would be displaced away from the backbone. Further 
examination of Figure 30, reveals that the a-helical conformation is 
favoured. The alternative y-tum geometry is now much less likely, due to 
the hindrance of the DAla methyl group on the backbone atoms.’*'
favoured
Q
Glv substituted by DAla in , (a) y-tum , and (b) a-helical conformations .
Figure 30
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3.4. CONCLUSION OF THE
STRUCTURE-CONFORMATION-ACTIVITY STUDY - "STAGE 2"
The structure-activity study has indicated that Gly8 and Tyr11 are key 
residues in determining the biologically active conformation, since their 
substitution has resulted in substantial decrease in activity.
The substitution of Tyr11 by Phe, in the cyclic MCH(5-14) fragment, 
negates the possibility of the transannular hydrogen bond; a feature that 
persisted throughout the dynamics simulations and which was also 
indicated by the n.m.r. analyses. The lower activities of the Phe analogues 
adds further support to this proposed feature, and experimental and 
theoretical conformational analyses of these fragments are now required.
The molecular dynamics simulations suggested that substitution of 
Gly8 by DAla in the cyclic ring portion of MCH is likely to favour an 
a-helical rather than a y-tum conformation in this region of the peptide, 
thus reducing flexibility. The reduced potency of the DAla8 analogues 
suggests that the biologically active conformation may require the adoption 
of the y-tum geometry around Gly8. The molecular dynamics simulation 
carried out previously (see Section 2.6.4.), indicated the possibility of a 
"near” type I Gly8-Arg9 [3-turn. Support for this feature is provided by the 
recent revelations of other workers.151* However, the (3-turn is only 
consistent with the a-helical conformation of Gly8, which is 
contra-indicated by the observed activities. However, conformational 
studies of MCH ring-contracted analogues,14 possessing MSH-like activity, 
revealed a preference for the a-helical geometry of Gly8. It is possible that 
the a-helical conformation is more critical to MSH-like activity, and the 
y-tum to MCH activity.
High-field *H n.m.r. analyses of [DAla8] cyclic MCH(5-14) (50) and 
[DAla8J5he11] cyclic MCH(5-14) (51) are currently in progress. It is our 
intention that such studies may indicate that changes in conformation have 
occurred on substitution of Gly8 by DAla, and Tyr11 by Phe. The nature of 
these conformational changes is of interest and will be investigated. This 
"Stage 2" study has therefore been successful in enabling a much improved 
definition of the conformational requirements for activity.
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3.5. CONCLUSION OF THE SYNTHETIC STUDY
Successful solid phase peptide syntheses have been accomplished by 
the continuous-flow Fmoc-polyamide method. The associated selectivity, 
mildness, and step-wise monitoring facilities, have been the essence of this 
proficient procedure.
The general application of Pfp esters with added HOBt, for coupling of 
Fmoc-amino acids, has proved to be as efficient as the use of Fmoc-amino 
acid anhydrides, whose preformation is thus avoided. The employment of 
Dhbt esters has also given promising results, where additional acylation 
monitoring is possible by visual inspection of the resin colouration. 
However, the use of anhydrides has been validated for the direct attachment 
to the resin of more sterically hindered amino acids eg. valine, due to the 
higher reactivity of these species.
Racemisation of cysteine has been a particularly poignant problem 
during esterification of this residue to the resin, when using the 
symmetrical anhydride as the method of activation. The epimerisation, 
apparently promoted by DMAP, was suppressed by reducing the amount of 
the base employed, and by using Pfp ester activation.
Following the first residue coupling, subsequent acylations were 
usually complete with a standard 25 min reaction period. However, certain 
residues, particularly Cys5, Arg9 and Val10, required extended coupling 
periods. These sluggish reactions could be due to steric factors, which may 
include sequence-dependent, intra- or inter-chain, interactions.
The cleavage/deprotection of the majority of peptidyl-resins was 
achieved using a standard mixture of TFA-phenol-EDT. Problems were 
associated with peptides possessing arginine and tryptophan residues. 
Removal of the Mtr group from arginine required protracted treatment with 
the cleavage/deprotection mixture. Moreover, side product formation 
occurred leading to a modification of tryptophan by Mtr, or dithioketal, 
depending on the reaction conditions. These problems were minimised by 
careful monitoring of the cleavage/deprotection process.
All protecting groups, apart from the TFA stable Acm of cysteine, 
were removed following cleavage/deprotection. This method of cysteine
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derivatisation enabled the isolation of linear peptides by preventing 
spontaneous disulphide bond formation.
Various cyclic peptides have been prepared for our study. The simple, 
mild method employing Trt protection of cysteine, cleaved by TFA, and 
subsequent air oxidation of the dihydro peptide, was found to be successful 
resulting in good yield of product. If dihydro peptides were isolated then 
polymerisation was found to occur and hence it is important that the 
controlled oxidation step should be employed as soon as possible. The 
value of the iodine oxidation procedure was that removal of S-protection 
and disulphide bond formation could be accomplished simultaneously. 
Cyclisation processes performed whilst the peptide remains attached to the 
resin should theoretically result in production of less polymeric material. 
Though the yield of product obtained using this procedure was slightly 
disappointing, further optimisation of the cleavage/deprotection step should 
lead to more promising results.
Homogeneous samples of each product were successfully obtained, 
where purification by preparative RPHPLC has proved particularly 
valuable.
To summarise, our synthetic study has illustrated that although solid 
phase peptide synthesis is facilitated by automation, sequences arise which 
defy facile preparation. Moreover, isolation of the product via cleavage, 
and subsequent purification, is by no means problem free, and requires 
scrupulous care. Control of first residue attachment, Mtr removal, and 
disulphide bond formation, was found to be particularly challenging.
- 1 2 6 -
3.6. FUTURE WORK - SUBSTITUTIONS AND STANDARD 
VARIATIONS
Our structure-conformation-activity studies have indicated key 
residues which are prime targets for substitution, in order to better define 
the exact conformational requirements for activity. To this end the 
replacements of Gly8 by DAla, and Tyr11 by Phe, have already been carried 
out. The former substitution has effectively "locked" this region of the 
peptide in an a-helical conformation. It would indeed be interesting to 
perform a substitution of Gly8 by a moiety predicted to enforce the y-tum 
geometry and to determine the potency of the resulting fragment.
In the cyclic portion, where Pro13 is the residue responsible for the 
characteristic rigidity in this region, the strategy behind substitution should 
be to retain the rigidity while forcing this part of the peptide to adopt a 
different conformation. A substitution of the residue before Pro13, namely 
Arg12, may have a crucial effect. Replacement by a D-residue, or 
a-aminoisobutyric acid (Aib), may force this part of the peptide to adopt a 
type IT p-tum or a type III p-tum (310 helix). Since these are structural 
features which are not possible for the Arg12-Pro13 combination, such 
analogues could show a pronounced effect of the backbone conformation 
on activity.
In addition to substitutions directed at selecting well defined, restricted 
conformations, substitutions can be aimed at stabilising the conformation of 
a residue. An example of this is Val10, which shows little mobility, and 
occurs in the left-handed a-helical region of the (<J>,\|/) map, which is 
energetically more favourable for a D-residue. Once again, substitution by 
a D-residue and a study of the effect could enhance our understanding of 
the importance of this conformational feature.
Further chemical modifications may also be made at specific points 
within the exocyclic residues, to test their possible binding function at the 
receptor molecule, or their involvement in the promotion of conformational 
changes. For this purpose Asp1 and Val17 could be linked by an amide 
bond to give a bicyclic peptide.
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Alterations to the stereochemistry of the active site could also be made 
by introducing spacer groups via (C H ^  or (C H ^  between the Cys-Cys 
linkage100 giving larger rings, or by substitution of Cys14 by, for example, 
penicillamine,101 thus reducing conformational flexibility near the proposed 
active site.
These structural alterations have established, or very recent, 
precedents. A tactically new variation is considered in the following 
Chapter, which to date has not found application in peptide modifications.
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Chapter 4
THE ALLENYL BIS-AMINO ACIDS - A NOVEL MIMIC FOR THE
DISULPHIDE BOND
A new method of altering cyclic peptide structure and conformation is 
proposed for the final phase of the structure-conformation-activity study.
Our preliminary analyses have already indicated the importance of the 
disulphide bond for activity. A surrogate was required for this functionality, in order 
to allow further scrutinisation of the suggested role of the cystine bond in promoting 
the biologically-active conformation. Such an analogue was further desirable since 
the S-S bond may be susceptable to cleavage under certain conditions.
4.1. THE PROPOSED SURROGATE
There are many reports in the literature on modifications of cystine 
designed to evoke conformational restrictions.58 The introduction of alkyl 
spacer groups between the S-S linkage has also been proposed.100 
However, there is a distinct lack of an effective cystine substitute.
Carba-analogues of oxytocin (53) have been prepared as replacements 
for the disulphide bond,85 and these have shown high biological activity.
c h 2 c h 2 s  c h 2
CH2-CO-Tyr-ne-Gln-Asn-NH-CH-CO-Pro-Leu-Gly-NH2
(53)
Extensive structural and conformational studies of the selenium analogue 
of oxytocin have also been reported,102 in which activity was comparable to 
that of the native hormone. Thus, in this peptide the normal S-S bond was 
replaced by an Se-Se linkage. However, such substitutes do not mimic the 
orthogonality that a disulphide bond (54) elicits on the cystine (3-carbons.
A suitable moiety of comparable configuration was therefore sought.
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V  ^
(54)
It was recognised that analogous orthogonality exists in allenes. In the 
case of the cumulated 1,2-diene system, the central carbon atom is 
sp-hybridised with two sets of orthogonal p-orbitals available for overlap 
with the remaining p-orbitals of the two terminal sp2 carbon atoms of the 
diene. For maximum overlap to occur between the p-orbitals, the resulting 
7r-bonds must be orthogonal to each other. Thus a novel surrogate for the 
cystine bond could be based on the allene subunit. To this end, the allenyl 
bis-amino acid (55) is suitable, where there is a close correlation between 
the c P-c P distance of 4.5 A compared to 4.0 A for the cystine bond.
T
CO NH
V  H h *^ 4,
(55)
The molecular dynamics studies carried out on MCH, and the cyclic 
MCH(5-14) fragment, have indicated that the torsion angle around the S-S 
bond was approximately +90°. However, conformations with 0 = -90° were 
not ruled out. In the proposed cystine-mimic, the allene unit can exist in 
two enantiomeric forms. Thus, both (R) and (S) configurations are possible 
giving +90° and -90° dihedral angle variability. This is of particular value, 
since conformational restriction is imposed, thus enabling further 
investigation of the effect of the torsion angle orientation on the overall 
conformation of the peptide.
Allenes are of widespread use as synthetic intermediates,103 and there 
is a rapidly increasing number of natural products identified, containing the
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allene unit.104 Moreover, allenes have found applications in medicinal 
chemistry where introduction has enhanced or modified biological 
activity.105 The penta-2,3-diene unit is the least space-requiring five 
carbon atom chain available, to serve as a rigid unit linking functional 
groups in probing structure-activity relationship.
To our knowledge, the allenyl bis-amino acids have found no previous 
application in peptide modifications.
4.2. POSTULATED SYNTHETIC ROUTE
Before considering a synthetic route to the allenyl to-ami no acids, a 
suitable method for inclusion of the subunit in the peptide is required.
4.2.1. Incorporation of the Allenyl Bis-Amino Acids
Introduction of the allenyl surrogate into MCH, or a related analogue, 
may be accomplished by the Fmoc-polyamide solid phase methodology. 
However, for this purpose, each of the amino acids must be suitably 
functionalised yet differentiated. To this end the derivatised product (56) 
may be suitable.
It is proposed that (56) would be most readily incorporated into the 
cyclic MCH(5-14) fragment. The solid phase procedure is outlined in 
Scheme 13. The allenyl subunit may be directly attached to the benzyl 
alcohol functionalised resin via the Pfp ester functionality (Y). On 
cleavage of the Fmoc group (Z), the next amino acid of the sequence, 
proline could then be coupled to the free amine in the usual fashion. The 
synthesis would then be continued until the complete 6-13 sequence of 
MCH had been assembled. The protecting groups, Dts and ONb, employed
Z = Fmoc; Z’ = Dts; Y = Pfp; Y’= ONb
(56)
- 1 3 1  -
for the amine, and carboxylic acid functionalities of the other amino acid of 











(i) 20% piperidine-DMF (ii) Fmoc-amino acid: Pfp ester, HOBt 
(iii) 20% piperidine-DMF
Scheme 13
The required cyclisation (Scheme 14) could be performed on the resin 
by the active azide procedure. However, cleavage of the ONb protection is 
first required and may be elicited by photolysis at hv:350 nm. Finally, 
removal of the Dts group is effected by thiols, and treatment with TFA and 
appropriate scavengers will cleave the peptide from the resin and remove 
remaining side-chain protection. This would yield the desired cyclic 
subunit where the allenyl moiety is a substitute for the Cys-Cys 
functionality.
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H-Met............................................Pro
(i) hv : 350 ran (ii) DPP A- HOBt (iii) RSH (iv) TFA, scavengers
Scheme 14
4.2.2. Preparation of the Allenyl f?is-Amino Acids
General methods are available for the preparation of racemic p-allenic 
a-amino acids. One procedure involves treatment of bromoalkadienes with 
diethyl formylaminomalonate (DFAM), using sodium hydride as the 
condensing agent,106 as shown in Scheme 15. The (S) enantiomer of the 
resultant compound, 2(S)-aminohexa-4,5-dienoic acid, is a natural 
product.107










(i) NaH, DFAM (ii) NaOH (iii) HC1
Scheme 15
Another route is based on the conversion of allenic aldehydes into 
allenic amino acids by a modified Strecker synthesis.108 However, 
moderate yields of product are obtained only from allenic aldehydes with 
blocking of the 2-position (Scheme 16), since unsubstituted 3,4-dienals 
tend to rearrange under the alkaline reaction conditions to 2,4-dienals.
OH
n h 7 n h 2
•x V< « x M
/ ^ = # = a \ '  CN  >  COOH 22%
(i) HCN, KCN, 0°C (ii) NH4C1 - NH4OH, 20°C , 7 days (iii) HC1
Scheme 16
The a-allenyl a-amino acids are of interest, due to their envisaged 
biological properties, and methods have been established for their 
preparation.109
As yet however there is no reported synthetic procedure for the allenyl 
ftif-amino acids. The (S,S)-diastereomers of the (R) and (S) allenes are 
required in order to maintain the natural amino acid chirality. Possible
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Thus, starting from the allenic dioKR^R^H), mono-protection enables 
subsequent distinction of each amino acid introduced. The remaining free 
hydroxyl may then be activated (possibly by conversion to a halogen), to 
enable alkylation of a glycine enolate (a-anion synthon). This may be 
achieved stereoselectively by applying the methodology of Schollkopf ,110 
whose general procedure utilises a bis-lactim ether derived from valine and 
glycine. The appropriate protection of the amino and carboxyl groups, as 
Dts and ONb respectively, may then be introduced on liberating the amino 
acid moiety of the desired chirality.
The other amino acid of the allenyl unit may then be incorporated in a 
similar fashion following deprotection of the masked hydroxyl. It is 
anticipated that the allene, Dts, and ONb functionalities will remain intact 
under the hydrolysis conditions required to liberate the amino acid, which 
can then be derivatised as the Fmoc protected Pfp ester.
Other stereoselective methods for synthesis of a-amino acids may also 
be envisaged, based on electrophilic amination of the corresponding 
enolate.111 Moreover, asymmetric synthesis on carbohydrate templates,112 
and asymmetric addition using a CN-modified Hemin-copolymer113 are 
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Thus the allenic diol was selected as the initial target compound.
SYNTHESIS OF l,5-DIHYDROXYPENTA-2,3-DIENE
A survey of the literature revealed that the allenic diol (57) was an 
unknown compound. A facile synthesis of this important starting material 
was therefore required.
(57)
A generally reliable method for the preparation of allenic alcohols is 
the addition of lithium aluminium hydride to propargylic alcohols114 as 
shown in Scheme 18.
X OH LiAlH4
H—I-------=  U h  ------------>  H H





However, a simple route involving the reduction of the known, 
corresponding, diester allene was envisaged. Synthesis of dimethyl 
penta-2,3-dienedioate (58) was accomplished according to the procedure of 
Bryson et al,115 (Scheme 19). An alternative method involves the 
intermediate enol phosphate.116
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(i) PC15 , 25°C (ii) H2S04 , MeOH, reflux, 18 h (iii) TEA, THF, 0 - 5°C , 18 h
Scheme 19
The product (58) was purified by distillation, with higher yields being 
obtained by performing this process in small batches. The compound 
required storage at low temperature to minimise polymerisation processes, 
detected by the increased viscosity and colouration. The strong i.r. 
absorption detected at 1960 cm-1 was characteristic of the allenic 
antisymmetric stretch. In addition, the extreme low field position of the 
allene central carbon was identified by 13C n.m.r. spectroscopy at 5 219.5 
ppm. Having obtained (58) in reasonable yield, a suitable method of 
reduction was sought.
Initial attempts by treatment with LiAlH4 were unsuccessful. The 
reaction was performed in ether, at various sub-zero temperature levels, but 
on each occasion no allene-containing products could be detected by i.r. 
spectroscopy, where the antisymmetric stretch at ca. 1950 cm'1 was absent. 
However, a strong OH peak was present and there was a lack of any 
carbonyl stretching frequency. Further examination by !H n.m.r. 
spectroscopy revealed the possibility that a mixture of 1,5-pentanediol and 
vinyl adducts had been formed.
Though it is generally accepted that sodium borohydride will not 
reduce carboxylic esters, cases are reported in the literature in which 
reduction of esters to primary alcohols has been observed.117 Many of the 
compounds which undergo such a reduction contain neighbouring 
functional groups which may participate in some way. A reduction with
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NaBH4 was attempted, in aqueous ethanol at 0°C. This reagent indeed 
effected reduction of the ester groups, but spectroscopic evidence indicated 
that reduction of the allene unit had also occurred.
The required reduction was finally achieved by employing 






It was found that decomposition of the aluminium salts was best 
achieved by treatment of the intermediate aluminium complex with 
potassium sodium tartrate solution, followed by a continuous extraction 
into ether to isolate the product. Use of MeOH/H20  as the initial treatment 
resulted in lower yield of product. Purification was best effected by 
column chromatography to furnish (57) in 44% yield. Use of distillation, 
even of small batches, resulted in extensive polymerisation and 
decomposition of the diol; this also occurred on standing at RT ,but was 
suppressed by storage at low temperature. Only a small proportion (ca. 
5%) of the totally reduced product 1,5-pentanediol was isolated.
The identity of (57) was confirmed from spectral data, which showed 
strong absorptions in the i.r. spectrum at 3600-3100 cm-1 (OH) and 1970 
cm'1 (allene), with no carbonyl absorption detected. In the n.m.r. 
spectrum no coupling was detected from the C-2 to C-4 proton or from C-l 
to C-5 protons due to the symmetry of the molecule (see Figure 31). 
Coupling of C-l protons to those of the adjacent C-2 and the long-range 
proton-proton coupling, 5J  (H-H) to C-4 protons was identical, giving rise 
to a triplet at 5 4.16 ppm. Similarly, coupling of the C-2 proton to the 
protons of C-l and C-5 elicits a triplet at 5 5.51 ppm. The allenic central 
carbon was evident in the 13C n.m.r. spectrum at 5 202.5 ppm.
Furthermore, mass spectrometric analysis by chemical ionisation (C.I.) 
revealed a weak (M+l)+ peak at m/z 101 with an intense signal at m/z 83
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(M+1-H20 )+. Due to decomposition of the product a satisfactory elemental 





Treatment of allenes with Dibal-H has been reported, where reduction 
of the more substituted double bond of the allenic linkage has been 
selectively achieved.118 However, in our system, Dibal-H has proved to be 
an effective reagent for the conversion of allenic ester to allenic alcohol, 
without affecting the integrity of the allene moiety to any great extent.
4.4. SYNTHESIS OF
5-(r-BUTYLDIPHENYLSILYLOXY)PENTA-23-DIENE-l-OL
Having obtained the allene diol (57), a method for selective protection 
was required.
The utility of f-butyldiphenylsilyl chloride (f-BDPSiCl)119 as a reagent 
for the protection of hydroxyl groups was explored. The ease of formation, 
adaptability to various analytical techniques, and compatibility with a 
variety of conditions encouraged the utility of the f-BDPSi ether. In 
addition, they have greater stability to acids than the related silyl and butyl 
ethers. This is desirable when protection is required to be maintained such 
as on acid hydrolysis reactions to yield the amino acid moiety at the other 
C-terminus of the allene unit. However, smooth cleavage is effected by 
treatment with fluoride ion.
The formation of the mono f-BDPSi ether was attempted by treatment 
of (57) with r-BDPSiCl and NaH in THF. However, after several attempts, 
no allenic product could be detected and hence the procedure was 
abandoned.
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However, the desired compound (60) was obtained by use of imidazole 
in place of NaH according to Scheme 21.
R1
H y - O H  t - BDPSiCl, DCM, H 0 $(-&  52%
/  •==zr\   >  )» • ■— \
H imidazole , RT, 2 h HO— H
(57) (60)
R ^ ^ C i R 2 , R3 = C6H5
Scheme 21
A portion of the disilylated product (ca. 10%) was also obtained.
All spectral data were consistent with the desired product. An OH 
band was present in the i.r. spectrum at 3600-3100 cm'1, with additional 
bands at 1100 and 820 cm"1 (Si-O-C). The presence of the f-BDPSi ether 
was indicated by r-Bu and aromatic signals in the *H and 13C n.m.r. spectra.
The mono-protection renders loss of symmetry, and this was shown by 
JH n.m.r. which revealed a doublet of doublets at 8 4.08 and 4.25 ppm for 
the protons of the hydroxy- and silyloxy-methines respectively, due to 3/  
(H-H) and 5J  (H-H) coupling in each case. Each allenic proton was now 
differentiated giving rise to a complex signal (theoretically of eighteen 
lines). Mass spectrometry (C.I.) revealed a major signal at m/z 321 due to 
loss of H20  from the molecule, in addition to the (M+l)+ peak at m/z 339.
The compound (60) was more stable than the non-functionalised 
allenic diol and polymerisation no longer took place.
4.5. ATTEMPTS TO ACTIVATE THE ALLENE MOIETY FOR 
ALKYLATION
Various methods of activation, for subsequent alkylation reactions 
were applicable.
Initially efforts were concentrated on the allenic diol (57) as a model
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compound. The successful reactions may then be performed on the 
mono-protected derivative (60).
However, many attempts to obtain the difunctionalised diol were 
unsuccessful. The ditosylated adduct was targeted and the allenic diol (57) 
was thus treated with tosyl chloride in pyridine. The tosyl groups might 
then be displaced by iodo functionalities to give halogen activation, if 
indeed alkylation could not be performed directly on the tosyl derivative. 
However, only a mixture of tosylated and vinylic material was obtained, 
devoid of any allenic product, as indicated by i.r. and n.m.r. spectroscopy.
The direct bromination of the allenic diol (57) was also attempted. The 
preparation of allenic bromides by treatment with triphenyl phosphite 
dibromide120 has been reported, but in our case monitoring of the reaction 
by i.r. and !H n.m.r. spectroscopy revealed that destruction of the allenic 
moiety had again occurred. Similarly, treatment of (57) with CBr4-PPh3121 
yielded uncharacterised vinylic product.
Thus, the derivatisation of (57) was not attainable by several standard 
procedures. It appears that activation of the alcohol moieties has increased 
the sensitivity toward decomposition as evident by its rapid destruction. 
Such activation may have caused the system to become extremely prone to 
elimination. Indeed, similar work has been carried out by Trost et al122 on 
the activation of a-silylated P-hydroxy allenes. Attempts at tosylation and 
bromination resulted in the exclusive formation of the elimination product 
(Scheme 22).
An analogous process may also have occurred in our case, though no i jr. 




Finally, attempts to activate the allenic diol (57), by formation of the
- 1 4 1 -
dimesylated derivative, appeared to have been successful. Therefore, we 
treated the mono-protected diol (60) similarly, according to Scheme 23, to 
obtain the mono-silylated, mono-mesylated product (61). The i.r. spectrum 
revealed absence of the OH band and the appearance of signals at 1340 and 
1160 cm-1, due to the sulphonate ester. Presence of this group was further 
revealed by the methyl singlet at 8 1.05 ppm in the n.m.r, and at 5 38.3 
ppm in the 13C n.m.r. spectra. The allene was identified by the usual 
characteristic signals in the i.r. and 13C n.m.r. analyses. Moreover, the 
mass spectrum (C.I.) showed peaks due to fragments where losses of 
sulphonate ester moieties had occurred, at m/z 338 (M+1-S02CH3)+ and 
321 (M-0S02CH3)+. Attempts to purify the product (61) by column 
chromatography resulted in its decomposition. The compound again 
required storage at low temperature.
(60) (61)
Scheme 23
Thus, the mono-protected, activated allene was obtained as required. 
There appears to be no obvious explanation for the success of the 
mesylation activation over the other procedures attempted. A model 
alkylation study was then carried out, designed to test the suitability of the 
mesylate (61) for such processes.
It was recognised that benzylidene derivatives of glycine can be readily 
alkylated to provide a simple route to a-amino acids.123 Thus we 
attempted this reaction according to Scheme 24, using (61) as the 
alkylating species.
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Our results indicated that after several hours reaction period, the 
yellow colour of the anion remained and starting material (61) was still 
evident by t.l.c. and n.m.r. spectroscopy. Traces of a new product were 
detected by these methods which may be attributed to the desired alkylated 
species. However, due to the small scale of the reaction this was not 
isolated, and the result remains inconclusive.
(i)




C2H502C " s, ---------- ✓^ ° Si\
C6H5CH=N
(i) C6H5CHO, DCM , TEA , MgS04 , RT, 15 h (ii) KO-f-Bu. THF, -78°C
(iii) (61) , -78°C-» RT, several hours
Scheme 24
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4.6. SUMMARY OF THE CYSTINE SURROGATE SYNTHETIC STUDY
Our results have indicated that the mesylate may not be an appropriate 
leaving group for the required alkylation reaction, and hence alternative 
methods must be pursued. Previous attempts to dibrominate the dihydroxy 
allene failed, but bromination or iodination may prove to be effective on the 
mono-protected allenic hydroxy compound (60), or indeed on the mesylate 
(61). Alternatively, palladium catalysed alkylation methodology may be 
employed on the benzylidene glycine ethyl ester as has been applied in 
other alkylation reactions124 (Scheme 25). It appears however that 
problems due to instability of intermediates must be overcome.
co2ch3
co2ch3
X = OAc, o -pcmoc^ ^
Scheme 25
Once a suitable method of activation for alkylation has been achieved 
for this model system, the synthesis of the suitably functionalised allenyl 
bis-amino acids (56) may be in prospect. Once incorporated into MCH, or 
a related analogue, as a cystine mimic, resolution of the diastereomeric 
peptides (where (R) and (S) allenic configurations are possible) may be 
achieved by application of RPHPLC. The subsequent structure-activity 
study, and n.m.r. analysis of conformation, will enable further investigation 
of the effect of the disulphide functionality on the biologically active 
conformation of MCH.
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CONCLUSION
Final Conclusion of the Synthetic and 
Structure-Conformation-Activity Studies of MCH
Our synthetic studies of MCH and related analogues have enabled us to 
gain knowledge of the preparation of synthetically challenging sequences. The 
Fmoc-polyamide solid phase approach was used effectively for this purpose. It is 
hoped that our findings may find useful applications in future preparations to 
overcome some of the difficulties.
Our overall aim was to elucidate the essential structural and 
conformational features of MCH that are required for activity. The results from the 
"Stage 1" and "Stage 2" studies obtained thus far, have enabled some understanding 
of these aspects. To further probe the importance of the disulphide bond, we have also 
commenced the synthesis of an unprecedented cystine substrate.
Our findings have suggested that peptides of the size of MCH may 
possess more structural and conformational integrity than could originally be 
anticipated. The study of this interesting molecule has indeed been justified. Further 
synthetic studies may be envisaged, designed to induce further conformational 
restrictions. The subsequent analysis of conformation, and assessment of biological 
activity, should lead to an increased understanding of the receptor site requirements of 
MCH.
EXPERIMENTAL





All solid phase syntheses were carried out on a semi-automatic Pepsynthesiser 
apparatus from Cambridge Research Biochemicals (CRB), fitted with two glass 
reaction columns (83 mm x 10 mm diameter). The various steps were monitored 
continuously by u.v. spectrophotometry at 330 nm, at a flow rate of 3 cm3 per minute. 
The 4-hydroxymethylphenoxyacetyl-norleucyl-derivatised-kieselguhr supported resin 
(Pepsyn KA), was a CRB product, as were all the Fmoc-amino acids and active 
esters.
Peptides were isolated from aqueous solutions by lyophilisation, after removal 
of excess organic solvents using a Buchi rotary evaporator employing water aspiration 
to avoid heating. All amino acid derivatives, and peptide products were stored at 
-20°C. All resins and peptidyl-resins were stored at 4°C.
AA-Dimethylformamide (DMF) was freshly, fractionally distilled under 
reduced pressure and both dichloromethane (DCM) and diethyl ether were purified 
immediately before use by percolation through active basic alumina. 
1-Hydroxybenzotriazole (HOBt) was recrystallised from hot water.
Trifluoroacetic acid (TFA), for reverse phase high performance liquid 
chromatography (RPHPLC), was purified by distillation from solid potassium 
permanganate. Water was double-distilled-de-ionised, and acetonitrile was far-u.v. 
transparent HPLC grade. All solutions were filtered through a Millipore membrane 
before use.
Unless otherwise stated, yields are quoted based on the theoretical amount of 
peptide that was expected, assuming 100% resin coverage and quantitative acylations 
during the solid phase assembly. For some cyclisation reactions, yields relate to the 
precursor linear peptide.
Volumes of reagents used that were less than 0.5 cm3, are quoted as the appropriate 
value in units of pi (microlitres).
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Chromatographv
Gel permeation chromatography was performed on a column (19 cm x 3 cm 
diameter) of Bio-Gel P-2 (Bio-Rad, exclusion limit 2000 Daltons), packed in an 
aqueous solution of 1 M acetic acid and eluted with the same solution. Alternatively, 
a column (19 cm x 3 cm diameter) of Sephadex LH20 (Pharmacia) packed in and 
eluted with an aqueous solution of 1% acetic acid was utilised. In both cases, the 
eluting solutions were degassed before use and the effluent monitored at 254 nm, at a 
flow rate of 0.5 cm3 per min. Any deviations from these procedures are noted.
Unless otherwise stated, RPHPLC was performed in the analytical mode on a 
5|X C18 Spherisorb column (250 mm x 4.6 mm diameter), at a flow rate of 1 cm3 per 
min. It was used extensively to monitor reactions and as a determination of product 
purity. Preparative RPHPLC was carried out on a 5|i C18 Hypersil column (250 mm x 
10 mm), at a flow rate of 4 cm3 per min. In both the analytical and preparative 
modes, gradients were generally formed between the degassed solvents, A (0.1% TFA 
in H20), and B (0.1% TFA in CH3CN-H20  9 :1 v/v), using a profile of 5 min at 5% 
B, followed by a linear gradient of 2% per min to 100% B. Peak detection was 
carried out at 214 nm. The % B at which the product peak appeared is quoted, 
together with the retention time (tR).
Thin layer chromatography (t.l.c.), on Merk DC-alufolien plates, coated with 
Kiesel gel 60 F254, was also used to establish homogeneity of products. Three general 
solvent systems were adopted:
(51) butan-l-ol-acetic acid-pyridine-water (4:1:1:2 v/v)
(52) butan-l-ol-acetic acid-pyridine-water (5:1:3:5:4 v/v)
(53) propan-1-ol-pyridine-water-acetic acid-ethyl acetate (5:4:6:1:4 v/v)
Visualisation was achieved by spraying with a solution of 1% ninhydrin in butan-l-ol 
(w/v), followed by gentle heating. The retention index (Rf) is quoted for each peptide.
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Amino Acid Analyses
Amino acid analyses were performed on samples hydrolysed at 120°C for 
18 h, using a modification of the Waters "Picotag" system,125 on a 250 mm x 4.6 mm 
Spherisorb ODS2 column, using two Waters 510 delivery systems. The solvents used 
were:
(A) 0.14 M sodium acetate (0.85 cm3) in triethylamine (TEA) (1000 cm3), pH 5.6
(B) CH3CH-H20  (6:4 v/v)
The profile consisted of 0% B for 2 min, followed by a convex gradient to
42% B over 15.5 min, and then to 100% B over 4 min.
Amino acid ratios are quoted based on valine as the reference.
Spectroscopy
Fast atom bombardment (F.A.B.) mass spectrometry was routinely applied to 
confirm the composition of each peptide. The molecular protonated species, (M+H)+, 
is quoted. Generally, matrices constituted glycerol, diglycerol and thioglycerol, often 
in various mixtures, and Xenon was used as the bombarding agent.
Nuclear magnetic resonance (n.m.r.) spectra were measured using the 
manufacturer’s standard spin sequences. 2D spectra were measured using a 1024 x 
256 matrix with zero-filling on the axis, and at 30°C to maintain temperature 
stability. Long range correlation spectroscopy (LRCOSY) refers to a COSY sequence 
with a fixed delay in the evolution period. Nuclear Overhauser effect (NOE) 
enhancements were detected by 2D NOE (NOESY) measurements using 100, 300, 
and 500 millisecond mixing time on each occasion, then measured using an NOE 
difference sequence with homo-gated decoupling applied at indicated signals.
Solvent suppression was achieved, where necessary, by selective saturation.







Petroleum ether (petrol) refers to petroleum spirit, b.p. range 60-80°C, and 
ether refers to diethyl ether. Reaction solvents were dried and distilled before use, as 
were solvents used for chromatography. Tetrahydrofuran (THF) was pre-dried over 
sodium wire, and then refluxed over sodium benzophenone ketyl until dry, and 
re-distilled prior to use. DCM and TEA were dried by distillation from calcium 
hydride, and methanol (MeOH) and ethanol (EtOH) were distilled from magnesium 
turnings.
For reactions performed under dry nitrogen, the glassware and apparatus were 
dried overnight in an oven at 125°C, then allowed to cool in a dessicator. Flasks were 
sealed with rubber septums and flame dried before use. All reactants were transferred 
with syringes and needles.
Jeol GX FT 400 (400 MHz)
Apparatus A: Gilson 303 pumps, LDC/Milton 
Roy variable wavelength u.v. detector,
Apple microprocessor controller.
Apparatus B: LKB 2150 pumps, 2140 diode 
array detector, 2152 controller, 2157 
autosampler
VG 7070E with 2000 data system 
High resolution ZAB-E
All yields quoted are of purified products, unless otherwise stated.
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Chromatographv
Reactions were monitored by t.l.c., on Merk DC-alufolien plates coated with 
Kiesel gel 60 F 254* Visualisation of reaction components was achieved by 
illumination under short wavelength (254 nm) ultraviolet light and/or spraying with 
any one of:
(a) 7% (w/v) methanolic solution of phosphomolybdic acid (PMA)
(b) 0.5% (w/v) aqueous potassium permanganate solution
(c) 1% ninhydrin in butan-l-ol (w/v)
Column chromatography was performed using short path pressurised columns 
packed with silica gel (Merk 7747), prepared in petrol, then eluted with petrol-ethyl 
acetate, increasing the polarity. Mixtures to be separated were pre-absorbed onto the 
column support, or introduced as a thin layer dissolved in the eluant solution.
Spectroscopy
N.m.r. spectra were recorded at 270MHz (!H), or 67.8 MHz (13C), and were 
run in deuteriochloroform (CDCI3) with tetramethylsilane (TMS) as internal standard, 
unless otherwise stated. Chemical shifts (8) are expressed as downfield shifts from 
TMS with multiplicities denoted by s (singlet), d (doublet), t (triplet), q (quartet), p 
(pentet), dd (doublet of doublets), dt (doublet of triplets), bs (broad singlet), m 
(multiplet), bm (broad multiplet) and c (complex). Infrared (i.r.) spectra were 
recorded as liquid film or nujol mulls, with the absorption frequencies (d) expressed 
in cm*1. Mass spectra (m.s.) were recorded using electron impact (E.I.) and/or 
chemical ionisation (CL, reagent gas isobutane) techniques, quoting the molecular 
ion (M)+ and/or molecular protonated ion (M+l)+ respectively. In addition, the base 
peak and sizeable fragmentations are denoted with assignments, where possible. All 
melting points (m.p.s) are uncorrected. Elemental microanalyses were obtained from 
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Jeol GX FT 270 (270 MHz)
Varian EM-360 (60MHz)
Hitachi Perkin-Elmer R24 (60MHz) 
Jeol GX FT 270 (67.8 MHz) 
Perkin-Elmer 197 and 1310 grating 
VG 7070E with 2000 data system 
Electrothermal MKII
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SOLID PHASE PEPTIDE SYNTHESES ■ THE GENERAL PROCEDURE
The following general procedure was followed for the synthesis of each 
peptide unless otherwise stated.
All solid phase peptide assemblies were carried out using the continuous-flow 
9-fluorenylmethyloxycarbonyl (Fmoc)- polyamide method.24
The 4-hydroxymethylphenoxyacetyl-norleucyl-derivatised 
polydimethylacrylamide-kieselguhr supported resin (Pepsyn KA) was used for each 
synthesis. The resin was allowed to swell in DMF and washed clear of fine material 
by several cycles of gentle swirling and decantation before being transferred in DMF 
to the reaction column(s) of the synthesiser.
The first amino acid of the sequence was esterified to the resin bound linkage 
agent using a 4-fold excess of either (a) the freshly prepared symmetrical anhydride or
(b) the pentafluorophenyl (Pfp) ester, of the Fmoc-amino acid to be coupled in the 
presence of 4-A^A^dimethylaminopyridine (DMAP). Unless otherwise stated, all 
Fmoc-amino acid anhydrides were prepared from the corresponding Fmoc-amino 
acids (8-fold excess) by the addition of A/^'-dicyclohexylcarbodiimide (DCC) (95% 
molar equivalents) to a solution of the Fmoc-amino acid in DCM. After stirring at RT 
(ca. 10 min) the precipitated N//'-dicyclohexylurea (DCU) was removed by filtration 
and the filtrate evaporated to dryness under reduced pressure to afford the anhydride 
which was then used immediately. In general, the quantity of DMAP used was 0.1 
molar equivalents of the number of moles of amino acid derivative employed. For 
incorporation, a solution of the Fmoc-amino acid derivative in DMF (ca. 3 cm3) was 
added to the top of the resin bed and rinsed on with DMF. A solution of DMAP in 
DMF (ca. 0.5 cm3) was then added and the recirculation mode entered as soon as the 
reactants were detected to have passed through the resin. After a certain recirculation 
period usually (a) 50 min for anhydrides and (b) 2 h for Pfp esters, the system was 
washed with DMF and a further batch of reactants employed in the same manner to 
ensure a high level of esterification of the resin active sites. This was monitored by 
the application of a quantitative ninhydrin colour test45 In some cases a quantitative 
Fmoc test was employed (both tests are described subsequently). If the extent of resin 
coverage was low then a further batch of reactants was added.
Having acylated the resin active sites satisfactorily, the Fmoc group was 
cleaved with 20% piperidine-DMF (v/v). In general, exposure to piperidine-DMF 
was for a 15 min period. The synthesis was then continued with repetitive cycles of
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acylation and Fmoc cleavage. Fmoc-amino acids were introduced in a stepwise 
fashion as part of a cycle using a 4-fold excess of the activated derivative. In general 
Pfp esters were used with the simultaneous addition of a molar equivalent of HOBl 
Freshly prepared symmetrical anhydrides were also employed and in some cases 
3,4-dihydro-3-hydroxy-4-oxo-l,2,3-benzotriazine (Dhbt) esters were utilised. On 
addition of the Dhbt ester of the Fmoc-amino acid, a yellow colouration appeared on 
the resin which was observed to fade as the acylation proceeded. All reactants were 
added as solutions in the minimum volume of DMF (ca. 3 cm3) and were recirculated 
through the resin in the usual fashion for an initial 25 min period. A qualitative 
ninhydrin colour test,43 (Kaiser test - described later) was then employed to check for 
a complete acylation reaction. This test is specific for primary amino groups, hence 
an extended acylation period (120 min) was automatically allowed for a coupling 
reaction when the amino terminal residue was proline. If an acylation reaction was 
judged to be incomplete, then an extended recirculation period was allowed until a 
satisfactory Kaiser test resulted (alternatively a fresh batch of reactant was employed 
when using anhydrides as the acylating species). On confirmation of complete 
reaction, the intermediate Fmoc-peptidyl-resin was treated with 20% piperidine-DMF 
to effect removal of the Fmoc group. On culmination of the synthesis, and removal of 
the Fmoc group, the peptidyl-resin was sequentially washed with DMF, r-amyl 
alcohol, glacial acetic acid, r-amyl alcohol, DCM and ether, using ca. 50 cm3 of each 
per gram of peptidyl-resin, which was then dried in a stream of nitrogen and stored at 
4°C.
Details of the Pepsynthesiser II Synthetic Cycles
Under FLOW conditions the solvent/reagent selected was pumped through the 
reaction column(s) and u.v. flow cell and out to waste. All washing of resin (with 
DMF, REAGENT A), deprotection (treatment with 20% piperidine-DMF, REAGENT 
B) and loading of reactants or DMF from the sample syringe (S) were carried out in 
this way. In the RECIRCULATE mode, the solution was continuously recycled 
through the reaction columns and flow cell; this was the situation during coupling of 
an Fmoc-amino acid. During CALL (indefinite period) the appropriate colour test 
was carried out.
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A programme for the incorporation of the first Fmoc-amino acid consisted of 
the following operations:
umber Operation Time/min
1 FLOW A 15
2 FLOW S (reactants) 1
3 RECIRCULATE (coupling) (a) 50 (for anhydride)
(b) 120 (for Pfp ester)
4 FLOW S (DMF) 1
5 FLOW A 5
6 RECIRCULATE 0.5
7 FLOW A 5
8 FLOW S (reactants) 1
9 RECIRCULATE (coupling) (a) 50 (for anhydride)
(b) 120 (for Pfp)
10 CALL
11 FLOW S (DMF) 1
12 FLOW A 5
13 RECIRCULATE 0.5
14 FLOW A 10
Steps 8-14 were repeated if resin coverage was shown to be low.
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A programme for the incorporation of each remaining Fmoc-amino acid 
consisted of the following:
umber Operation Time/min
1 FLOW A 5
2 FLOWB 15
3 FLOW A 15




8 FLOW S (DMF) 1
9 FLOW A 5
10 RECIRCULATE 0.5
11 FLOW A 5
Steps 5 and 6 were repeated if acylation is incomplete.
Procedures Adopted For The Various Colour Tests
Quantitative Determinations
(i) Quantitative Ninhvdrin Colour Test
The following solutions were prepared: 
aqueous KCN (0.01 M, 2 cm3) in pyridine (98 cm3) added to a solution of 
phenol (40.0 g) in EtOH (10 cm3); ninhydrin (2.5 g) in EtOH (50 cm3).
The acylated resin (<ca. 2 mg) was removed from the reaction 
column and placed in a sintered glass filter tube. A solution of 20% 
piperidine-DMF was passed through the column (3x5  cm3), followed by 
washes with DMF (3x5 cm3), r-amyl alcohol (3x5  cm3), glacial acetic acid 
(3x5  cm3), f-amyl alcohol (3x5 cm3), DCM (3x5  cm3) and ether (4x5 
cm3). The acylated resin was dried in a stream of nitrogen and the weight 
determined accurately. After transferance to a small ignition tube the 
solution of KCN and phenol (100 pi) was added followed by the solution of 
ninhydrin (25 pi). These test solutions were also added in the same 
quantities to a blank tube (reference). Both tubes were incubated at 100°C
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for 10 min. After this time the tubes were placed in a cold water bath for 5 
min. An aqueous solution of EtOH (60% v/v, 1 cm3) was added to each tube. 
The resulting solutions were then mixed thoroughly and each filtered through 
a plug of glass wool. The sample and reference filtrates were made up to 3 
cm3 with the aqueous solution of 60% EtOH in sample and reference u.v. 
curvettes respectively. The absorbance of the sample solution was then 
measured against the reference blank at 570 nm.
(ii) Quantitative Fmoc Test
The acylated resin (ca. 3 mg) was removed from the reaction 
column and transferred to a sintered glass filter tube and washed as in the 
quantitative ninhydrin colour test (i) above but omitting treatment with 
piperidine-DMF. The acylated resin was then dried in a stream of nitrogen, 
the weight determined accurately, and transferred to a volumetric flask (10 
cm3) which was made up to the marie with a solution of 20% 
piperidine-DMF. After standing for a few minutes the absorbance of the 
sample solution was measured against a reference of 20% piperidine-DMF 
from 390-190 nm in sample and reference u.v. curvettes respectively.
Qualitative Determination
Qualitative Ninhydrin Colour Test, Kaiser Test
The following solutions were prepared: ninhydrin (0.5 g) in EtOH (10 cm3); 
phenol (40.0 g) in EtOH (10 cm3); aqueous KCN (0.001 M, 2 cm3) in 
pyridine (98 cm3).
A few beads of the acylated resin {ca. 5) were removed from the reaction 
column and transferred to a sintered glass filter tube and washed with DMF 
(2x3 cm3), DCM (2x3  cm3) and ether (2x3 cm3). The beads were dried 
in a stream of nitrogen and transferred to a small ignition tube. One drop of 
each of the three solutions (prepared as above) was then added to the tube 
and to a blank tube (reference). Both tubes were then placed in an oven at 
100°C for 5 min. To judge for complete acylation the colour of the contents 
of the sample tube was then compared to the colour of the contents of the 
reference tube. Complete reaction was indicated by the respective colours 
being identical, any blue colouration in the sample tube being indicative of 
incomplete reaction.
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General Procedure for Cleavage/Deprotection
On completion of each synthesis the peptidyl-resin was subjected to 
cleavage/deprotection, using the following general method. Any deviations are 
indicated in the appropriate sections.
A trial cleavage/deprotection was initially employed; a small portion of the 
peptidyl-resin (ca. 25 mg) was treated with a mixture of TFA (40 cm3), ethanedithiol 
(EDT) (40 pi, 1.0% v/v) and phenol (0.13 g, 3.3% w/v) at RT and small aliquots (ca. 
100 pi) taken at intervals to determine the optimum reaction period for cleavage and 
deprotection. Each sample was evaporated under reduced pressure and the residue 
taken up in water, washed with ether and then analysed by analytical RPHPLC. 
Having optimised the conditions, the.bulk of the peptidyl-resin was divided into two 
batches and each treated for the determined period with the nitrogen-purged 
cleavage/deprotection mixture (the amounts of reagents being adjusted accordingly).
The work-up procedure was then employed similarly as for the trial cleavages. 
The resin was first removed by filtration and washed with TFA. The combined 
filtrate and washings were evaporated under reduced pressure and the residue 
partitioned between water and ether, the aqueous layer washed further with four equal 
portions of ether and the combined ether layers back-extracted once with an equal 
volume of water. The combined aqueous layers were then lyophilised, having first 
removed residual ether by evaporation under reduced pressure, to yield the crude 
peptide generally as a white, fluffy solid, which was analysed by RPHPLC. The 
isolated crude peptide was then subjected to purification usually by a combination of 
gel permeation chromatography followed by preparative RPHPLC.
Purification Procedures
(i) Gel Permeation Chromatography
In some cases the crude peptides were subjected to gel permeation 
chromatography. The crude peptide (not more than 10 mg at a time) was 
applied to the column in the minimum volume of the eluting solution (in 
some instances a few drops of glacial acetic acid were added to achieve 
dissolution). Fractions (5 cm3) were collected every 10 min, examined by 
analytical RPHPLC, and selected ones were pooled and lyophilised to afford 
the purified peptide.
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(ii) Preparative RPHPLC
Preparative RPHPLC was used as a final purification technique 
usually following gel permeation chromatography. In general the standard 
preparative gradient was employed (as already described), unless otherwise 
stated. A trial purification was initially performed (using ca. 2 mg of 
material) before scale-up (on not more than 10 mg of material). The peptide 
to be purified was added to the column dissolved in the minimum volume of 
an aqueous solution of CH3CN (10%, v/v). In some instances a further few 
drops of neat CH3CN were required to achieve complete solubility.
Having loaded the material the gradient was initiated, and fractions 
(4 cm3) collected each minute were examined by analytical RPHPLC. Those 
fractions seen to give rise to a single symmetrical peak were combined and 
lyophilised to yield the purified material.
Characterisation And Evaluation Of Purity
Each product was characterised by a combination of analytical RPHPLC, t.l.c., 
amino acid analysis and F.A.B. mass spectrometry. As a determination of purity it 
was imperative that each compound gave rise to a single, symmetrical peak by 
analytical RPHPLC and a single spot by t.l.c.. Certain compounds were studied 
further by *H n.m.r., the results of which are considered in the discussion. A small 
sample of each pure peptide was also subjected to biological testing.
*Bioassay Procedure4
In early experiments, test peptides were weighed on an Oertling microbalance, 
dissolved in 1 mM HC1 combining 0.1% bovine serum albumin (HPA) buffer, and 
stored at -40°C. In later experiments, peptides were dissolved in water-acetonitrile 
(1:1 v/v) and an aliquot taken for amino acid analysis. The remaining solution was 
dried under vacuum, and dissolved in an appropriate volume of HPA buffer as before.
A Chinese grass carp Ctenophryngodon idellus of 25-40 g was decapitated, the 
scales scraped off and placed into Hanks balanced salt solution combining 1% bovine 
serum albumin and 10A M phentolamine. The pH was adjusted to 7.5 with sodium 
bicarbonate. After the melanophores of the skin had fully dispersed, 2-3 scales were 
placed into each of the serial dilutions of the peptide solution to be assessed, prepared
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with the same solution in a tissue-culture well-plate. The melanophore index was 
determined after 1 h. Synthetic MCH (Peninsula Laboratories) was used as a 
standard. The potency of each peptide was determined in two or three separate 
assays.*
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linear MCH( 15-17) (17) 
[Acm-Cys14] linear MCH( 14-17) (18) 
[Acm-Cys14] linear MCH( 13-17) (19) 
[Acm-Cys14] linear MCH( 12-17) (20) 
[Acm-Cys14] linear MCH(11-17) (21) 
[Acm-Cys14] linear MCH( 10-17) (22) 
[Acm-Cys14] linear MCH(9-17) (23)
[Acm-Cys14] linear MCH(8-17) (24)
[Acm-Cys14] linear MCH(7-17) (25) 
[Acm-Cys14] linear MCH(6-17) (26)
[Acm-Cys5>14] linear MCH(5-17) (27) 
[Acm-Cys5’14] linear MCH(4-17) (28) 
[Acm-Cys5’14] linear MCH(3-17) (29) 
[Acm-Cys5’14] linear MCH(2-17) (30) 
[Acm-Cys5’14] linear MCH (31)
A total of 2.5 g of resin (0.25 mequiv.) was used. For incorporation of the first 
Fmoc-amino acid, two sequential batches of Fmoc-Val-OPfp and DMAP were added 
with recirculation periods of 4 h and 15 h respectively. No quantitative ninhydrin 
colour test or Fmoc determination was employed for these early syntheses. The 
Fmoc group was cleaved and the synthesis was then continued following the usual 
synthetic cycle adding each Fmoc-amino acid derivative until the complete MCH 
sequence had been assembled. After each deprotection stage from the tripeptide 
onwards, a portion of the peptidyl-resin was removed and washed and dried in the 
usual manner, to make available the corresponding peptides, (17)-(31). The following 
Fmoc-amino acids were coupled employing Pfp esters unless otherwise stated (the 
coupling times are indicated in parentheses): Fmoc-Glu(O-r-Bu) (25 min); Fmoc-Trp 
(25 min); Fmoc-Cys(Acm) (25 min); Fmoc-Pro (120 min); Fmoc-Arg(Mtr) (Dhbt 
ester, 25 min); Fmoc-Tyr(f-Bu) (25 min); Fmoc-Val (25 min); Fmoc-Arg(Mtr) (Dhbt 
ester, 100 min); Fmoc-Gly (25 min); Fmoc-Val (25 min); Fmoc-Met (25 min);
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Fmoc-Cys(Acm) (120 min); Fmoc-Arg(Mtr) (Dhbt ester, 25 min); Fmoc-Met (25 
min); Fmoc-Thr(f-Bu) (Dhbt ester, 25 min); Fmoc-Asp(O-f-Bu) (25 min).
Cleavage/deprotection of these peptidyl-resins gave samples of all the 
peptides in the series (17)-(31) with Acm protecting groups on cysteine residues 
where present. The general procedure for cleavage/deprotection was utilised in each 
case on 100 mg of the peptidyl-resin. The optimum period was found to be 7 h. 
However, a modified cleavage/deprotection regime was used for the peptidyl-resins of 
the title compounds (17), (18) and (19). In these cases the TFA contained anisole 
(3.6% v/v) and EDT (1% v/v), and the optimum cleavage/deprotection period was 2 h.
Purification of the crude peptides obtained after work-up was effected by 
semi-preparative RPHPLC in the usual fashion to afford the following title 
compounds:
(17) 0.8 mg (19%); (18) 1.1 mg (18%); (19) 1.2 mg (17%); (20) 2.2 mg (26%); (21)
2.4 mg (23%); (22) 2.4 mg (21%); (23) 2.7 mg (21%); (24) 2.8 mg (21%); (25) 3.0 
mg (21%); (26) 2.9 mg (19%); (27) 3.1 mg (18%); (28) 3.1 mg (16%); (29) 3.2 mg 
(16%); (30) 3.0 mg (14%); (31) 3.1 mg (14%).
Each compound was characterised as follows:
(17) analytical RPHPLC (apparatus A) 51% B, tR 28.0 min; t.l.c. Rf 0.34 (SI), Rf 
0.61 (S2), Rf 0.83 (S3); amino acid analysis: Glu 1.06, Val 1.00; m/z 
(F.A.B., glycerol matrix) 433 (M+H)+ [(M+H)+ calcd. 433.2].
(18) analytical RPHPLC (apparatus A) 50% B, tR 27.5 min; t.l.c. Rf 0.33 (SI), Rf 
0.61 (S2), Rf 0.82 (S3); amino acid analysis: Glu 1.08, Val 1.00; m/z 
(F.A.B., glycerol matrix) 607 (M+H)+ [(M+H)+ calcd. 607.3].
(19) analytical RPHPLC (apparatus A) 50% B, tR 27.5 min; t.l.c. Rf 0.34 (SI), Rf 
0.60 (S2), Rf 0.83 (S3); amino acid analysis: Glu 1.04, Pro 0.95, Val 1.00; 
m/z (F.A.B., thioglycerol matrix) 704 (M+H)+ [(M+H)+ calcd. 704.3].
(20) analytical RPHPLC (apparatus A) 51% B, tR 28.0 min; t.l.c. Rf 0.35 (SI), Rf 
0.59 (S2), Rf 0.71 (S3); amino acid analysis: Glu 1.05, Arg 0.92, Pro 1.05, 
Val 1.00; m/z (F.A.B., glycerol matrix) 860 (M+H)+ [(M+H)+ calcd. 860.4].
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(21) analytical RPHPLC (apparatus A) 53% B, tR 29.0 min; t.l.c. Rf 0.39 (SI), Rf 
0.62 (S2), Rf 0.72 (S3); amino acid analysis: Glu 1.07, Arg 1.05, Pro 1.06, 
Tyr 0.90, Val 1.00; m/z (F.A.B., glycerol matrix) 1023 (M+H)+ [(M+H)+ 
calcd. 1023.5].
(22) analytical RPHPLC (apparatus A) 53% B, tR 29.0 min; t.l.c. Rf 0.38 (SI), Rf 
0.60 (S2), Rf 0.73 (S3); amino acid analysis: Glu 1.05, Arg 1.04, Pro 0.96, 
Tyr 0.92, Val 2.00; m/z (F.A.B., glycerol matrix) 1123 (M+H)+ [(M+H)+ 
calcd. 1122.6].
(23) analytical RPHPLC (apparatus A) 54% B, tR 29.5 min; t.l.c. Rf 0.40 (SI), Rf 
0.64 (S2), Rf 0.77 (S3); amino acid analysis: Glu 1.03, Arg 2.16, Pro 1.02, 
Tyr 0.89, Val 2.00; m/z (F.A.B., thioglycerol matrix) 1279 (M+H)+
[(M+H)+ calcd. 1278.7].
(24) analytical RPHPLC (apparatus A) 53% B, tR 29.0 min; t.l.c. Rf 0.40 (S1), Rf 
0.62 (S2), Rf 0.75 (S3); amino acid analysis: Glu 1.07, Gly 1.05, Arg 2.13, 
Pro 0.94, Tyr 0.90, Val 2.00; m/z (F.A.B., thioglycerol matrix) 1336 
(M+H)+ [(M+H)+ calcd. 1335.7].
(25) analytical RPHPLC (apparatus A) 54% B, tR 29.5 min; t.l.c. Rf 0.40 (SI), Rf 
0.66 (S2), Rf 0.78 (S3); amino acid analysis: Glu 1.08, Gly 1.02, Arg 2.07, 
Pro 0.98, Tyr 0.90, Val 3.00; m/z (F.A.B., thioglycerol matrix) 1435 
(M+H)+ [(M+H)+ calcd. 1434.8].
(26) analytical RPHPLC (apparatus A) 55% B, tR 30.0 min; t.l.c. Rf 0.42 (SI), Rf 
0.68 (S2), Rf 0.78 (S3); amino acid analysis: Glu 1.02, Gly 1.08, Arg 2.03, 
Pro 1.01, Tyr 0.95, Val 3.00, Met 0.88; m/z (F.A.B.,thioglycerol matrix) 
1566 (M+H)+ [(M+H)+ calcd. 1565.8].
(27) analytical RPHPLC (apparatus A) 57% B, tR 31.0 min; tl.c. Rf 0.44 (SI), Rf 
0.69 (S2), Rf 0.80 (S3); amino acid analysis: Glu 1.05, Gly 0.93, Arg 1.98, 
Pro 0.98, Tyr 0.89, Val 3.00, Met 0.89; m/z (F.A.B., thioglycerol matrix) 
1740 (M+H)+ [(M+H)+ calcd. 1739.9].
(28) analytical RPHPLC (apparatus A) 57% B, tR 31.0 min; t ic .  Rf 0.44 (SI), Rf 
0.68 (S2), Rf 0.81 (S3); amino acid analysis: Glu 0.98, Gly 0.94, Arg 3.04, 
Pro 0.94, Tyr 0.93, Val 3.00, Met 0.90; m/z (F.A.B., thioglycerol matrix) 
1896 (M+H)+ [(M+H)+ calcd. 1896.0].
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(29) analytical RPHPLC (apparatus A) 58% B, tR 31.5 min; t.l.c. Rf 0.44 (SI), Rf 
0.67 (S2), Rf 0.83 (S3); amino acid analysis: Glu 1.06, Gly 0.98, Arg 3.03, 
Pro 1.01, Tyr 0.91, Val 3.00, Met 1.94; m/z (F.A.B., glycerol matrix) 2027 
(M+H)+ [(M+H)+ calcd. 2027.0].
(30) analytical RPHPLC (apparatus A) 58% B, 31.5 min; t.l.c. Rf 0.63 (SI), Rf 
0.69 (S2), Rf 0.81 (S3); amino acid analysis: Glu 0.99, Gly 1.01, Arg 3.09, 
Thr 0.99, Pro 1.02, Tyr 0.90, Val 3.00, Met 1.89; m/z (F.A.B., glycerol 
matrix) 2128 (M+H)+ [(M+H)+calcd. 2128.1].
(31) analytical RPHPLC (apparatus A) 58% B, tR 31.5 min; t.l.c. Rf 0.63 (SI), Rf 
0.69 (S2), Rf 0.80 (S3); amino acid analysis: Asp 1.01, Glu 1.10, Gly 1.07, 
Arg 3.03, Thr 1.05, Pro 1.07, Tyr 0.89, Val 3.00, Met 1.89; m/z (F.A.B., 
thioglycerol matrix) 2243 (M+H)+ [(M+H)+ calcd. 2243.1].
[Acm-Cys5,14, Phe11] linear MCH (32).- In a parallel synthesis with that described 
above the Phe analogue (32) was prepared, adding Fmoc-Phe-OPfp with a coupling 
time of 50 min, in place of Fmoc-Tyr-OPfp.
The general procedure for cleavage/deprotection was adhered to on 100 mg of 
peptidyl-resin with an optimum period of 7 h. In this case analytical RPHPLC was 
performed on a 10 p C18 Vydac column (250 mm x 4.6 mm diameter) with all other 
conditions as normal. Purification was carried out by preparative RPHPLC alone 
under different conditions to those normally used. Chromatography was performed 
on a 10 p C18 Vydac column (250 mm x 10 mm diameter) using the standard profile, 
at a flow rate of 3 cm3 per min. The crude peptide was loaded in the minimum 
volume of 5% B and fractions (3 cm3) were collected each minute. All other 
conditions were as normal. This gave the purified title compound (32) (3.2 mg, 14%); 
analytical RPHPLC (apparatus B, 10 p C18 Vydac column) 43% B, tR 24.0 min; t.l.c. 
Rf 0.62 (SI), Rf 0.70 (S2), Rf 0.82 (S3); amino acid analysis: Asp 1.02, Glu 0.98, Gly 
0.97, Arg 2.97, Thr 1.01, Pro 1.01, Val 3.00, Met 1.80, Phe 0.96; m/z (F.A.B., 
glycerol matrix) 2227 (M+H)+ [(M+H)+ calcd. 2227.1].
Linear MCH(1-4,15-17)(35).- A total of 1.19 g of resin (0.1 mequiv.) was utilised. 
Two sequential batches of the freshly prepared symmetrical anhydride of Fmoc-Val 
were added with DMAP and each recirculated for 50 min. The quantitative ninhydrin 
colour test indicated that 91% esterification had been achieved. After removal of the 
Fmoc group the cycle for the incorporation of the remaining Fmoc-amino acids was
- 1 6 3 -
employed using Pfp esters unless stated otherwise. The following Fmoc-amino acids 
were coupled: Fmoc-Glu(O-r-Bu) (25 min); Fmoc-Trp (25 min). On removal of the 
Fmoc group the symmetrical anhydride of Fmoc-Arg(Mtr) was prepared and added 
immediately in the usual fashion. After a recirculation time of 50 min, the Kaiser test 
indicated that acylation was incomplete. A fresh batch of anhydride was added and, 
following a recirculation time of 50 min, a satisfactory Kaiser test result was 
obtained. The synthesis then proceeded in the usual fashion, following cleavage of 
the Fmoc group. The following Fmoc-amino acids were coupled: Fmoc-Met (25 
min); Fmoc-Thr(f-Bu) (Dhbt ester, 25 min); Fmoc-Asp(O-f-Bu) (25 min).
Using the usual conditions the cleavage/deprotection of 500 mg of 
peptidyl-resin was allowed to proceed for an optimum period of 7 h. All analytical 
RPHPLC was performed using a profile of 5 min at 25% followed by a linear gradient 
of 2% per min to 90% B, all other conditions being as standard. Purification was 
effected by a combination of gel permeation chromatography (Bio-Gel P-2) and 
preparative RPHPLC using a profile of 5 min at 30% B followed by a linear gradient 
of 1% per min to 70% B (other conditions were as usual) loading the peptide as a 
solution in 30% B. This furnished the title compound (35) (15.4 mg, 33%); analytical 
RPHPLC (apparatus A, profile of 5 min at 25% B followed by a linear gradient of 2% 
per min to 90% B) 48% B, t^ 16.5 min; t.l.c. Rf 0.23 (SI), Rf 0.36 (S2); amino acid 
analysis: Asp 1.11, Glu 1.01, Arg 1.10, Thr 1.01, Val 1.00, Met 0.88; m/z (F.A.B., 
glycerol matrix) 936 (M+H)+ [(M+H)+ calcd. 936.5].
Linear MCH (1-4Aha, 15-17) (36)
(a) Preparation o f Pentafluorophenyl Na -
(9-fluorenylmethyloxycarbonyl)-7-aminoheptanoate (37)
(i) 7-Aminoheptanoic acid hydrochloride (38).- 2-Azacyclooctanone (2.00 g,
15.7 mmol) was dissolved in 2 N  hydrochloric acid (100 cm3) and heated 
under reflux for 1.5 h. The solution was then evaporated under reduced 
pressure and the residue triturated with ether to afford 7-aminoheptanoic 
acid hydrochloride (38) (2.78 g, 98%) as a pale brown solid which was used 
without further purification. A small portion was purified for analytical 
purposes by recrystallisation from acetone to give a clear crystalline solid, 
m.p. 105-106°C; omax (Nujol) 3200-2700 (COOH and NH3+), 2000 (NH3+), 
1710 (COOH), 1610 (NH3+), 1440 cm 1; 8H (DMSO-d6) 1.29-1.57 (8H, c, 
(CH2)4), 2.21 (2H, t, J  = 7.3Hz, CB^COOH), 2.73 (2H, c, CH2NH3+), 8.15 
(4H, bs, NH3+ and COOH); 5C (DMSO-dg) 24.2,25.5,26.6,27.9 ((CH2)4),
- 1 6 4 -
33.4 (CH2COOH), 38.5 (CH2NH3+), 174.3 (COOH); m/z (C.I., NH3) no 
(M+H)+, 146 (M-C1)+ (100%), 128 (5); [Found: C, 46.6; H, 9.1; N, 7.8. 
C7H160 2NC1 requires C, 46.6; H, 8.9; N, 7.7%].
(ii) Na-(9-Fluorenylmethyloxycarbonyl)-7-aminoheptonoic acid11 (39).- 
7-Aminoheptanoic acid hydrochloride (38) (2.56 g, 14.1 mmol) was 
suspended with stirring in aqueous Na2C 03 (10% w/v, 70 cm3) and cooled in 
an ice-bath. Dioxan (14 cm3) was added followed by the slow addition of a 
solution of 9-fluorenylmethyl chloroformate (3.70 g, 14.3 mmol) in dioxan 
(22 cm3). The mixture was stirred at 0°C for 1 h and then at RT for 18 h 
during which time further white solid developed in the suspension. The 
mixture was concentrated to low bulk under reduced pressure and was added 
to cold aqueous Na2C03 (10% w/v, 200 cm3) and then washed with ether (3 
x 50 cm3). The aqueous layer was acidified with concentrated hydrochloric 
acid to pH 2 to yield a white crystalline solid which was collected by 
filtration, washed with 0.1 N  hydrochloric acid (2 x 20 cm3) and water (2 x 
30 cm3) and air dried. Purification was effected by column chromatography 
[silica gel, CHC13 - EtOH (8:1)] and afforded
Na-(9-fluorenylmethyloxycarbonyl)-7-ctminoheptanoic acid (39) (3.21 g, 
62%) as a white solid, m.p. 149-151°C, t.l.c. Rf 0.64 (CHCl3-EtOH 7:1 v/v); 
Dmax (Nujol) 3320 (NH), 3100-2600 (COOH), 1710 (COOH), 1680 
(O-CO-NH), 1520 (CO-NH), 1440 cm 1; 5h (DMSO-d6) 1.25-1.49 (8H, c, 
(CH2)4), 2.20 (2H, t, /  = 7.3Hz, CBjCOOH), 2.96 (2H, dt, J  = 7.2, 6.2Hz, 
CH^NH), 3.35 (1H, bs, NH), 4.29 (3H, m, Fmoc CHCH2), 7.31,7.41,7.67, 
7.87 (2H, d, J  = 7.5Hz; 2H, d, /  = 7.3Hz; 2H, dd, J  = 7.0,7.3Hz; 2H, dd, J  = 
7.3,7.5Hz, Fmoc H-aromatic); 5C (DMSO-d6) 24.5,25.9,28.3,29.2 
((CH2)4), 33.8 (CH2COOH), 40.1 (CH2NH), 46.7 (Fmoc CHCH^, 65.1 
(Fmoc CHCHj), 120.0,125.1,127.0,127.5,140.7,143.9 (Fmoc C-aromatic),
156.4 (Fmoc C=0), 174.5 (COOH); m/z (C.I., NH3) 368 (M+H)+ (2%), 214
(50), 179 (72), 146 (100); [Found: C, 71.8; H, 6.6; N, 3.5. 0 2 ^ ^ 0 4  
requires C, 71.9; H, 6.9; N, 3.8%].
(iii) Pentafluorophenyl Na-(9-fluorenylmethyloxycarbonyl)-7-aminoheptanoate79 
(37).- iVa -(9-fluorenylmethyloxycarbony])-7-aminoheptanoic acid (39) (1.04 
g, 2.8 mmol) and pentafluorophenol (0.50 g, 2.7 mmol) were dissolved in a 
stirred mixture of DMF-EtOAc (1:1 v/v, 12 cm3) at 0°C while DCC (0.58 g, 
2.8 mmol) was added portionwise. The solution was stirred for 1 h at 0°C 
and for 1 h at R.T. The precipitated DCU was then removed by filtration and 
the filtrate concentrated under reduced pressure. The residue was triturated
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with w-hexane and filtered to afford the title compound (37) (1.21 g, 80%) as 
a white solid, m.p. 99-101°C (recrystallised petrol), t.l.c. Rf 0.57 
(petrol-EtOAc 4:1 v/v). (Quantitative comparison with a sample of 
Fmoc-Leu-OPfp by 19F n.m.r. showed the pentafluorophenyl group to be 
present as required); \)max (Nujol) 3340 (NH), 1780 (CO-O), 1680 
(O-CO-NH), 1510 (NH), 1440 cm 1; 5h (DMSO-d6) 1.32-1.66 (8H, c, 
( C H ^ , 2.77 (2H, t , /  = 7.3 Hz, CHr CO-OPfp), 2.98 (2H, dt, J  = 7.2,
6.2Hz, CH2NH), 3.35 (1H, bs, NH), 4.26 (3H, m, Fmoc CHCH2), 7.33,7.41, 
7.69,7.89 (2H, d, /  = 7.5 Hz; 2H, d, /  = 7.3 Hz; 2H, dd, J  = 7.0,7.3 Hz; 2H, 
dd, J  = 7.3,7.5 Hz, Fmoc H-aromatic); 5C (DMSO-d6) 24.2,25.7,27.8, 29.1 
((CH2)4), 32.4 (CH2-CO-OPfp), 40.1 (CH2NH), 46.7 (Fmoc CHCH2), 65.1 
(Fmoc CHCH2), 120.0,125.1,127.0,127.5,140.7,143.9 (Fmoc C-aromatic), 
156.0 (Fmoc C=0), 169.5 (CO-OPfp); m/z (C.I.) 534 (M+l)+ (53%), 350
(24), 312 (77), 265 (50), 225 (CH2-CO-OPfp)+ (67), 178 (100); [Found: C, 
62.7; H, 4.6; N, 2.7. C28H24N04F5 requires C, 63.0; H, 4.5; N, 2.6%].
(b) Incorporation o f 7-Aminoheptanoic acid in the synthesis o f (36)
In a parallel synthesis to that of (35), Fmoc-Aha-OPfp was 
incorporated into the growing peptide chain in the usual manner. Although 
acylation was complete after the normal 25 min period, the removal of the 
Fmoc group was observed to be exceptionally slow and exposure to 
piperidine-DMF was continued for 15 h. All subsequent acylations and 
deprotections were as normal.
The usual cleavage/deprotection procedure was adhered to, for 500 mg of 
peptidyl-resin, with an optimum period of 7 h. On work-up the crude 
peptide was subjected to an initial purification by gel permeation 
chromatography (Bio-Gel P-2). Preparative RPHPLC was then performed, 
using identical conditions to those employed for the purification of (35), 
though a few drops of neat CH3CN were required to achieve dissolution of 
the peptide in the loading medium. All analytical RPHPLC was also 
carried out under the same conditions used for (35). The purified title 
compound (36) (20.7 mg, 39%) was furnished; analytical RPHPLC 
(apparatus A, profile of 5 min at 25% B followed by a linear gradient of 2% 
per min to 90% B) 50% B, tR 17.5 min; t.l.c. Rf 0.28 (SI), Rf 0.42 (S2); 
amino acid analysis: Asp 0.97, Glu 1.10, Arg 1.08, Thr 1.09, Val 1.00, Met 
0.85; m/z (F.A.B., glycerol matrix) 1064 (M+H)+ [(M+H)+ calcd. 1063.6].
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[Acm-Cys5,14] linear MCH(5-14) (43).- A total of 1.1 g of resin (0.1 mequiv.) was 
used. Two batches of Fmoc-Cys(Acm)-OPfp were employed, each with recirculation 
periods of 4 h, using 0.025 molar equivalents of DMAP. The quantitative ninhydrin 
colour test indicated that esterification had proceeded to an extent of 85%. The Fmoc 
group was cleaved and the synthesis carried out conforming to the usual protocol.
The following Fmoc-amino acids were coupled employing Pfp esters throughout 
unless stated otherwise: Fmoc-Pro (120 min); Fmoc-Arg(Mtr) (Dhbt ester, 25 min); 
Fmoc-Tyr(f-Bu) (25 min); Fmoc-Val (25 min); Fmoc-Arg(Mtr) (Dhbt ester, 50 min); 
Fmoc-Gly (25 min); Fmoc-Val (25 min); Fmoc-Met (25 min); Fmoc-Cys(Acm) (25 
min).
Cleavage/deprotection proceeded as usual on 1.0 g of peptidyl-resin with an 
optimum period of 15 h. Following work-up purification was achieved by gel 
permeation chromatography (Bio-Gel P-2) followed by preparative RPHPLC under 
the customary conditions to furnish the title compound (43) (91.4 mg, 69%); 
analytical RPHPLC (apparatus A) 49% B, tR 27.0 min; t.l.c. Rf 0.30 (SI), Rf 0.81 
(S3); amino acid analysis: Gly 1.03, Arg 2.05, Pro 1.01, Tyr 0.89, Val 2.00, Met 0.96; 
m/z (F.A.B., thioglycerol matrix) 1326 (M+H)+ [(M+H)+ calcd. 1325.7].
[Acm-Cys5,14, Phe11) linear MCH(5-14) (45).- In a parallel synthesis to that of (43), 
the Phe analogue was prepared by the addition of Fmoc-Phe-OPfp, substituted for 
Fmoc-Tyr(r-Bu)-OPfp with a coupling time of 25 min. The cleavage/deprotection on 
500 mg of peptidyl-resin proceeded in the usual fashion with an optimum period of 15 
h. The crude peptide was purified by a combination of gel permeation 
chromatography (Bio-Gel P-2) and preparative RPHPLC to render the title compound 
(45) (42.3 mg, 65%); analytical RPHPLC (apparatus A) 53% B, tR 29.0 min; t.l.c. Rf 
0.35 (SI), Rf 0.83 (S3); amino acid analysis: Gly 0.99, Arg 1.89, Pro 0.94, Val 2.00, 
Met 0.88, Phe 0.97; m/z (F.A.B., thioglycerol matrix) 1310 (M+H)+ [(M+H)+ calcd. 
1309.7].
Cvclisation Reactions
In most cases a quantitative thiol test was employed, based on the Ellman 
procedure73, as a monitor of the cyclisation reaction. By this method it was possible 
to detect and quantify any free thiol present.
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Quantitative Thiol Test Procedure
The Ellman stock solution was prepared by dissolving 
5,5'-dithio£is-(2-nitrobenzoic acid) (3.0 mg, 7.6 pmol) in 100 cm3 of 10 mAf aqueous 
ammonium bicarbonate solution. A solution of cysteine hydrochloride (1.6 mg, 10.0 
jimol) in distilled water (5 cm3) was also prepared as a standard for comparison with 
the sample to be estimated. The stock solution (2.5 cm3) was added to a u.v. curvette, 
which was placed in a constant wavelength detector at 450 nm and the absorbance 
adjusted to zero. The following quantities of the standard cysteine solution were 
added to the curvette and the absorbance measured at 450 nm in each case: 5 pi, 10 
pi, 20 pi, 40 pi. An aqueous solution of the sample to be tested was then prepared 
(ca. 0.4 pmol of sample in 100 pi of distilled water). A portion (10 pi) of the sample 
solution was added to 2.5 cm3 of fresh stock solution in the curvette and the 
absorbance determined at 450 nm. Alternatively the appropriate volume was 
removed from the oxidation solution during aeration processes and added directly to 
the curvette. The development of a yellow colour on addition of the sample solution 
to the stock solution was an indication of the presence of free thiol in the sample.
Cyclic MCH(5-14) (7) - From (1) [Acm-Cys5-14] linear MCH(5-14) (43)
(i) Iodine Mediated Oxidation
The MCH derivative (43) (10.0 mg, 7.5 pmol) was dissolved in an 
aqueous solution of 90% acetic acid (v/v, 1.5 cm3) containing 2 M 
hydrochloric acid (10 pi). The resulting mixture was added dropwise over 4 
min to a stirred solution of iodine (195 mg, 0.8 mmol) in 90% acetic acid (15 
cm3). Stirring was continued for a further 30 min at RT and the mixture was 
poured into cold water (150 cm3) and the unreacted iodine extracted with 
carbon tetrachloride (3 x 30 cm3). The combined organic layers were 
back-extracted with water (3 x 30 cm3). The combined aqueous layers were 
then lyophilised to afford a yellow residue which was dissolved in an 
aqueous solution of 90% acetic acid (2 cm3) and concentrated aqueous 
ascorbic acid solution was then added until a colourless mixture resulted. 
This was then added directly to a gel permeation column (Bio-Gel P-2) run 
under the usual conditions. The peptidic material yielded was further 
purified by preparative RPHPLC to afford only 0.5 mg (6%) of material 
which was shown by F.A.B. mass spectrometry to correspond to [O-Met6] 
cyclic MCH(5-14) (47). It was later found that the undesired oxidation of 
the methionine residue could be suppressed by performing the reaction under
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nitrogen, in purged solutions, with the addition of methionine. However, 
isolation of the product from this system proceeded with difficulty and 
recovered yields of pure product never exceeded 6%.
(ii) Treatment with Mercuric Acetate Followed by (a) Air Mediated 
Oxidation (b) Ferricyanide Mediated Oxidation
An ammonium acetate buffer was prepared at pH 4.0 using aqueous 
acetic acid and aqueous ammonia solution. The compound (43) (33.1 mg, 25 
pmol) was dissolved in the buffer (7 cm3) under nitrogen with stirring. A 
solution of mercuric acetate (31.0 mg, 100 pmol) in the buffer (1 cm3) was 
then added and the mixture stirred for 4 h at RT. Hydrogen sulphide was 
then bubbled through the mixture for 30 min followed by a nitrogen purge 
for 15 min. The precipitated HgS was removed by centrifugation in a sealed 
nitrogen purged centrifuge tube. The supernatant solution was concentrated 
to ca. 2 cm3 under reduced pressure and a mixture of 2-mercaptoethanol (1 
cm3) and 4 M acetic acid (1 cm3) added and the resultant solution stirred for 
15 h under nitrogen. The mixture was then added directly to a gel 
permeation column (Bio-Gel P -2 ,140 cm x 3.5 cm diameter) packed in and 
eluted with a nitrogen purged solution of 4 M acetic acid containing 10 mM 
mercaptoethanol. The effluent was monitored at the usual wavelength at a 
flow rate of 0.5 cm3 per min; fractions (5 cm3) being collected every 10 min. 
This afforded 13.0 mg (44%) of the crude dihydro peptide (linear 
MCH(5-14) (48)) which was used in the following cyclisation reactions 
without further purification.
A small portion (3.0 mg) was subjected to preparative RPHPLC to 
afford 2.1 mg of material which gave rise to a single symmetrical peak on 
analytical RPHPLC at 49% B, tR 27.5 min using the standard gradient 
(apparatus A). A quantitative thiol test indicated that free sulphydryl was 
present (61% of free SH).
(a) Air Mediated Oxidation
A buffer was prepared from 0.5 M  acetic acid with the pH adjusted 
to 7.0 using ammonium hydroxide solution. The crude linear dihydro 
peptide (linear MCH(5-14 (48)) (10.2 mg, 8.5 pmol) was dissolved in the 
nitrogen purged buffer (10 cm3) in a 10 cm3 conical flask (1 mg per cm3 
dilution). The solution was allowed to stand open to the atmosphere for 15 h
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at RT during which time a small amount of precipitate developed. The thiol 
test confirmed the absence of free sulphydryls, the solution was lyophilised, 
and the crude material taken up in 2 M acetic acid (1 cm3) and applied to a 
gel permeation column (Bio-Gel P -2 ,140 cm x 3.5 cm diameter) packed in 
and eluted with 2 M  acetic acid. The effluent was monitored at the usual 
wavelength, at a flow rate of 0.5 cm3 per minute and fractions (5 cm3) were 
collected every 10 min. This yielded 5.7 mg of material which was further 
purified by preparative RPHPLC to render the title compound (7) (2.1 mg, 
20%); analytical RPHPLC (apparatus A) 49% B, tR 27.0 min; t.l.c. Rf 0.29
(SI), Rf 0.58 (S2), Rf 0.80 (S3); amino acid analysis: Gly 1.08, Arg 2.10,
Pro 1.08, Tyr 0.87, Val 2.00, Met 0.90; m/z (F.A.B., glycerol/diglycerol 
matrix) 1181 (M+H)+ [(M+H)+ calcd. 1181.5].
(b) Ferricvanide Mediated Oxidation
The linear dihydro peptide linear MCH(5-14) (48) (4.5 mg, 3.8 
pmol) was dissolved in an aqueous solution of ammonium acetate buffer at 
pH 7.0 under nitrogen with stirring. An aqueous solution of potassium 
ferricyanide (10 mAf) (420 pi, 4.2 pmol) was added dropwise and a 
permanent yellow colouration resulted. The solution was stirred for 2 h at 
RT and was then evaporated to dryness under reduced pressure. The residue 
was dissolved in 2 M acetic acid (2 cm3) and applied to a gel permeation 
column (Bio-Gel P-2) using identical conditons to those employed for the 
purification of the product from the air oxidation process (a). Further 
purification by RPHPLC rendered 1.0 mg (22%) of product shown to be 
identical to that furnished by the air oxidation process (a). Complete 
absence of free sulphydryls was confirmed by the thiol test.
Cyclic MCH(5-14) (7) - From (2) [Trt-Cys5,14]-peptidyl-resin
(i) Preparation of the Peptidyl-resin
The synthesis was performed in the usual fashion using 2.22 g of 
resin (0.2 mequiv.). For incorporation of the first Fmoc-amino acid, 
Fmoc-Cys(Trt)-OPfp and DMAP (0.025 molar equivalents) were added with 
a recirculation time of 2 h. Two further batches were then employed with 
recirculation periods of 15 h and 2 h respectively. The quantitative ninhydrin 
colour test indicated a resin coverage of 74%. The Fmoc group was then 
cleaved and the following Fmoc-amino acids were coupled, using Pfp esters
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unless stated otherwise: Fmoc-Pro (120 min); Fmoc-Arg(Mtr) (Dhbt ester,
25 min); Fmoc-Tyr(r-Bu) (25 min); Fmoc-Val (60 min); Fmoc-Arg(Mtr) 
(Dhbt ester, 60 min); Fmoc-Gly (25 min); Fmoc-Val (90 min); Fmoc-Met 
(25 min); Fmoc-Cys(Trt) (25 min).
(ii) Cyclisation Procedure
The peptidyl-resin (1.00 g) was added to the usual 
cleavage/deprotection mixture and a yellow colour instantly developed in 
solution. The mixture was left to stand for 15 h, then filtered and the resin 
washed with TFA. In contrast to the normal work-up procedure the filtrate 
and washings were reduced in volume to about one sixth of the original and 
were then poured into 10-fold the volume of water. The solution was then 
washed as usual using r-butyl methyl ether and lyophilisation of the 
combined aqueous layers yielded 50.1 mg of the crude linear disulphydryl 
compound linear MCH(5-14) (48). The quantitative thiol test indicated the 
presence of free thiol groups (70%). The crude peptide was added without 
delay to a nitrogen purged solution of ammonium acetate buffer (50 cm3) at 
pH 7.5 in a 50 cm3 conical flask (ca. 1 mg per cm3). The mixture was left to 
stand open to the air for 15 h at RT. The thiol test confirmed that no free 
sulphydryls were present. The solution was lyophilised and the crude 
material applied to a gel permeation column (Bio-Gel P-2) using identical 
conditions to those employed in (1) (ii) (a) to afford 41.4 mg of material 
which was further purified by preparative RPHPLC to yield the title 
compound (7) (33.2 mg, 28%). The product was characterised identically to 
the compound yielded from method (1) (ii) (a).
Cyclic MCH (5-17) (5)
(i) Preparation of the peptidyl-resin
The synthesis was performed as usual on 2.00 g of resin (0.2 
mequiv.). The symmetrical anhydride of Fmoc-Val was first prepared and 
added with DMAP employing a recirculation period of 50 min before a 
second batch was added and recirculated similarly. The quantitative 
ninhydrin colour test indicated a resin coverage of 77% had been attained. 
The Fmoc group was cleaved and the synthesis proceeded using Pfp esters 
unless otherwise stated. The following Fmoc-amino acids were coupled: 
Fmoc-Glu(O-f-Bu) (25 min); Fmoc-Trp (25 min); Fmoc-Cys(Trt) (25 min);
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Fmoc-Pro (120 min); Fmoc-Arg(Mtr) (Dhbt ester, 25 min); Fmoc-Tyr(r-Bu) 
(25 min); Fmoc-Val (25 min); Fmoc-Arg(Mtr) (Dhbt ester, 60 min); 
Fmoc-Gly (25 min); Fmoc-Val (25 min); Fmoc-Met (25 min);
Fmoc-Cys(Trt) (90 min).
(ii) Cyclisation Procedure
The peptidyl-resin (500 mg) was subjected to the usual 
cleavage/deprotection mixture, for 7 h. An identical work-up procedure as 
that used for cyclic MCH(5-14) (7) in method (2) (ii) was employed. 
However, air oxidation was allowed to proceed before lyophilisation of the 
aqueous layers. After the ether wash the combined aqueous layers were 
placed in a suitable narrow necked conical flask and the total volume 
adjusted by the addition of water so as to give an estimated concentration of 
ca. 1 mg of peptide per cm3. The pH of the solution was adjusted to 7.6 by 
the addition of ammonium hydroxide solution whilst degassing with a 
nitrogen purge. The solution was left to stand for 30 h before lyophilisation. 
This afforded the crude peptide in the presence of contaminating ammonium 
trifluoroacetate salt. The peptide was isolated by solid phase extraction. 
This was achieved by passage through a small cartridge of C18 silica (8 mm 
x 5 mm diameter), connected to a mini pump, at a flow rate of ca. 2 cm3 per 
min. The initially dry packing material was pretreated by pumping through 
an aqueous solution of 70% CH3CN (10 cm3) followed by 5% CH3CN (10 
cm3). A portion (200 mg) of the peptide/salt material was then suspended in 
5% CH3CN containing a drop of TFA (30 cm3). The suspension was pumped 
through the column whilst collecting the effluent, which was then 
recirculated through the column for 20 minutes. Water (20 cm3) followed by 
5% CH3CN (20 cm3) were then passed successively through the column to 
wash away any remaining salt and other contaminants. Finally the 
concentration of CH3CN was increased to 70% to elute the peptide to a 
saved vessel. After pumping 70% CH3CN for a further 10 min, the effluent 
was lyophilised to yield the crude peptide now free of the contaminating salt. 
The procedure was then repeated for the remainder of the peptide/salt 
material to afford a total of 22.1 mg of crude peptide. The thiol test 
indicated the absence of free sulphydryls.
The crude peptide was further purified by gel permeation 
chromatography on a column of Bio-Gel P-2 (140 cm x 3 cm diameter) 
packed in and eluted with 2 M acetic acid at a flow rate of 0.5 cm3 per min.
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Glacial acetic acid was added dropwise to achieve dissolution of the crude 
peptide in the loading medium. Fractions (5 cm3) were collected every 10 
min with other conditions as usual. This afforded the title compound (5)
(22.4 mg, 28%). A portion (7.1 mg) was subjected to purification by 
preparative RPHPLC to render 3.0 mg of material (a higher concentration of 
CH3CN, ca. 70%, was required to dissolve the peptide for loading); 
analytical RPHPLC (apparatus A) 55% B, tR 30.0 min; t.l.c. Rf 0.41 (SI), Rf 
0.66 (S2), Rf 0.79 (S3); amino acid analysis: Glu 1.01, Gly 1.09, Arg 2.01, 
Pro 1.06, Tyr 0.93, Val 3.00, Met 0.89; m/z (F.A.B., glycerol/diglycerol 
matrix) 1596 (M+H)+ [(M+H)+ calcd. 1595.8].
MCH (1)
(i) Preparation of the peptidyl-resin
In a parallel synthesis to that of cyclic MCH(5-17) (5) the assembly 
was continued until the complete MCH sequence had been assembled. The 
following Fmoc-amino acid derivatives were added: Fmoc-Arg(Mtr)-ODhbt 
(25 min); Fmoc-Met-OPfp (25 min); Fmoc-Thr(f-Bu)-ODhbt (25 min); 
Fmoc-Asp(0-f-Bu)-OPfp (25 min).
(ii) Cyclisation Procedure
The peptidyl-resin (500 mg) was added to the usual 
cleavage/deprotection mixture for 7 h. The work-up, cyclisation procedure 
and subsequent removal of ammonium trifluoroacetate salt proceeded as for 
(5). The crude peptide, which was shown to lack any free sulphydryls, was 
purified by gel permeation chromatography (Sephadex LH20) under the 
usual conditions to afford 30.1 mg. Preparative RPHPLC was earned out on 
a 10 p Cjg Vydac column (250 mm x 10 mm diameter) using the standard 
gradient, at a flow rate of 3 cm3 per minute. The peptide was loaded in the 
minimum volume of 5% B and fractions (3 cm3) were collected each minute, 
to afford the title compound (1) (14.4 mg, 13%). The product was shown to 
give rise to a single peak on analytical RPHPLC corresponding exactly to 
that of a sample of synthetic MCH (Peninsula Laboratories); analytical 
RPHPLC (apparatus B, 10 p C18 Vydac column (250 mm x 4.6 mm 
diameter)) 38% B, tR 21.5 min; tl.c. Rf 0.38 (SI), Rf 0.61 (S2), Rf 0.75 (S3); 
amino acid analysis: Asp 1.07, Glu 1.09, Gly 1.01, Arg 3.09, Thr 1.09, Pro 
1.06, Tyr 0.86, Val 3.00, Met 1.89; m/z (F.A.B., glycerol matrix) 2099
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(M+H)+ [(M+H)+ calcd. 2099.0].
MCH (1) By Cyclisation On The Solid Support.- To an agitated suspension of the 
peptidyl-resin of MCH (50 mg) (synthesised as previously described) in DMF (5 
cm3), containing D,L-methionine (3.7 mg, 25 pmol) and D,L-tryptophan (5.1 mg, 25 
pmol), was added a solution of iodine (254 mg, 1.0 mmol) in DMF (50 cm3) under 
nitrogen. The mixture was agitated for a further 25 min and a cold aqueous solution 
of ascorbic acid (200 mg in 16 cm3) was added to the mixture in an ice bath. The 
resin was isolated by filtration and washed with water-DMF (1:1 v/v, 15 cm3), DMF 
(15 cm3), DCM (15 cm3) and diethyl ether (30 cm3) and dried in a stream of nitrogen. 
The peptidyl-resin was then added to the nitrogen purged cleavage/deprotection 
mixture of TFA (7.5 cm3), phenol (400 mg), D,L-methionine (20 mg) and 
D,L-tryptophan (20 mg) and was left to stand for 2 h at RT. The resin was then 
removed by filtration and washed with TFA. The combined filtrate and washings 
were left to stand for a further 5 h at RT, then concentrated under reduced pressure, 
water (10 cm3) added, and the resultant solution washed with ether (3 x 10 cm3). The 
combined ether layers were back-extracted once with an equal volume of water. The 
combined aqueous layers were lyophilised to afford a pale brown solid.
An initial purification was carried out by solid phase extraction. This was 
followed by preparative RPHPLC under the standard conditions to yield the title 
compound (1) (1.1 mg, 10%). The purified product was shown to possess no free 
sulphydryls by the thiol test and was identical to the compound (1) prepared by the 
previous method.
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Experimental to Chapter 3
[Phe11] cyclic MCH(5-14) (49).- A solution of iodine (389 mg, 1.5 mmol) in an 
aqueous solution of 80% acetic acid (v/v, 31 cm3) was added under nitrogen to a 
stirred solution of (45) (10.0 mg, 7.6 pmol), D,L-methionine (5.5 mg, 38 nmol) and 2 
N  hydrochloric acid (10 |xl) in 50% acetic acid (1 cm3). After stirring for 15 h at RT 
the reaction mixture was added to a stirred suspension of zinc dust (1.34 g, 20.6 
mmol) in water (215 cm3) under nitrogen. After stirring for 18 h the mixture was 
filtered through a short plug of celite. After washing with water (30 cm3) the 
combined filtrate and washings were lyophilised to yield crude material as a mixture 
of peptide and iodide salt Isolation of the peptide was achieved by solid phase 
extraction to yield crude peptide (8.0 mg). The product showed the absence of free 
thiol. The material was further purified by chromatography on Sephadex LH20 
followed by preparative RPHPLC to render the title compound (49) (1.2 mg, 14%); 
analytical RPHPLC (apparatus B) 52% B, tR 28.5 min; t.l.c. Rf 0.38 (SI), Rf 0.64
(S2), Rf 0.79 (S3); amino acid analysis: Gly 1.03, Arg 1.89, Pro 1.01, Val 2.00, Met
0.90, Phe 0.98; m/z (F.A.B., glycerol matrix) 1166 (M+H)+ [(M+H)+ calcd. 1165.6].
[DAla8] cyclic MCH(5-14) (50)
(i) Preparation of the peptidyl-resin
Synthesis was carried out using a total of 0.8 g of resin (0.2 m 
equiv.). For incorporation of the first Fmoc-amino acid, 
Fmoc-Cys(Trt)-OPfp and DMAP (0.025 molar equivalents) were added and 
recirculated for 3 h. A second batch was similary employed and recirculated 
for 15 h followed by a third batch recirculated for 1 h. The quantitative 
Fmoc determination indicated that a resin coverage of 73% had been 
obtained. The Fmoc group was cleaved and the synthesis continued as usual, 
employing Pfp esters, unless otherwise stated. The following Fmoc-amino 
acids were coupled: Fmoc-Pro (120 min); Fmoc-Arg(Mtr) (Dhbt ester, 25 
min); Fmoc-Tyr(r-Bu) (25 min); Fmoc-Val (25 min); Fmoc-Arg(Mtr) (Dhbt 
ester, 25 min). Following cleavage of the Fmoc group the symmetrical 
anhydride of Fmoc-DAla was prepared in the usual manner, adding a few 
drops of DMF to achieve dissolution of Fmoc-DAla in DCM. The anhydride 
formed was seen to precipitate with DCU and the mixture was concentrated 
under reduced pressure. The resultant suspension was loaded onto the resin 
in DMF and coupling was complete after the usual 25 min period.
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The synthesis was then continued coupling the remaining 
Fmoc-amino acids: Fmoc-Val (45 min); Fmoc-Met (25 min); Fmoc-Cys(Trt) 
(25 min).
(ii) Cyclisation
The peptidyl-resin (400 mg) was added to the standard 
cleavage/deprotection mixture for 15 h. An identical work-up and 
cyclisation procedure to that used for the cyclic MCH(5-14) (7) in method
(2) (ii) (Chapter 2 Experimental) was employed. Before addition to the air 
oxidation buffer the crude disulphydryl peptide (35.9 mg) was shown to 
contain 71% free thiol. The crude cyclic material was subjected to 
chromatography on Sephadex LH20 to afford the title compound (50) (22.4 
mg, 19%). A portion (6.3 mg) was subjected to preparative RPHPLC to 
render the pure material (4.3 mg); analytical RPHPLC (apparatus B) 43% B, 
tR 24.0 min; t.l.c. Rf 0.26 (SI), Rf 0.40 (S2), Rf 0.61 (S3); amino acid 
analysis Arg 2.09, DAla 1.08, Pro 1.03, Tyr 0.90, Val 2.00, Met 0.89; m/z 
(F.A.B., glycerol matrix) 1196 (M+H)+ [(M+H)+ calcd. 1195.6].
[DAla8J*he11] cyclic MCH(5-14) (51)
(i) Preparation of the peptidyl-resin
In a parallel synthesis to that of (50) the Phe analogue was prepared, 
substituting for Tyr11 at the appropriate point.
(ii) Cyclisation
An identical procedure was employed to that used for the synthesis 
of (50), starting from 400 mg of peptidyl-resin. Chromatography on 
Sephadex LH20 afforded the title compound (51) (51.6 mg, 44%). A portion 
(7.2 mg) was subjected to preparative RPHPLC to furnish the purified 
product (5.5 mg); analytical RPHPLC (apparatus A) 44% B, tR 24.5 min; 
t.l.c. Rf 0.28 (SI), Rf 0.45 (S2), Rf 0.64 (S3); amino acid analysis: Arg 2.06, 
DAla 0.91, Pro 1.01, Val 2.00, Met 0.92, Phe 0.98; m/z (F.A.B., glycerol 
matrix) 1180(M+H)+ [(M+H)+calcd. 1179.6].
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Experimental to Chapter 4
Dimethyl 3-chloropent-2-enedioate115 (59).- Phosphorus pentachloride (54.00 g, 260 
mmol) was added portionwise to diethyl 3-oxo-pentanedioate (47.97 g, 237 mmol) 
under an atmosphere of nitrogen with stirring. After the addition was complete, the 
reaction mixture was warmed to 40°C in a water bath for 30 min, during which time a 
red colouration developed. The reaction mixture was then cooled in an ice bath and 
poured onto ice (80 cm3) in an ice-cooled flask. A mixture of water and DCM (1:1 
v/v, 100 cm3) was used to rinse traces of product from the reaction vessel, and the 
resulting mixture was stirred for 15 min. After separating the two layers, the aqueous 
phase was extracted with DCM (3 x 80 cm3) and the combined organic extracts dried 
(Na2S04) and concentrated under reduced pressure to yield a red oil. This was added 
to a mixture of concentrated sulphuric acid (13 cm3) and dry methanol (195 cm3) and 
heated under reflux for 18 h. Excess methanol (130 cm3) was removed by distillation, 
the residue allowed to cool to RT and then poured into water (80 cm3). Sodium 
chloride was added to saturation and the solution extracted with ether (8 x 80 cm3). 
The combined ether extracts were washed successively with saturated aqueous 
NaHC03 solution (120 cm3) and saturated aqueous NaCl solution (120 cm3), dried 
(MgS04) and concentrated under reduced pressure to afford a yellow oil. Purification 
was effected by distillation under reduced pressure to afford the title compound (59) 
(26.03 g, 57%) as a colourless liquid, b.p. 70-80°C at 0.1 mmHg, (lit.,115 b.p. 50-60°C 
at 0.02 mmHg), t.l.c. Rf 0.36 (petrol-EtOAc 9:1 v/v). The product was determined to 
be a mixture of stereoisomers (approximately 6:1) by n.m.r. The spectral data of 
(59) were in accord with published data;115 vmax (liquid film) 3080 (C=C), 2940, 
1720 (CO-O), 1630 (C=C), 1430 cm'1; §h (CDC13) 3.73 (3H, s, O^O-COCH^, 3.75 
(3H, s, C=CHCO-Oai3), 4.12 (2H, s, CH^-COCf^), 6.21, 6.28 (1H, 2 x s, 
stereoisomeric C=CH); 5C (CDC13), 41.2 (C=CHCH2), 51.6 (CT^O-COCTy, 52.3 
(C=CHCO-OCH3), 121.5 (C1C=CH), 150.0 (C1C=CH), 164.4 (CH30-C0CH2), 168.1 
(C=CHCO-OCH3); m/z (C.I.) 193 (M+l)+ (19%), 161 (M-CH30 )+ (100); [Found: C, 
43.7; H, 4.9. C7H90 4C1 requires C, 43.6; H, 4.7%].
Dimethyl penta-2 J-dienedioate115 (58).- To a stirred solution of dimethyl 
3-chloropent-2-enedioate (59) (25.19 g, 130 mmol) in dry THF (93 cm3) at 0°C under 
a nitrogen atmosphere was added freshly distilled triethylamine (21 cm3, 151 mmol) 
portionwise over a 10 min period. The nitrogen inlet/outlet was then replaced by a 
drying tube (CaCl2) and the mixture stirred for 18 h at 0-5°C. During this time a 
precipitate of triethylamine hydrochloride formed which was removed by filtration 
and washed with ether (3 x 25 cm3). The combined filtrate and washings were 
washed successively with 0.1 N  hydrochloric acid (3 x 20 cm3) and saturated aqueous
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NaCl solution (25 cm3). After drying (Na2S04) the ethereal solution was 
concentrated under reduced pressure to yield a red brown oil. The oil was purified by 
distillation under reduced pressure to afford the title compound (58) (12.62 g, 62%) as 
a colourless liquid, b.p. 78-80°C at 0.1 mmHg (lit.,115 b.p. 58°C at 0.02 mmHg), t.l.c. 
Rf 0.18 (petrol-EtOAc 9:1 v/v). The product became yellow and viscous on standing 
at RT, due to polymerisation, and was thus stored at -20°C. The spectral data of (58) 
were in accordance with published data;115 0)max (liquid film) 2960,1960 (C=C=C), 
1710 (CO-O) cm 1; 8h (CDC13) 3.78 (6H, s, 2 x CH3O-CO), 6.07 (2H, s, HC=C=CH); 
8C (CDC13) 52.3 (2 x CH30-CO), 91.9 (C=C=C), 163.5 (CH30-CO), 219.5 (C=C=C); 
m/z (E.I.) no (M)t, 125 (M-CH30)+ (77%), 66 (34), 59 (100), (C.I.) 157 (M+l)+
(100), 125 (64).
1.5-Dihydroxypenta-2,3-diene (57).- A 1.5 M solution of Dibal-H in toluene (17 cm3,
25.6 mmol) was added portionwise over 1 h to a stirred solution of dimethyl 
penta-2,3-dienedioate (58) (1.00 g, 6.4 mmol) in dry toluene (9.5 cm3) at 0°C under 
nitrogen. After 1.5 h of additional stirring at 0-5°C, a saturated aqueous solution of 
potassium sodium tartrate (23 cm3) was slowly added to the cooled reaction mixture 
which was then allowed to warm to RT. The product was isolated by continuous 
extraction into ether over two consecutive 15 h periods. The combined ethereal 
isolates were evaporated under reduced pressure to afford an orange oil. Purification 
of the crude product by column chromatography [silica gel, CHCl3-EtOH (19:1)] gave 
the title compound (57) (0.28 g, 44%) as a colourless oil, t.l.c. Rf 0.37 (EtOAc). The 
product was stored at -20°C as polymerisation occurred on standing at RT; omax 
(liquid film) 3600-3100 (OH), 2920,2860,1970 (C=C=C) cm*1; 8H (CDC13) 2.39 
(2H, bs, OH), 4.16 (4H, t, /  = 4.2 Hz, 2 x CH ^H ), 5.51 (2H, t, /  = 4.2 Hz, 
HC=C=CH); 5C (CDC13) 60.1 (2 x CH2OH), 94.7 (C=C=C), 202.5 (C=C=C); m/z 
(E.I.) no (M)+, 82 (M-H20)+ (99%), 55 (100), (C.I.) 101 (M+l)+ (8), 100 (69), 83 
(M+l-H2O)+ (100), 56 (26).
5-(t-Butyldiphenylsilyloxy)penta-2j-diene-l -ol (60).- To a stirred solution of
1.5-dihydroxypenta-2,3-diene (57) (174 mg, 1.7 mmol) in dry DCM (10 cm3) 
containing imidazole (118 mg, 1.7 mmol) under a nitrogen atmosphere was added 
f-butyldiphenylsilyl chloride (479 mg, 1.7 mmol) dropwise at RT. After 2 h the 
reaction mixture was filtered through a celite pad and evaporated under reduced 
pressure to afford the crude silyl ether which was purified by column chromatography 
[silica gel, petrol-EtOAc (10:1)] to yield the title compound (60) (304 mg, 52%) as a 
colourless oil, t.l.c. Rf 0.41 (petrol-EtOAc 4:1 v/v); \)max (liquid film) 3600-3100 
(OH), 3060 and 3020 (Ar), 2920,2840,1950 (C=C=C), 1100 and 820 (SiOC) cm"1;
5h (CDC13) 1.05 (9H, s, C(CH3)3), 1.54 (1H, bs, OH), 4.08 (2H, dd, J  = 8.6,3.2 Hz,
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HOCH2), 4.25 (2H, dd, J  = 8.8, 3.1 Hz, CH2OSi), 5.41 (2H, c, HC=C=CH), 7.35-7.73 
(10H, c, H-aromatic), 8C (CDC13) 19.3 (C(CH3)3), 26.9 (C(CH3)3), 60.5 (HOCH^, 
61.9 (CH2OSi), 93.6 (HC=C=CH-CH2OSi), 94.4 (HOH2C-HC=C=CH), 127.7,129.7,
133.7,135.6 (C-aromatic), 202.8 (C=C=C); m/z (C.I.) 339 (M+l)+ (5%), 321 
(M+1-H20 )+ (83), 229 (58), 199 (100), 143 (75); [Found: C, 74.4; H, 7.9. C21H20O2Si 
requires C, 74.5; H, 7.8%].
5-(t-Butyldiphenylsilyloxy)penta-2 J-diene-1 -oxy-methylsulphone (61).- 
Triethylamine (75 mg, 0.7 mmol) was added dropwise to a stirred solution of (60)
(248 g, 0.7 mmol) and methanesulphonyl chloride (84 mg, 0.7 mmol) in dry DCM (5 
cm3) at 0°C under nitrogen. After stirring for a further 2 h at 0-5°C the solution was 
poured into a mixture of 2 N  hydrochloric acid and ice (2:1 v/v, 5 cm3). The organic 
layer was isolated and the aqueous layer extracted further with DCM ( 2x5 cm3).
The combined organic layers were washed with saturated aqueous NaHC03 solution 
(2 x 10 cm3) and saturated aqueous NaCl solution (10 cm3), dried (Na2SC>4) and 
concentrated under reduced pressure to afford the mesylate (61) (224 mg, 77%) as a 
pale yellow oil. Storage at -20°C was employed to prevent decomposition. The 
compound was to be used without further purification as decomposition occurred 
during column chromatography; omax (liquid film) 3040 and 3020 (Ar), 2940,2840, 
1960 (C=C=C), 1340 and 1160 (S020), 1090 and 820 (SiOC) cm 1; 5H (CDC13) 1.05 
(9H, s, C(CH3)3), 2.97 (3H, s, CH3S020), 4.26 (2H, dd, /  = 8.6,2.9 Hz, CH2OSi), 
4.66 (2H, dd, J  = 9.3,2.0 Hz, S020CH2), 5.42 (2H, c, HC=C=CH), 7.37-7.69 (10H, c, 
H-aromatic); 8C (CDC13) 19.2 26.8 (C(CH3)3), 38.3 (CH30 S 0 2), 61.6
(CH2OSi), 67.8 (S020CH2), 87.7 (S020CH2-CH=C=CH), 94.4 
(HC=C=CH-CH2OSi),127.7,129.8,133.7,135.5 (C-aromatic), 202.5 (C=C=C); m/z 
(CL, NH3) 434 (M+NH4)+ (98%), 417 (M+l)+ (21), 338 (M+1-S02CH3)+ (13), 321 
(M-0S02CH3)+ (52), 143 (74).
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Melanin Concentrating Hormone; Molecular Modelling and Experimental Analysis of 
Conformation
Bridget I. Baker,* David W. Brown,b Malcolm M. Campbell,6 Richard G. Kinsman,6 Cheryl A.-Moss,b David J. 
Osguthorpe,' Prem K. C. Paul,' and Peter D. White6
•  School o f Biological Sciences, 6 School of Chemistry, c Molecular Modelling Unit, University o f Bath, Claverton 
Down. Bath BA2 7AY, U.K.
Molecular dynam ics analyses and associated  energy m inim izations for the  peptide horm one MCH and  the related 
cyclic decapep tide MCH(5—14) suggest that it m ay access tw o m ajor fam ilies of conform ations; experim ental 
support com es from  n.m.r. studies of MCH(5— 14).
M elanin concentrating horm one (M C H ) ( I )  is a neuropeptide  
produced in the hypothalam us. In te leosts it serves to  
concentrate m elanin within the p igm ent cells o f  the sk in . * — 3  It 
also induces m elanosom e dispersion w ithin tetrapod m elano- 
phores . 4  M C H  also  acts as a p otent pituitary horm on e, 
inhibiting the release o f  A C T H  in m am m als , 5  and stim ulating  
growth horm one release in rats . 6
A s the first phase in elucidating th e shape and charge 
characteristics o f  M C H  receptors w e  have perform ed theor­
etical analyses o f  the conform ational features o f  the cyclic 
decap ep tid e, M C H (5— 14) (2 ) , and o f  the intact p eptide (1). 
A dd ition ally , w e have synthesized  these tw o p ep tid es , 7  and a 
range o f  fragm ents, for b iological assay and for n .m .r. analysis 
o f  conform ation . In th is com m unication  w e report the results 
o f  the theoretical predictions from m olecular dynam ics 
analyses, together with structural inform ation obtained  from  
n.m .r. spectroscopy.




I ,* IHO—  Val— G lu— T rp— Cys — Pro— A rg— Tyr
(1)





I u  IHO—C y s —P ro —Arg — Tyr
( 2 )
Table 1. Chemical shift assignments for MCH(5— 14) in DMSO solution at 293 K.
NH a P y b e
5 Cys 4.54 - 3 .0
6 Met _b 4.52 1.90,2.09 2.96.2.56
7 Val 7.73 4.12 1.90 0.83
8 Gly 8.41 3.90,3.65
9 Arg* 7.83 4.55 1.78,1.55 2.40 -3 .1 9.23 or 8.70
10 Val 8.10 4.10 1.92 0.70
11 Tyr 8.16 4.52 2.90.2.78
12 Arg* 8.12 4.17 1.77.1.52 2.43 -3 .2 9.23 or 8.70
13 Pro 4.33 2.02.1.97 2.40 -3 .5
14 Cys 8.08 3.98 2.92.3.24
M olecu lar dynam ics m ethods have b een  em ployed  recently  
to  reveal accessib le conform ations and to  characterize the 
dynam ic conform ational transitions o f  proteins and peptide  
h orm on es . 8  W e therefore applied  m olecu lar dynam ics simula­
tion s and energy m inim ization  procedures using a valence 
force fie ld  softw are package for M C H  and for th e cyclic 
d ecap ep tid e M C H (5— 14). In th e valence force fie ld , 9  the 
potentia l en ergy o f  a m olecu lar system  is represented as a sum  
o f  the internal o r  valence d egrees o f  freedom  and the  
in teratom ic d istances. T h e analytical expression o f  the poten­
tial en ergy 1 0  includes (a ) strain en erg ies arising from deform a­
tions o f  internal co-ord inates (like bond  length , bond angle, 
and torsion  an gle) and ‘cross term s’ caused by coupling  
b etw een  d eform ation s o f  tw o  or m ore internals and (b)
( a )  '  (b )
Figure 1. Region of the peptide around VaP-Gly'*- Arg" when Gly is in 
conformations which are (a) an a-helical and (b) a y turn.
* Assignment uncertain. b Cross-peak absent.
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( 2 )
Figure 2. Typical conformations of MCH(5— 14) showing n.O .e.s.
interaction energies w hich are a result o f  the exchange  
repulsioh , d ispersion, and cou lom b interactions b etw een  the 
non-bonded  atom s. T h e hydrogen bond energy term is 
represented as a general non-bonded interaction but with  
specific param eters. A  fixed dielectric with a d ielectric  
constant o f  1 w as used in the calculations. T he param eters  
included in the various energy terms have b een  determ ined by 
fitting experim ental crystal structure d ata, sublim ation en er­
g ies, m olecular d ipole m om ents, vibrational spectra, and  
strain en erg ies o f  sm all organic com pounds. A b  in itio  m ol­
ecular orbital calculations have also b een  used to  provide  
inform ation on  charge d istributions, energy barriers, and  
coupling term s . 11 The effec t o f  solvent has not b een  m odelled . 
Thus, g iven  the potential energy o f  a m olecular system , the 
force exerted  on each atom  by all the other atom s in the system  
is  d efined  and consequently  the equations o f  m otion can be 
so lved . This yields a detailed  description o f  the dynam ical 
behaviour o f  the system . The conform ations accessed  at 
different instances in the dynam ics trajectory can then be 
m inim ised and studied. H ere main chain torsion angles o f  
energy m inim ized conform ations were analysed at p icosecond  
intervals along a dynam ics trajectory o f  50 p icoseconds. Each  
conform ation w as m inim ized to a maximum first derivative o f  
less than 0 .05  kcal/A  (cal =  4.184 J) and (4>.'q0 angles analysed  
for all am ino acids.
The initial conform ation o f  M CH w as built on  an E& S  
PS330 picture system , using the IN S IG H T  package. T he  
residues in the tw o tails (i.e . residues 1— 1 and 15— 17) w ere  
then rem oved to  gen erate the initial structure o f  cyclic  
M C H (5— 14). This structure w as partially m inim ised (to  a 
m axim um  first derivative o f  0 .5  kcal m o l - 1  A-1) to  relieve  
excessive strain and elim inate unrealistic m otion . Initial 
random velocities consistent with a M axw ell-B oltzm ann  
distribution for an average tem perature o f  300 K w ere 
assigned to  each o f  the atom s. M olecular dynam ics sim ula­
tions with a tim e step o f  1 0 ' 15 s  w ere perform ed for a total 
tim e period o f  50 picoseconds (50 x  1 (1-  s). The results o f  the
sim ulations show ed  som e interesting structural features. 
Firstly, the m axim um  conform ational change occurred in the 
G ly 8 -A r g 9  region o f  the pep tid e. Transitions betw een two 
conform ational sta tes persisted throughout the sim ulations. 
T he G ly 8  residue existed  in either a 7  turn ( -8 0 .5 0 )  or an 
a-helical ( - 7 0 . - 4 0 )  type o f  conform ation (Figure 1). The 
A rg 9  residue a lso  existed  in tw o conform ations, with (<|>.v) 
values o f  ( -1 5 5 .1 0 0 )  and ( -8 0 .1 0 0 ) .  In o ther w ords the <p of  
Gly* and th e o f  A rg 9  do not undergo much chan ge, w hereas 
the v  o f  G ly 8  and the 41 o f  A rg9  undergo concerted  transitions. 
W henever the near type f G ly^-A re9  p-turn occurs the 
A rg 9- V a l 1 0  form s a near type II P-turn. T he other m obile 
residue in this region is V al7. M et6  and V al7  exist m ainly in a 
left-handed helix  or in a p-sheet structure.
R eg ion s o f  steric constraint em erged  from the sim ulation. 
V a l111 to  C ys 14 show ed  little chan ge. Tyr11 to C ys14 being in a 
stable helix  w ith  (<J>.y) around ( -8 0 .1 1 0 )  (near the poly­
proline h elix ). Interestingly. Pro1-' which is known to  be an 
initiator o f  P-turns d o es  not participate in any o f  these in the 
sim ulation . A  m ajor conform ational feature which persisted  
throughout the analyses w as a transannular hydrogen bond  
from T yr11 to  C ys5  or T yr 11 to M et6. The preference for-this 
conform ationally  constraining feature w as m ost significant. 
Further features leading to relative rigidity in this section o f  
the m olecu le included the stable + 9 0 c disulphide conform a­
tion and a stable hydrogen bond b etw een  the «-N H  o f  Arg9  
and the N H  o f  V a l10.
A dditional m olecu lar dynam ics sim ulations w ere perfor­
m ed on M C H (5— 14) starting from a conform ation which was 
not characterised by the cross-ring T yr11 to  Cvs5  hydrogen  
bond. H ow ever, it was found that the con fon hational features 
o f  the m inim a accessed  during the new sim ulations w ere very 
similar to  th ose found previously. In particular, the T yr11 to  
Cys5  transannular hydrogen bond was on ce  again found to be 
present in all the minim um  energy conform ations. It was 
further apparent that the overall backbone conform ations of  
M CH(5— 14) and M C H  w ere closely sim ilar, and that the
- 1 9 0 -
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Table 2. Inter-residue ID  nuclear Overhauser enhancements for 
MCH(5— 14) in DMSO solution.
Enhance- Interatom ic distance/A*
1 C?.H
2 q , H


























■ The interatomic distances are obtained from conformations ob­
served in molecular dynamics simulations and where more than one 
hydrogen is designated represents the smallest value. b N .m.r. 
assignments ambiguous. Distances based on C MH .
m obile side chains did not ind u ce significant changes. M C H -  
(5— 14) retains significant activity relative to  M C H .1-4
Independent n .m .r. analyses w ere perform ed on  M CH- 
(5— 14) at 400 M H z both in  w ater and in d im ethyl sulphoxide  
(D M S O ). C hem ical shift assignm ents w ere m ade (T able 1) 
from C O S Y , long range C O S Y , and N O E S Y  m easurem ents. 
T he proton signals for M C H (S —14) w ere highly d ispersed in 
relation to  linear M C H (5— 14), th e  a -p roton s o f  G ly8, for 
exam ple , being strongly d ifferentiated  and com p lete resolu­
tion o f  all N H  and C a-H  protons w as ach ieved , consistent with  
greater conform ational restraints. V ariab le tem perature 
studies o f  backbone am ide and arginine e -N H  protons w ere 
perform ed. In H 20  th e shallow est s lop e w as show n by the  
A rg9 guanidinium  proton s, the rem aining coefficients being  
large and therefore n ot strongly internally hydrogen bonded . 
In D M S O  the guanidinium  N H  units had th e  largest tem pera­
ture coefficients, w ith uniform ly low  values for the am ide N H  
units w ith  th e  excep tion  o f  C ys14 and Gly*. T his m ay be 
regarded as indicating m ore rigid, hydrogen b onded  confor­
m ations existing in D M S O . C onform ationally  significant 
n .O .e . data w ere obtained  on ly  in  D M S O . T h e m ost 
interesting o f  th ese involved  Tyr11, w hich , by I D  differential 
n .O .e . show ed  connectiv ities from  T yrn -C £H  to  Pro13-C aH  
(1 .5% ), T yrn -C 6H  to  V a l‘°-C aH  (1% ), and from  T yr» -C eH  
to  on e  o f  the C ys C{5-H protons (0 .5% ). T h ese  sm all, but 
reproducible, effects suggest a conform ation  in w hich T yr11 
occupies a  transannularly hydrogen b ond ed  conform ation. 
(Tyru O H  w as not d etected .) O th er inter-residue n .O .e .
effec ts (T able 2 ) w ere also in accord with the tw o conform a­
tions show n in Figure 2 w hich had previously been predicted  
by m olecular dynam ics and are typical o f  the tw o different 
fam ilies o f  accessib le , m inim ized cpnform ations obtained  
from each o f  the dynam ics trajectories. T he great m ajority o f  
th ese m inim ized conform ations satisfy the spatial require­
m ents for either six o f  the eight or seven  o f  the eight observed  
n .O .e . effects d epending upon  the fam ily. A ll  accessible 
m inim ized conform ations feature the transannular tyrosine 
hydrogen bond .
Indep en d en t theoretical and experim ental studies are thus 
mutually com patib le in these prelim inary studies. Constrain­
ing features and regions o f  conform ational flexibility have 
b een  defin ed . Further synthetic stud ies designed to  lock one  
or o th er conform ation , togeth er with n .m .r. analysis o f  
conform ation  and assessm ent o f  biological activity are in 
progress and w ill be reported.
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